5 Ultra-Popular Stocks to Avoid Like the Plague in July_老虎社区_美港股上老虎

5 Ultra-Popular Stocks to Avoid Like the Plague in July

The motley fool2021-07-06

For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020. While ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

181

holdnotfold
·2021-07-06
Orh ok
回复
点赞
举报
Sephy
·2021-07-06
Newbie analysts gg. Load up coinbase now u will be HUGELY rewarded by August earnings report at least a 20% profit, projected 20-40%.
回复
2
举报
收起
- 6c65da76:
  Seems Like you are a bagholder, Its a pump and dump, I got burnt in this stock too.
  2021-07-06
  回复
  举报
- 6c65da76:
  Look how ERs didnt even affect the stock price hugely
  2021-07-06
  回复
  举报
- Sephy:
  its correlated to bitcoin and ethereum prices
  2021-07-06
  回复
  举报
查看更多 2 条评论
StanleyO
·2021-07-06
Good Read
回复
点赞
举报
Patek1975
·2021-07-06
Lousy article as usual from fools , how much yougetting paid for this article
回复
3
举报
Patek1975
·2021-07-06
Apes hold [Smile]
回复
1
举报
Xuehao
·2021-07-06
Too the moonn, like n share tq
回复
点赞
举报
GohHW
·2021-07-06
Yes but highrisk high gain
回复
1
举报
收起
- GohHW:
  Great
  2021-07-07
  回复
  举报
- Xuehao回复OpenSesame88:
  noted
  2021-07-06
  回复
  举报
- OpenSesame88:
  yes
  2021-07-06
  回复
  举报
查看更多 1 条评论
Skai
·2021-07-06
The one news source to avoid is the fool. Thanks for the daily FUD.
回复
点赞
举报
收起
- 3nn:
  good one lol
  2021-07-06
  回复
  举报
balm
·2021-07-06
Good reminder
回复
1
举报
JessHang
·2021-07-06
Great advise 👍
回复
1
举报
Zacific
·2021-07-06
Okay
回复
1
举报
收起
- clingling:
  Ok
  2021-07-06
  回复
  举报
Vin309
·2021-07-06
Like and comment
回复
2
举报
收起
- loti:
  ok
  2021-07-06
  回复
  举报
Edylc
·2021-07-06
Buy stocks u like
回复
2
举报
Jaminwu
·2021-07-06
yes
回复
3
举报
KVCGTan
·2021-07-06
Interesting
回复
3
举报
收起
- Bodoh:
  Yes
  2021-07-06
  回复
  举报
Jo5tarz
·2021-07-06
FUD news by the same fools yet again[捂脸]
回复
7
举报
收起
- Jaminwu:
  yes
  2021-07-06
  回复
  举报
- Skai:
  They write all sorts of articles with the goal of targeting AMC and GME daily. Lousy news source.
  2021-07-06
  回复
  举报
ShawnKoh1
·2021-07-06
Like and comment
回复
3
举报
Prashant
·2021-07-06
Like
回复
6
举报
Jenjorjack
·2021-07-06
Popular usually means you are too late
回复
10
举报
收起
- Poopingmons:
  Yeah ikr
  2021-07-06
  回复
  举报
- ZJ0429:
  AMC!
  2021-07-06
  回复
  举报
- yvneyng:
  Agreed
  2021-07-06
  回复
  举报
JensenLee
·2021-07-06
Like pls
回复
6
举报
收起
- L1324:
  done, i need like too.tia
  2021-07-06
  回复
  举报

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1164348327?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-07-06 09:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1164348327","market":"us","top_or_hot":-1,"title":"5 Ultra-Popular Stocks to Avoid Like the Plague in July","media":"The motley fool","content":"<div>\nFor the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.\nWhile ...\n\n<a href=\"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/\">网页链接</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Ultra-Popular Stocks to Avoid Like the Plague in July</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Ultra-Popular Stocks to Avoid Like the Plague in July\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 09:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/>The motley fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nFor the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.\nWhile ...\n\n<a href=\"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GME","symbol_name":"游戏驿站","start_time":0,"source_url":"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/","article_id":"1164348327","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1164348327","pubTimestamp":1625535165,"columns":[],"sourceInfo":null,"weMediaInfo":null,"summary":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The ben","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"GME":"游戏驿站","SAVA":"Cassava Sciences Inc","INO":"伊诺维奥制药","COIN":"Coinbase Global, Inc.","AMC":"AMC院线"},"translate_title":"5只超人气股要避开7月的瘟疫","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SAVA":0.9,"INO":0.9,"GME":0.9,"COIN":0.9,"AMC":0.9},"content_text":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.\nWhile a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.\nCoinbase Global\nFirst up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.\nTo start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.\nSecond,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.\nAnd third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.\nCassava Sciences\nAnother ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).\nCassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.\nI'd love for simufilam to be successful, but history has shown that Alzheimer's is one of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.\nAlthough Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.\nGameStop\nIf you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).\nOn one hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.\nHowever, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.\nGameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.\nInovio Pharmaceuticals\nBiotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.\nInovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.\nFor example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.\nIf you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.\nAMC Entertainment\nFinally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.\nAMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.\nAMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.\nI've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.","kind":"news","is_publish_news":false,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[{"id":157056825,"gmtCreate":1625556968867,"gmtModify":1631891845827,"author":{"id":"3585783282279083","authorId":"3585783282279083","name":"holdnotfold","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3585783282279083","authorIdStr":"3585783282279083"},"htmlText":"Orh ok","listText":"Orh ok","text":"Orh ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/157056825","repostId":1164348327,"repostType":2,"repost":{"id":"1164348327","kind":"news","pubTimestamp":1625535165,"share":"https://www.laohu8.com/m/news/1164348327?lang=zh_CN&edition=full","pubTime":"2021-07-06 09:32","market":"us","language":"en","title":"5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1164348327","media":"The motley fool","summary":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The ben","content":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&amp;P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.<blockquote>在过去的15个月里，华尔街和投资者享受了历史性的反弹。基准标普500自2020年3月23日触及熊市底部以来，已上涨超过90%。</blockquote> While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.<blockquote>虽然许多高质量和创新的企业引领了这场反弹，但它也让相当多糟糕的公司蓬勃发展。我建议像七月瘟疫一样避开以下五只超受欢迎的股票。</blockquote> Coinbase Global<blockquote>比特币基地全球</blockquote> First up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin&nbsp;andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.<blockquote>首先是加密货币交易所和生态系统比特币基地全球（纳斯达克：硬币）。Coinbase很受欢迎，因为投资者纷纷涌入Coinbase等公司，其第一季度收入和利润飙升得如此之快比特币和以太币.问题是有三种催化剂对Coinbase经纪模式不利。</blockquote> To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.<blockquote>首先，没有什么可以阻止竞争交易所降低Coinbase Global的费用。目前它可能具有经过验证的用户优势，但不要低估加密货币投资者为节省交易费用而跳槽的意愿。我们在传统券商中目睹了这一点，该行业最终实现了免佣金。</blockquote> Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.<blockquote>其次，加密货币有繁荣和萧条周期的历史。在过去十年中，比特币曾发生过三起独立的事件，其价值至少缩水80%。这是一项完全基于动量的投资，当上行动力枯竭时，Coinbase的交易收入也会枯竭。继2017年达到峰值后，Coinbase的收入在随后几年几乎减半。</blockquote> And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.<blockquote>第三，根据CoinShares数字资产基金流量周刊的数据，截至6月28日的过去四周内，加密货币资金流出量为2.573亿美元。这进一步证明，随着这些资产远低于高点，人们对加密货币的兴趣已经在下降。可以说，Coinbase并不是一只您未来想要拥有的股票。</blockquote> Cassava Sciences<blockquote>木薯科学</blockquote> Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).<blockquote>另一家风险回报比糟糕的超受欢迎公司是临床阶段的生物技术股票木薯科学（纳斯达克：萨瓦）。</blockquote> Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.<blockquote>Cassava在2月份宣布了simufilam治疗阿尔茨海默病的中期分析的积极临床数据，这理所当然地引起了轰动。这项开放标签试验显示，在六个月时认知和行为有所改善，最近允许Cassava概述其涉及其主要候选药物的3期试验计划。</blockquote> I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.<blockquote>我希望simufilam能够成功，但历史表明阿尔茨海默氏症是<a href=\"https://laohu8.com/S/AONE\">一</a>最难治疗的疾病。除了BiogenAduhelm获得了美国食品和药物管理局(FDA)的批准，但因缺乏明确的益处而受到严厉批评，十多年来，每种阿尔茨海默病药物都在后期研究中失败。投资者所要做的就是一项旨在招募100名患者的试验的早期开放标签数据。在大型3期阿尔茨海默病试验中，早期或中期的积极结果被粉碎的情况并不罕见。</blockquote> Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.<blockquote>尽管Cassava筹集了大量现金来继续其研究，但历史表明simufilam成功的机会非常渺茫。这使得木薯科学很容易避免。</blockquote> GameStop<blockquote>游戏驿站</blockquote> If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).<blockquote>如果您一直在关注零售贸易运动（即Reddit股票），散户投资者正在寻找大量卖空的公司并试图进行轧空，您可能知道视频游戏和配件零售商游戏驿站（纽约证券交易所代码：GME）。</blockquote> On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.<blockquote>在<a href=\"https://laohu8.com/S/AONE.U\">一</a>另一方面，游戏驿站能够利用其最近的名气，通过出售股票为其正在进行的向数字游戏公司的转型筹集资金。这是一项急需的举措，此前电子商务销售额在2020财年增长了191%，在假期期间比去年同期增长了四倍多。</blockquote> However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.<blockquote>然而，这些融资并没有忽视前任管理团队让公司失望的事实。二十年来，实体游戏模式运行良好。然而，当游戏走向数字化时，坚持这种实体模式会让公司陷入不稳定的境地。如今，即使电子商务快速增长，游戏驿站仍在继续亏损，去年同店销售额下降了近10%。数字销售可能在增长，但随着游戏驿站关闭其实体店以降低成本，总收入将无处可去。</blockquote> GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.<blockquote>游戏驿站绝不是破产的候选者，我实际上可以看到几年后实现盈利的道路。但话虽如此，考虑到未来漫长的转型和运营亏损，所看到的收益毫无意义。</blockquote> Inovio Pharmaceuticals<blockquote>Inovio制药公司</blockquote> Biotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.<blockquote>生物科技股可以提供充足的机会，或者Inovio制药公司（纳斯达克：INO）案例，吸走长期投资者的命脉。</blockquote> Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.<blockquote>Inovio似乎是一家仅基于纸张的有趣公司。它的产品线目前包括十几种治疗癌症、传染病和人乳头瘤病毒的临床候选药物。最有前途的看起来是INO-4800，这是该公司的冠状病毒病2019（COVID-19）候选疫苗，已准备好进行3期研究。但如果你深入研究Inovio的临床表现，你会非常失望。</blockquote> For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.<blockquote>例如，INO-4800在美国已被部分临床搁置，而监管机构要求提供有关Inovio疫苗及其输送系统Cellectra的更多数据。最近，INO-4800的后期资金被美国政府取消，这就是为什么它现在正在为其COVID-19候选药物寻求国际研究。</blockquote> If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.<blockquote>如果你认为我不公平地指责Inovio在新冠肺炎的挣扎，那就更进一步吧。四十年来，Inovio一直未能获得FDA批准的药物。这并不是我希望Inovio发生不好的事情——这是现实，希望和结果很长一段时间都没有与这家公司保持一致。在Inovio在后期临床试验中证明自己之前，值得避免使用。</blockquote> AMC Entertainment<blockquote>AMC院线</blockquote> Finally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.<blockquote>最后，我不能忘记正在进行的抽水和转储计划AMC院线（纽约证券交易所代码：AMC）。尽管在AMC通过发行大量股票和高息债务自救后，散户投资者能够通过1月份的轧空来宣称胜利，但最近的上涨与轧空无关。相反，它主要基于炒作，在留言板上故意混淆具体的基本数据，以及广泛的，公然的错误信息。</blockquote> AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.<blockquote>AMC的散户投资者希望你相信基本面并不重要，但尝试驾驶一辆没有发动机的汽车，看看你能走多远。AMC正在应对行业票房收入连续19年下降的问题，并且随着电影制片厂依赖流媒体，其部分电影独家经营权正在消失。电影院将会有一席之地，但AMC的潜在市场逐年萎缩。</blockquote> AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.<blockquote>AMC的散户投资者还会让您相信该公司在筹集20亿美元资本后状况良好。尽管近期破产传闻已被搁置，但2027年债券价格远未接近面值。你会问，为什么？因为债券持有人不相信AMC会逃脱破产。</blockquote> I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.<blockquote>我一生中见过足够多的泵和转储活动来识别它们，并且AMC检查了所有的框。我的建议是不要做空AMC。我的建议是完全避免。所有的抽水和转储计划最终都会崩溃，AMC也不例外。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nThe motley fool2021-07-06 09:32\n\n</h4>\n</header>\n<article>\nFor the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&amp;P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.<blockquote>在过去的15个月里，华尔街和投资者享受了历史性的反弹。基准标普500自2020年3月23日触及熊市底部以来，已上涨超过90%。</blockquote> While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.<blockquote>虽然许多高质量和创新的企业引领了这场反弹，但它也让相当多糟糕的公司蓬勃发展。我建议像七月瘟疫一样避开以下五只超受欢迎的股票。</blockquote> Coinbase Global<blockquote>比特币基地全球</blockquote> First up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin&nbsp;andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.<blockquote>首先是加密货币交易所和生态系统比特币基地全球（纳斯达克：硬币）。Coinbase很受欢迎，因为投资者纷纷涌入Coinbase等公司，其第一季度收入和利润飙升得如此之快比特币和以太币.问题是有三种催化剂对Coinbase经纪模式不利。</blockquote> To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.<blockquote>首先，没有什么可以阻止竞争交易所降低Coinbase Global的费用。目前它可能具有经过验证的用户优势，但不要低估加密货币投资者为节省交易费用而跳槽的意愿。我们在传统券商中目睹了这一点，该行业最终实现了免佣金。</blockquote> Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.<blockquote>其次，加密货币有繁荣和萧条周期的历史。在过去十年中，比特币曾发生过三起独立的事件，其价值至少缩水80%。这是一项完全基于动量的投资，当上行动力枯竭时，Coinbase的交易收入也会枯竭。继2017年达到峰值后，Coinbase的收入在随后几年几乎减半。</blockquote> And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.<blockquote>第三，根据CoinShares数字资产基金流量周刊的数据，截至6月28日的过去四周内，加密货币资金流出量为2.573亿美元。这进一步证明，随着这些资产远低于高点，人们对加密货币的兴趣已经在下降。可以说，Coinbase并不是一只您未来想要拥有的股票。</blockquote> Cassava Sciences<blockquote>木薯科学</blockquote> Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).<blockquote>另一家风险回报比糟糕的超受欢迎公司是临床阶段的生物技术股票木薯科学（纳斯达克：萨瓦）。</blockquote> Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.<blockquote>Cassava在2月份宣布了simufilam治疗阿尔茨海默病的中期分析的积极临床数据，这理所当然地引起了轰动。这项开放标签试验显示，在六个月时认知和行为有所改善，最近允许Cassava概述其涉及其主要候选药物的3期试验计划。</blockquote> I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.<blockquote>我希望simufilam能够成功，但历史表明阿尔茨海默氏症是<a href=\"https://laohu8.com/S/AONE\">一</a>最难治疗的疾病。除了BiogenAduhelm获得了美国食品和药物管理局(FDA)的批准，但因缺乏明确的益处而受到严厉批评，十多年来，每种阿尔茨海默病药物都在后期研究中失败。投资者所要做的就是一项旨在招募100名患者的试验的早期开放标签数据。在大型3期阿尔茨海默病试验中，早期或中期的积极结果被粉碎的情况并不罕见。</blockquote> Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.<blockquote>尽管Cassava筹集了大量现金来继续其研究，但历史表明simufilam成功的机会非常渺茫。这使得木薯科学很容易避免。</blockquote> GameStop<blockquote>游戏驿站</blockquote> If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).<blockquote>如果您一直在关注零售贸易运动（即Reddit股票），散户投资者正在寻找大量卖空的公司并试图进行轧空，您可能知道视频游戏和配件零售商游戏驿站（纽约证券交易所代码：GME）。</blockquote> On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.<blockquote>在<a href=\"https://laohu8.com/S/AONE.U\">一</a>另一方面，游戏驿站能够利用其最近的名气，通过出售股票为其正在进行的向数字游戏公司的转型筹集资金。这是一项急需的举措，此前电子商务销售额在2020财年增长了191%，在假期期间比去年同期增长了四倍多。</blockquote> However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.<blockquote>然而，这些融资并没有忽视前任管理团队让公司失望的事实。二十年来，实体游戏模式运行良好。然而，当游戏走向数字化时，坚持这种实体模式会让公司陷入不稳定的境地。如今，即使电子商务快速增长，游戏驿站仍在继续亏损，去年同店销售额下降了近10%。数字销售可能在增长，但随着游戏驿站关闭其实体店以降低成本，总收入将无处可去。</blockquote> GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.<blockquote>游戏驿站绝不是破产的候选者，我实际上可以看到几年后实现盈利的道路。但话虽如此，考虑到未来漫长的转型和运营亏损，所看到的收益毫无意义。</blockquote> Inovio Pharmaceuticals<blockquote>Inovio制药公司</blockquote> Biotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.<blockquote>生物科技股可以提供充足的机会，或者Inovio制药公司（纳斯达克：INO）案例，吸走长期投资者的命脉。</blockquote> Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.<blockquote>Inovio似乎是一家仅基于纸张的有趣公司。它的产品线目前包括十几种治疗癌症、传染病和人乳头瘤病毒的临床候选药物。最有前途的看起来是INO-4800，这是该公司的冠状病毒病2019（COVID-19）候选疫苗，已准备好进行3期研究。但如果你深入研究Inovio的临床表现，你会非常失望。</blockquote> For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.<blockquote>例如，INO-4800在美国已被部分临床搁置，而监管机构要求提供有关Inovio疫苗及其输送系统Cellectra的更多数据。最近，INO-4800的后期资金被美国政府取消，这就是为什么它现在正在为其COVID-19候选药物寻求国际研究。</blockquote> If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.<blockquote>如果你认为我不公平地指责Inovio在新冠肺炎的挣扎，那就更进一步吧。四十年来，Inovio一直未能获得FDA批准的药物。这并不是我希望Inovio发生不好的事情——这是现实，希望和结果很长一段时间都没有与这家公司保持一致。在Inovio在后期临床试验中证明自己之前，值得避免使用。</blockquote> AMC Entertainment<blockquote>AMC院线</blockquote> Finally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.<blockquote>最后，我不能忘记正在进行的抽水和转储计划AMC院线（纽约证券交易所代码：AMC）。尽管在AMC通过发行大量股票和高息债务自救后，散户投资者能够通过1月份的轧空来宣称胜利，但最近的上涨与轧空无关。相反，它主要基于炒作，在留言板上故意混淆具体的基本数据，以及广泛的，公然的错误信息。</blockquote> AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.<blockquote>AMC的散户投资者希望你相信基本面并不重要，但尝试驾驶一辆没有发动机的汽车，看看你能走多远。AMC正在应对行业票房收入连续19年下降的问题，并且随着电影制片厂依赖流媒体，其部分电影独家经营权正在消失。电影院将会有一席之地，但AMC的潜在市场逐年萎缩。</blockquote> AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.<blockquote>AMC的散户投资者还会让您相信该公司在筹集20亿美元资本后状况良好。尽管近期破产传闻已被搁置，但2027年债券价格远未接近面值。你会问，为什么？因为债券持有人不相信AMC会逃脱破产。</blockquote> I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.<blockquote>我一生中见过足够多的泵和转储活动来识别它们，并且AMC检查了所有的框。我的建议是不要做空AMC。我的建议是完全避免。所有的抽水和转储计划最终都会崩溃，AMC也不例外。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/\">The motley fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GME":"游戏驿站","SAVA":"Cassava Sciences Inc","INO":"伊诺维奥制药","COIN":"Coinbase Global, Inc.","AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164348327","content_text":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.\nWhile a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.\nCoinbase Global\nFirst up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.\nTo start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.\nSecond,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.\nAnd third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.\nCassava Sciences\nAnother ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).\nCassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.\nI'd love for simufilam to be successful, but history has shown that Alzheimer's is one of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.\nAlthough Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.\nGameStop\nIf you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).\nOn one hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.\nHowever, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.\nGameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.\nInovio Pharmaceuticals\nBiotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.\nInovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.\nFor example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.\nIf you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.\nAMC Entertainment\nFinally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.\nAMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.\nAMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.\nI've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.","news_type":1,"symbols_score_info":{"SAVA":0.9,"INO":0.9,"GME":0.9,"COIN":0.9,"AMC":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":157068326,"gmtCreate":1625554713865,"gmtModify":1631884614003,"author":{"id":"3579782126622830","authorId":"3579782126622830","name":"Sephy","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3579782126622830","authorIdStr":"3579782126622830"},"htmlText":"Newbie&nbsp;analysts gg. Load up coinbase now u will be HUGELY rewarded by August earnings report at least a 20% profit, projected 20-40%.&nbsp;&nbsp;","listText":"Newbie&nbsp;analysts gg. Load up coinbase now u will be HUGELY rewarded by August earnings report at least a 20% profit, projected 20-40%.&nbsp;&nbsp;","text":"Newbie analysts gg. Load up coinbase now u will be HUGELY rewarded by August earnings report at least a 20% profit, projected 20-40%.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/157068326","repostId":1164348327,"repostType":2,"repost":{"id":"1164348327","kind":"news","pubTimestamp":1625535165,"share":"https://www.laohu8.com/m/news/1164348327?lang=zh_CN&edition=full","pubTime":"2021-07-06 09:32","market":"us","language":"en","title":"5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1164348327","media":"The motley fool","summary":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The ben","content":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&amp;P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.<blockquote>在过去的15个月里，华尔街和投资者享受了历史性的反弹。基准标普500自2020年3月23日触及熊市底部以来，已上涨超过90%。</blockquote> While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.<blockquote>虽然许多高质量和创新的企业引领了这场反弹，但它也让相当多糟糕的公司蓬勃发展。我建议像七月瘟疫一样避开以下五只超受欢迎的股票。</blockquote> Coinbase Global<blockquote>比特币基地全球</blockquote> First up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin&nbsp;andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.<blockquote>首先是加密货币交易所和生态系统比特币基地全球（纳斯达克：硬币）。Coinbase很受欢迎，因为投资者纷纷涌入Coinbase等公司，其第一季度收入和利润飙升得如此之快比特币和以太币.问题是有三种催化剂对Coinbase经纪模式不利。</blockquote> To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.<blockquote>首先，没有什么可以阻止竞争交易所降低Coinbase Global的费用。目前它可能具有经过验证的用户优势，但不要低估加密货币投资者为节省交易费用而跳槽的意愿。我们在传统券商中目睹了这一点，该行业最终实现了免佣金。</blockquote> Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.<blockquote>其次，加密货币有繁荣和萧条周期的历史。在过去十年中，比特币曾发生过三起独立的事件，其价值至少缩水80%。这是一项完全基于动量的投资，当上行动力枯竭时，Coinbase的交易收入也会枯竭。继2017年达到峰值后，Coinbase的收入在随后几年几乎减半。</blockquote> And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.<blockquote>第三，根据CoinShares数字资产基金流量周刊的数据，截至6月28日的过去四周内，加密货币资金流出量为2.573亿美元。这进一步证明，随着这些资产远低于高点，人们对加密货币的兴趣已经在下降。可以说，Coinbase并不是一只您未来想要拥有的股票。</blockquote> Cassava Sciences<blockquote>木薯科学</blockquote> Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).<blockquote>另一家风险回报比糟糕的超受欢迎公司是临床阶段的生物技术股票木薯科学（纳斯达克：萨瓦）。</blockquote> Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.<blockquote>Cassava在2月份宣布了simufilam治疗阿尔茨海默病的中期分析的积极临床数据，这理所当然地引起了轰动。这项开放标签试验显示，在六个月时认知和行为有所改善，最近允许Cassava概述其涉及其主要候选药物的3期试验计划。</blockquote> I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.<blockquote>我希望simufilam能够成功，但历史表明阿尔茨海默氏症是<a href=\"https://laohu8.com/S/AONE\">一</a>最难治疗的疾病。除了BiogenAduhelm获得了美国食品和药物管理局(FDA)的批准，但因缺乏明确的益处而受到严厉批评，十多年来，每种阿尔茨海默病药物都在后期研究中失败。投资者所要做的就是一项旨在招募100名患者的试验的早期开放标签数据。在大型3期阿尔茨海默病试验中，早期或中期的积极结果被粉碎的情况并不罕见。</blockquote> Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.<blockquote>尽管Cassava筹集了大量现金来继续其研究，但历史表明simufilam成功的机会非常渺茫。这使得木薯科学很容易避免。</blockquote> GameStop<blockquote>游戏驿站</blockquote> If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).<blockquote>如果您一直在关注零售贸易运动（即Reddit股票），散户投资者正在寻找大量卖空的公司并试图进行轧空，您可能知道视频游戏和配件零售商游戏驿站（纽约证券交易所代码：GME）。</blockquote> On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.<blockquote>在<a href=\"https://laohu8.com/S/AONE.U\">一</a>另一方面，游戏驿站能够利用其最近的名气，通过出售股票为其正在进行的向数字游戏公司的转型筹集资金。这是一项急需的举措，此前电子商务销售额在2020财年增长了191%，在假期期间比去年同期增长了四倍多。</blockquote> However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.<blockquote>然而，这些融资并没有忽视前任管理团队让公司失望的事实。二十年来，实体游戏模式运行良好。然而，当游戏走向数字化时，坚持这种实体模式会让公司陷入不稳定的境地。如今，即使电子商务快速增长，游戏驿站仍在继续亏损，去年同店销售额下降了近10%。数字销售可能在增长，但随着游戏驿站关闭其实体店以降低成本，总收入将无处可去。</blockquote> GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.<blockquote>游戏驿站绝不是破产的候选者，我实际上可以看到几年后实现盈利的道路。但话虽如此，考虑到未来漫长的转型和运营亏损，所看到的收益毫无意义。</blockquote> Inovio Pharmaceuticals<blockquote>Inovio制药公司</blockquote> Biotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.<blockquote>生物科技股可以提供充足的机会，或者Inovio制药公司（纳斯达克：INO）案例，吸走长期投资者的命脉。</blockquote> Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.<blockquote>Inovio似乎是一家仅基于纸张的有趣公司。它的产品线目前包括十几种治疗癌症、传染病和人乳头瘤病毒的临床候选药物。最有前途的看起来是INO-4800，这是该公司的冠状病毒病2019（COVID-19）候选疫苗，已准备好进行3期研究。但如果你深入研究Inovio的临床表现，你会非常失望。</blockquote> For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.<blockquote>例如，INO-4800在美国已被部分临床搁置，而监管机构要求提供有关Inovio疫苗及其输送系统Cellectra的更多数据。最近，INO-4800的后期资金被美国政府取消，这就是为什么它现在正在为其COVID-19候选药物寻求国际研究。</blockquote> If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.<blockquote>如果你认为我不公平地指责Inovio在新冠肺炎的挣扎，那就更进一步吧。四十年来，Inovio一直未能获得FDA批准的药物。这并不是我希望Inovio发生不好的事情——这是现实，希望和结果很长一段时间都没有与这家公司保持一致。在Inovio在后期临床试验中证明自己之前，值得避免使用。</blockquote> AMC Entertainment<blockquote>AMC院线</blockquote> Finally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.<blockquote>最后，我不能忘记正在进行的抽水和转储计划AMC院线（纽约证券交易所代码：AMC）。尽管在AMC通过发行大量股票和高息债务自救后，散户投资者能够通过1月份的轧空来宣称胜利，但最近的上涨与轧空无关。相反，它主要基于炒作，在留言板上故意混淆具体的基本数据，以及广泛的，公然的错误信息。</blockquote> AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.<blockquote>AMC的散户投资者希望你相信基本面并不重要，但尝试驾驶一辆没有发动机的汽车，看看你能走多远。AMC正在应对行业票房收入连续19年下降的问题，并且随着电影制片厂依赖流媒体，其部分电影独家经营权正在消失。电影院将会有一席之地，但AMC的潜在市场逐年萎缩。</blockquote> AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.<blockquote>AMC的散户投资者还会让您相信该公司在筹集20亿美元资本后状况良好。尽管近期破产传闻已被搁置，但2027年债券价格远未接近面值。你会问，为什么？因为债券持有人不相信AMC会逃脱破产。</blockquote> I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.<blockquote>我一生中见过足够多的泵和转储活动来识别它们，并且AMC检查了所有的框。我的建议是不要做空AMC。我的建议是完全避免。所有的抽水和转储计划最终都会崩溃，AMC也不例外。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nThe motley fool2021-07-06 09:32\n\n</h4>\n</header>\n<article>\nFor the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&amp;P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.<blockquote>在过去的15个月里，华尔街和投资者享受了历史性的反弹。基准标普500自2020年3月23日触及熊市底部以来，已上涨超过90%。</blockquote> While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.<blockquote>虽然许多高质量和创新的企业引领了这场反弹，但它也让相当多糟糕的公司蓬勃发展。我建议像七月瘟疫一样避开以下五只超受欢迎的股票。</blockquote> Coinbase Global<blockquote>比特币基地全球</blockquote> First up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin&nbsp;andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.<blockquote>首先是加密货币交易所和生态系统比特币基地全球（纳斯达克：硬币）。Coinbase很受欢迎，因为投资者纷纷涌入Coinbase等公司，其第一季度收入和利润飙升得如此之快比特币和以太币.问题是有三种催化剂对Coinbase经纪模式不利。</blockquote> To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.<blockquote>首先，没有什么可以阻止竞争交易所降低Coinbase Global的费用。目前它可能具有经过验证的用户优势，但不要低估加密货币投资者为节省交易费用而跳槽的意愿。我们在传统券商中目睹了这一点，该行业最终实现了免佣金。</blockquote> Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.<blockquote>其次，加密货币有繁荣和萧条周期的历史。在过去十年中，比特币曾发生过三起独立的事件，其价值至少缩水80%。这是一项完全基于动量的投资，当上行动力枯竭时，Coinbase的交易收入也会枯竭。继2017年达到峰值后，Coinbase的收入在随后几年几乎减半。</blockquote> And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.<blockquote>第三，根据CoinShares数字资产基金流量周刊的数据，截至6月28日的过去四周内，加密货币资金流出量为2.573亿美元。这进一步证明，随着这些资产远低于高点，人们对加密货币的兴趣已经在下降。可以说，Coinbase并不是一只您未来想要拥有的股票。</blockquote> Cassava Sciences<blockquote>木薯科学</blockquote> Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).<blockquote>另一家风险回报比糟糕的超受欢迎公司是临床阶段的生物技术股票木薯科学（纳斯达克：萨瓦）。</blockquote> Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.<blockquote>Cassava在2月份宣布了simufilam治疗阿尔茨海默病的中期分析的积极临床数据，这理所当然地引起了轰动。这项开放标签试验显示，在六个月时认知和行为有所改善，最近允许Cassava概述其涉及其主要候选药物的3期试验计划。</blockquote> I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.<blockquote>我希望simufilam能够成功，但历史表明阿尔茨海默氏症是<a href=\"https://laohu8.com/S/AONE\">一</a>最难治疗的疾病。除了BiogenAduhelm获得了美国食品和药物管理局(FDA)的批准，但因缺乏明确的益处而受到严厉批评，十多年来，每种阿尔茨海默病药物都在后期研究中失败。投资者所要做的就是一项旨在招募100名患者的试验的早期开放标签数据。在大型3期阿尔茨海默病试验中，早期或中期的积极结果被粉碎的情况并不罕见。</blockquote> Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.<blockquote>尽管Cassava筹集了大量现金来继续其研究，但历史表明simufilam成功的机会非常渺茫。这使得木薯科学很容易避免。</blockquote> GameStop<blockquote>游戏驿站</blockquote> If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).<blockquote>如果您一直在关注零售贸易运动（即Reddit股票），散户投资者正在寻找大量卖空的公司并试图进行轧空，您可能知道视频游戏和配件零售商游戏驿站（纽约证券交易所代码：GME）。</blockquote> On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.<blockquote>在<a href=\"https://laohu8.com/S/AONE.U\">一</a>另一方面，游戏驿站能够利用其最近的名气，通过出售股票为其正在进行的向数字游戏公司的转型筹集资金。这是一项急需的举措，此前电子商务销售额在2020财年增长了191%，在假期期间比去年同期增长了四倍多。</blockquote> However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.<blockquote>然而，这些融资并没有忽视前任管理团队让公司失望的事实。二十年来，实体游戏模式运行良好。然而，当游戏走向数字化时，坚持这种实体模式会让公司陷入不稳定的境地。如今，即使电子商务快速增长，游戏驿站仍在继续亏损，去年同店销售额下降了近10%。数字销售可能在增长，但随着游戏驿站关闭其实体店以降低成本，总收入将无处可去。</blockquote> GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.<blockquote>游戏驿站绝不是破产的候选者，我实际上可以看到几年后实现盈利的道路。但话虽如此，考虑到未来漫长的转型和运营亏损，所看到的收益毫无意义。</blockquote> Inovio Pharmaceuticals<blockquote>Inovio制药公司</blockquote> Biotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.<blockquote>生物科技股可以提供充足的机会，或者Inovio制药公司（纳斯达克：INO）案例，吸走长期投资者的命脉。</blockquote> Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.<blockquote>Inovio似乎是一家仅基于纸张的有趣公司。它的产品线目前包括十几种治疗癌症、传染病和人乳头瘤病毒的临床候选药物。最有前途的看起来是INO-4800，这是该公司的冠状病毒病2019（COVID-19）候选疫苗，已准备好进行3期研究。但如果你深入研究Inovio的临床表现，你会非常失望。</blockquote> For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.<blockquote>例如，INO-4800在美国已被部分临床搁置，而监管机构要求提供有关Inovio疫苗及其输送系统Cellectra的更多数据。最近，INO-4800的后期资金被美国政府取消，这就是为什么它现在正在为其COVID-19候选药物寻求国际研究。</blockquote> If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.<blockquote>如果你认为我不公平地指责Inovio在新冠肺炎的挣扎，那就更进一步吧。四十年来，Inovio一直未能获得FDA批准的药物。这并不是我希望Inovio发生不好的事情——这是现实，希望和结果很长一段时间都没有与这家公司保持一致。在Inovio在后期临床试验中证明自己之前，值得避免使用。</blockquote> AMC Entertainment<blockquote>AMC院线</blockquote> Finally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.<blockquote>最后，我不能忘记正在进行的抽水和转储计划AMC院线（纽约证券交易所代码：AMC）。尽管在AMC通过发行大量股票和高息债务自救后，散户投资者能够通过1月份的轧空来宣称胜利，但最近的上涨与轧空无关。相反，它主要基于炒作，在留言板上故意混淆具体的基本数据，以及广泛的，公然的错误信息。</blockquote> AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.<blockquote>AMC的散户投资者希望你相信基本面并不重要，但尝试驾驶一辆没有发动机的汽车，看看你能走多远。AMC正在应对行业票房收入连续19年下降的问题，并且随着电影制片厂依赖流媒体，其部分电影独家经营权正在消失。电影院将会有一席之地，但AMC的潜在市场逐年萎缩。</blockquote> AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.<blockquote>AMC的散户投资者还会让您相信该公司在筹集20亿美元资本后状况良好。尽管近期破产传闻已被搁置，但2027年债券价格远未接近面值。你会问，为什么？因为债券持有人不相信AMC会逃脱破产。</blockquote> I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.<blockquote>我一生中见过足够多的泵和转储活动来识别它们，并且AMC检查了所有的框。我的建议是不要做空AMC。我的建议是完全避免。所有的抽水和转储计划最终都会崩溃，AMC也不例外。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/\">The motley fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GME":"游戏驿站","SAVA":"Cassava Sciences Inc","INO":"伊诺维奥制药","COIN":"Coinbase Global, Inc.","AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164348327","content_text":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.\nWhile a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.\nCoinbase Global\nFirst up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.\nTo start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.\nSecond,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.\nAnd third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.\nCassava Sciences\nAnother ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).\nCassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.\nI'd love for simufilam to be successful, but history has shown that Alzheimer's is one of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.\nAlthough Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.\nGameStop\nIf you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).\nOn one hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.\nHowever, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.\nGameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.\nInovio Pharmaceuticals\nBiotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.\nInovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.\nFor example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.\nIf you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.\nAMC Entertainment\nFinally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.\nAMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.\nAMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.\nI've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.","news_type":1,"symbols_score_info":{"SAVA":0.9,"INO":0.9,"GME":0.9,"COIN":0.9,"AMC":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5136859,"gmtCreate":1625566914781,"gmtModify":1635236002796,"authorId":3579334079758210,"author":{"id":3579334079758210,"idStr":"3579334079758210","authorId":3579334079758210,"name":"6c65da76","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":157068326,"type":1,"supId":0,"prevId":0,"content":"Seems Like you are a bagholder, Its a pump and dump, I got burnt in this stock too.","text":"Seems Like you are a bagholder, Its a pump and dump, I got burnt in this stock too.","html":"Seems Like you are a bagholder, Its a pump and dump, I got burnt in this stock too."},{"id":5136865,"gmtCreate":1625566956617,"gmtModify":1635236002290,"authorId":3579334079758210,"author":{"id":3579334079758210,"idStr":"3579334079758210","authorId":3579334079758210,"name":"6c65da76","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":157068326,"type":1,"supId":0,"prevId":0,"content":"Look how ERs didnt even affect the stock price hugely","text":"Look how ERs didnt even affect the stock price hugely","html":"Look how ERs didnt even affect the stock price hugely"},{"id":5138635,"gmtCreate":1625578387374,"gmtModify":1635235883358,"authorId":3579782126622830,"author":{"id":3579782126622830,"idStr":"3579782126622830","authorId":3579782126622830,"name":"Sephy","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":157068326,"type":1,"supId":5136865,"prevId":0,"content":"its correlated to bitcoin and ethereum prices","text":"its correlated to bitcoin and ethereum prices","html":"its correlated to bitcoin and ethereum prices"},{"id":5138717,"gmtCreate":1625578658767,"gmtModify":1635235877992,"authorId":3579782126622830,"author":{"id":3579782126622830,"idStr":"3579782126622830","authorId":3579782126622830,"name":"Sephy","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":3579782126622830,"repliedAuthor":{"id":3579782126622830,"idStr":"3579782126622830","authorId":3579782126622830,"name":"Sephy","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"objectId":157068326,"type":1,"supId":5136859,"prevId":5138681,"content":"The previous ER their price went up to 300, the upcoming ER i am confident it will go to 32x at least depending on btc n eth price","text":"The previous ER their price went up to 300, the upcoming ER i am confident it will go to 32x at least depending on btc n eth price","html":"The previous ER their price went up to 300, the upcoming ER i am confident it will go to 32x at least depending on btc n eth price"},{"id":5138775,"gmtCreate":1625578847799,"gmtModify":1635235874673,"authorId":3579782126622830,"author":{"id":3579782126622830,"idStr":"3579782126622830","authorId":3579782126622830,"name":"Sephy","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":157068326,"type":1,"supId":5136859,"prevId":0,"content":"Btw im not a bagholder im a professional trader, good luck @@","text":"Btw im not a bagholder im a professional trader, good luck @@","html":"Btw im not a bagholder im a professional trader, good luck @@"}],"langContent":"EN"},{"id":157018461,"gmtCreate":1625552980053,"gmtModify":1631890737445,"author":{"id":"4088222297029790","authorId":"4088222297029790","name":"StanleyO","avatar":"https://static.tigerbbs.com/95419e33f00da5cc2a2d8341c1c80638","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"4088222297029790","authorIdStr":"4088222297029790"},"htmlText":"Good Read","listText":"Good Read","text":"Good Read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/157018461","repostId":1164348327,"repostType":4,"repost":{"id":"1164348327","kind":"news","pubTimestamp":1625535165,"share":"https://www.laohu8.com/m/news/1164348327?lang=zh_CN&edition=full","pubTime":"2021-07-06 09:32","market":"us","language":"en","title":"5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1164348327","media":"The motley fool","summary":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The ben","content":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&amp;P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.<blockquote>在过去的15个月里，华尔街和投资者享受了历史性的反弹。基准标普500自2020年3月23日触及熊市底部以来，已上涨超过90%。</blockquote> While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.<blockquote>虽然许多高质量和创新的企业引领了这场反弹，但它也让相当多糟糕的公司蓬勃发展。我建议像七月瘟疫一样避开以下五只超受欢迎的股票。</blockquote> Coinbase Global<blockquote>比特币基地全球</blockquote> First up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin&nbsp;andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.<blockquote>首先是加密货币交易所和生态系统比特币基地全球（纳斯达克：硬币）。Coinbase很受欢迎，因为投资者纷纷涌入Coinbase等公司，其第一季度收入和利润飙升得如此之快比特币和以太币.问题是有三种催化剂对Coinbase经纪模式不利。</blockquote> To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.<blockquote>首先，没有什么可以阻止竞争交易所降低Coinbase Global的费用。目前它可能具有经过验证的用户优势，但不要低估加密货币投资者为节省交易费用而跳槽的意愿。我们在传统券商中目睹了这一点，该行业最终实现了免佣金。</blockquote> Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.<blockquote>其次，加密货币有繁荣和萧条周期的历史。在过去十年中，比特币曾发生过三起独立的事件，其价值至少缩水80%。这是一项完全基于动量的投资，当上行动力枯竭时，Coinbase的交易收入也会枯竭。继2017年达到峰值后，Coinbase的收入在随后几年几乎减半。</blockquote> And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.<blockquote>第三，根据CoinShares数字资产基金流量周刊的数据，截至6月28日的过去四周内，加密货币资金流出量为2.573亿美元。这进一步证明，随着这些资产远低于高点，人们对加密货币的兴趣已经在下降。可以说，Coinbase并不是一只您未来想要拥有的股票。</blockquote> Cassava Sciences<blockquote>木薯科学</blockquote> Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).<blockquote>另一家风险回报比糟糕的超受欢迎公司是临床阶段的生物技术股票木薯科学（纳斯达克：萨瓦）。</blockquote> Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.<blockquote>Cassava在2月份宣布了simufilam治疗阿尔茨海默病的中期分析的积极临床数据，这理所当然地引起了轰动。这项开放标签试验显示，在六个月时认知和行为有所改善，最近允许Cassava概述其涉及其主要候选药物的3期试验计划。</blockquote> I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.<blockquote>我希望simufilam能够成功，但历史表明阿尔茨海默氏症是<a href=\"https://laohu8.com/S/AONE\">一</a>最难治疗的疾病。除了BiogenAduhelm获得了美国食品和药物管理局(FDA)的批准，但因缺乏明确的益处而受到严厉批评，十多年来，每种阿尔茨海默病药物都在后期研究中失败。投资者所要做的就是一项旨在招募100名患者的试验的早期开放标签数据。在大型3期阿尔茨海默病试验中，早期或中期的积极结果被粉碎的情况并不罕见。</blockquote> Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.<blockquote>尽管Cassava筹集了大量现金来继续其研究，但历史表明simufilam成功的机会非常渺茫。这使得木薯科学很容易避免。</blockquote> GameStop<blockquote>游戏驿站</blockquote> If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).<blockquote>如果您一直在关注零售贸易运动（即Reddit股票），散户投资者正在寻找大量卖空的公司并试图进行轧空，您可能知道视频游戏和配件零售商游戏驿站（纽约证券交易所代码：GME）。</blockquote> On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.<blockquote>在<a href=\"https://laohu8.com/S/AONE.U\">一</a>另一方面，游戏驿站能够利用其最近的名气，通过出售股票为其正在进行的向数字游戏公司的转型筹集资金。这是一项急需的举措，此前电子商务销售额在2020财年增长了191%，在假期期间比去年同期增长了四倍多。</blockquote> However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.<blockquote>然而，这些融资并没有忽视前任管理团队让公司失望的事实。二十年来，实体游戏模式运行良好。然而，当游戏走向数字化时，坚持这种实体模式会让公司陷入不稳定的境地。如今，即使电子商务快速增长，游戏驿站仍在继续亏损，去年同店销售额下降了近10%。数字销售可能在增长，但随着游戏驿站关闭其实体店以降低成本，总收入将无处可去。</blockquote> GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.<blockquote>游戏驿站绝不是破产的候选者，我实际上可以看到几年后实现盈利的道路。但话虽如此，考虑到未来漫长的转型和运营亏损，所看到的收益毫无意义。</blockquote> Inovio Pharmaceuticals<blockquote>Inovio制药公司</blockquote> Biotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.<blockquote>生物科技股可以提供充足的机会，或者Inovio制药公司（纳斯达克：INO）案例，吸走长期投资者的命脉。</blockquote> Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.<blockquote>Inovio似乎是一家仅基于纸张的有趣公司。它的产品线目前包括十几种治疗癌症、传染病和人乳头瘤病毒的临床候选药物。最有前途的看起来是INO-4800，这是该公司的冠状病毒病2019（COVID-19）候选疫苗，已准备好进行3期研究。但如果你深入研究Inovio的临床表现，你会非常失望。</blockquote> For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.<blockquote>例如，INO-4800在美国已被部分临床搁置，而监管机构要求提供有关Inovio疫苗及其输送系统Cellectra的更多数据。最近，INO-4800的后期资金被美国政府取消，这就是为什么它现在正在为其COVID-19候选药物寻求国际研究。</blockquote> If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.<blockquote>如果你认为我不公平地指责Inovio在新冠肺炎的挣扎，那就更进一步吧。四十年来，Inovio一直未能获得FDA批准的药物。这并不是我希望Inovio发生不好的事情——这是现实，希望和结果很长一段时间都没有与这家公司保持一致。在Inovio在后期临床试验中证明自己之前，值得避免使用。</blockquote> AMC Entertainment<blockquote>AMC院线</blockquote> Finally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.<blockquote>最后，我不能忘记正在进行的抽水和转储计划AMC院线（纽约证券交易所代码：AMC）。尽管在AMC通过发行大量股票和高息债务自救后，散户投资者能够通过1月份的轧空来宣称胜利，但最近的上涨与轧空无关。相反，它主要基于炒作，在留言板上故意混淆具体的基本数据，以及广泛的，公然的错误信息。</blockquote> AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.<blockquote>AMC的散户投资者希望你相信基本面并不重要，但尝试驾驶一辆没有发动机的汽车，看看你能走多远。AMC正在应对行业票房收入连续19年下降的问题，并且随着电影制片厂依赖流媒体，其部分电影独家经营权正在消失。电影院将会有一席之地，但AMC的潜在市场逐年萎缩。</blockquote> AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.<blockquote>AMC的散户投资者还会让您相信该公司在筹集20亿美元资本后状况良好。尽管近期破产传闻已被搁置，但2027年债券价格远未接近面值。你会问，为什么？因为债券持有人不相信AMC会逃脱破产。</blockquote> I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.<blockquote>我一生中见过足够多的泵和转储活动来识别它们，并且AMC检查了所有的框。我的建议是不要做空AMC。我的建议是完全避免。所有的抽水和转储计划最终都会崩溃，AMC也不例外。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nThe motley fool2021-07-06 09:32\n\n</h4>\n</header>\n<article>\nFor the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&amp;P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.<blockquote>在过去的15个月里，华尔街和投资者享受了历史性的反弹。基准标普500自2020年3月23日触及熊市底部以来，已上涨超过90%。</blockquote> While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.<blockquote>虽然许多高质量和创新的企业引领了这场反弹，但它也让相当多糟糕的公司蓬勃发展。我建议像七月瘟疫一样避开以下五只超受欢迎的股票。</blockquote> Coinbase Global<blockquote>比特币基地全球</blockquote> First up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin&nbsp;andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.<blockquote>首先是加密货币交易所和生态系统比特币基地全球（纳斯达克：硬币）。Coinbase很受欢迎，因为投资者纷纷涌入Coinbase等公司，其第一季度收入和利润飙升得如此之快比特币和以太币.问题是有三种催化剂对Coinbase经纪模式不利。</blockquote> To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.<blockquote>首先，没有什么可以阻止竞争交易所降低Coinbase Global的费用。目前它可能具有经过验证的用户优势，但不要低估加密货币投资者为节省交易费用而跳槽的意愿。我们在传统券商中目睹了这一点，该行业最终实现了免佣金。</blockquote> Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.<blockquote>其次，加密货币有繁荣和萧条周期的历史。在过去十年中，比特币曾发生过三起独立的事件，其价值至少缩水80%。这是一项完全基于动量的投资，当上行动力枯竭时，Coinbase的交易收入也会枯竭。继2017年达到峰值后，Coinbase的收入在随后几年几乎减半。</blockquote> And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.<blockquote>第三，根据CoinShares数字资产基金流量周刊的数据，截至6月28日的过去四周内，加密货币资金流出量为2.573亿美元。这进一步证明，随着这些资产远低于高点，人们对加密货币的兴趣已经在下降。可以说，Coinbase并不是一只您未来想要拥有的股票。</blockquote> Cassava Sciences<blockquote>木薯科学</blockquote> Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).<blockquote>另一家风险回报比糟糕的超受欢迎公司是临床阶段的生物技术股票木薯科学（纳斯达克：萨瓦）。</blockquote> Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.<blockquote>Cassava在2月份宣布了simufilam治疗阿尔茨海默病的中期分析的积极临床数据，这理所当然地引起了轰动。这项开放标签试验显示，在六个月时认知和行为有所改善，最近允许Cassava概述其涉及其主要候选药物的3期试验计划。</blockquote> I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.<blockquote>我希望simufilam能够成功，但历史表明阿尔茨海默氏症是<a href=\"https://laohu8.com/S/AONE\">一</a>最难治疗的疾病。除了BiogenAduhelm获得了美国食品和药物管理局(FDA)的批准，但因缺乏明确的益处而受到严厉批评，十多年来，每种阿尔茨海默病药物都在后期研究中失败。投资者所要做的就是一项旨在招募100名患者的试验的早期开放标签数据。在大型3期阿尔茨海默病试验中，早期或中期的积极结果被粉碎的情况并不罕见。</blockquote> Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.<blockquote>尽管Cassava筹集了大量现金来继续其研究，但历史表明simufilam成功的机会非常渺茫。这使得木薯科学很容易避免。</blockquote> GameStop<blockquote>游戏驿站</blockquote> If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).<blockquote>如果您一直在关注零售贸易运动（即Reddit股票），散户投资者正在寻找大量卖空的公司并试图进行轧空，您可能知道视频游戏和配件零售商游戏驿站（纽约证券交易所代码：GME）。</blockquote> On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.<blockquote>在<a href=\"https://laohu8.com/S/AONE.U\">一</a>另一方面，游戏驿站能够利用其最近的名气，通过出售股票为其正在进行的向数字游戏公司的转型筹集资金。这是一项急需的举措，此前电子商务销售额在2020财年增长了191%，在假期期间比去年同期增长了四倍多。</blockquote> However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.<blockquote>然而，这些融资并没有忽视前任管理团队让公司失望的事实。二十年来，实体游戏模式运行良好。然而，当游戏走向数字化时，坚持这种实体模式会让公司陷入不稳定的境地。如今，即使电子商务快速增长，游戏驿站仍在继续亏损，去年同店销售额下降了近10%。数字销售可能在增长，但随着游戏驿站关闭其实体店以降低成本，总收入将无处可去。</blockquote> GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.<blockquote>游戏驿站绝不是破产的候选者，我实际上可以看到几年后实现盈利的道路。但话虽如此，考虑到未来漫长的转型和运营亏损，所看到的收益毫无意义。</blockquote> Inovio Pharmaceuticals<blockquote>Inovio制药公司</blockquote> Biotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.<blockquote>生物科技股可以提供充足的机会，或者Inovio制药公司（纳斯达克：INO）案例，吸走长期投资者的命脉。</blockquote> Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.<blockquote>Inovio似乎是一家仅基于纸张的有趣公司。它的产品线目前包括十几种治疗癌症、传染病和人乳头瘤病毒的临床候选药物。最有前途的看起来是INO-4800，这是该公司的冠状病毒病2019（COVID-19）候选疫苗，已准备好进行3期研究。但如果你深入研究Inovio的临床表现，你会非常失望。</blockquote> For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.<blockquote>例如，INO-4800在美国已被部分临床搁置，而监管机构要求提供有关Inovio疫苗及其输送系统Cellectra的更多数据。最近，INO-4800的后期资金被美国政府取消，这就是为什么它现在正在为其COVID-19候选药物寻求国际研究。</blockquote> If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.<blockquote>如果你认为我不公平地指责Inovio在新冠肺炎的挣扎，那就更进一步吧。四十年来，Inovio一直未能获得FDA批准的药物。这并不是我希望Inovio发生不好的事情——这是现实，希望和结果很长一段时间都没有与这家公司保持一致。在Inovio在后期临床试验中证明自己之前，值得避免使用。</blockquote> AMC Entertainment<blockquote>AMC院线</blockquote> Finally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.<blockquote>最后，我不能忘记正在进行的抽水和转储计划AMC院线（纽约证券交易所代码：AMC）。尽管在AMC通过发行大量股票和高息债务自救后，散户投资者能够通过1月份的轧空来宣称胜利，但最近的上涨与轧空无关。相反，它主要基于炒作，在留言板上故意混淆具体的基本数据，以及广泛的，公然的错误信息。</blockquote> AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.<blockquote>AMC的散户投资者希望你相信基本面并不重要，但尝试驾驶一辆没有发动机的汽车，看看你能走多远。AMC正在应对行业票房收入连续19年下降的问题，并且随着电影制片厂依赖流媒体，其部分电影独家经营权正在消失。电影院将会有一席之地，但AMC的潜在市场逐年萎缩。</blockquote> AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.<blockquote>AMC的散户投资者还会让您相信该公司在筹集20亿美元资本后状况良好。尽管近期破产传闻已被搁置，但2027年债券价格远未接近面值。你会问，为什么？因为债券持有人不相信AMC会逃脱破产。</blockquote> I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.<blockquote>我一生中见过足够多的泵和转储活动来识别它们，并且AMC检查了所有的框。我的建议是不要做空AMC。我的建议是完全避免。所有的抽水和转储计划最终都会崩溃，AMC也不例外。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/\">The motley fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GME":"游戏驿站","SAVA":"Cassava Sciences Inc","INO":"伊诺维奥制药","COIN":"Coinbase Global, Inc.","AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164348327","content_text":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.\nWhile a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.\nCoinbase Global\nFirst up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.\nTo start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.\nSecond,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.\nAnd third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.\nCassava Sciences\nAnother ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).\nCassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.\nI'd love for simufilam to be successful, but history has shown that Alzheimer's is one of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.\nAlthough Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.\nGameStop\nIf you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).\nOn one hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.\nHowever, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.\nGameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.\nInovio Pharmaceuticals\nBiotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.\nInovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.\nFor example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.\nIf you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.\nAMC Entertainment\nFinally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.\nAMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.\nAMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.\nI've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.","news_type":1,"symbols_score_info":{"SAVA":0.9,"INO":0.9,"GME":0.9,"COIN":0.9,"AMC":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":157001438,"gmtCreate":1625550244324,"gmtModify":1633939729034,"author":{"id":"3566293775093626","authorId":"3566293775093626","name":"Patek1975","avatar":"https://static.tigerbbs.com/a2e5f9a5d563704aaf5f2473be16f148","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3566293775093626","authorIdStr":"3566293775093626"},"htmlText":"Lousy article as usual from fools , how much yougetting paid for this article&nbsp;","listText":"Lousy article as usual from fools , how much yougetting paid for this article&nbsp;","text":"Lousy article as usual from fools , how much yougetting paid for this article","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/157001438","repostId":1164348327,"repostType":2,"repost":{"id":"1164348327","kind":"news","pubTimestamp":1625535165,"share":"https://www.laohu8.com/m/news/1164348327?lang=zh_CN&edition=full","pubTime":"2021-07-06 09:32","market":"us","language":"en","title":"5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1164348327","media":"The motley fool","summary":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The ben","content":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&amp;P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.<blockquote>在过去的15个月里，华尔街和投资者享受了历史性的反弹。基准标普500自2020年3月23日触及熊市底部以来，已上涨超过90%。</blockquote> While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.<blockquote>虽然许多高质量和创新的企业引领了这场反弹，但它也让相当多糟糕的公司蓬勃发展。我建议像七月瘟疫一样避开以下五只超受欢迎的股票。</blockquote> Coinbase Global<blockquote>比特币基地全球</blockquote> First up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin&nbsp;andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.<blockquote>首先是加密货币交易所和生态系统比特币基地全球（纳斯达克：硬币）。Coinbase很受欢迎，因为投资者纷纷涌入Coinbase等公司，其第一季度收入和利润飙升得如此之快比特币和以太币.问题是有三种催化剂对Coinbase经纪模式不利。</blockquote> To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.<blockquote>首先，没有什么可以阻止竞争交易所降低Coinbase Global的费用。目前它可能具有经过验证的用户优势，但不要低估加密货币投资者为节省交易费用而跳槽的意愿。我们在传统券商中目睹了这一点，该行业最终实现了免佣金。</blockquote> Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.<blockquote>其次，加密货币有繁荣和萧条周期的历史。在过去十年中，比特币曾发生过三起独立的事件，其价值至少缩水80%。这是一项完全基于动量的投资，当上行动力枯竭时，Coinbase的交易收入也会枯竭。继2017年达到峰值后，Coinbase的收入在随后几年几乎减半。</blockquote> And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.<blockquote>第三，根据CoinShares数字资产基金流量周刊的数据，截至6月28日的过去四周内，加密货币资金流出量为2.573亿美元。这进一步证明，随着这些资产远低于高点，人们对加密货币的兴趣已经在下降。可以说，Coinbase并不是一只您未来想要拥有的股票。</blockquote> Cassava Sciences<blockquote>木薯科学</blockquote> Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).<blockquote>另一家风险回报比糟糕的超受欢迎公司是临床阶段的生物技术股票木薯科学（纳斯达克：萨瓦）。</blockquote> Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.<blockquote>Cassava在2月份宣布了simufilam治疗阿尔茨海默病的中期分析的积极临床数据，这理所当然地引起了轰动。这项开放标签试验显示，在六个月时认知和行为有所改善，最近允许Cassava概述其涉及其主要候选药物的3期试验计划。</blockquote> I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.<blockquote>我希望simufilam能够成功，但历史表明阿尔茨海默氏症是<a href=\"https://laohu8.com/S/AONE\">一</a>最难治疗的疾病。除了BiogenAduhelm获得了美国食品和药物管理局(FDA)的批准，但因缺乏明确的益处而受到严厉批评，十多年来，每种阿尔茨海默病药物都在后期研究中失败。投资者所要做的就是一项旨在招募100名患者的试验的早期开放标签数据。在大型3期阿尔茨海默病试验中，早期或中期的积极结果被粉碎的情况并不罕见。</blockquote> Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.<blockquote>尽管Cassava筹集了大量现金来继续其研究，但历史表明simufilam成功的机会非常渺茫。这使得木薯科学很容易避免。</blockquote> GameStop<blockquote>游戏驿站</blockquote> If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).<blockquote>如果您一直在关注零售贸易运动（即Reddit股票），散户投资者正在寻找大量卖空的公司并试图进行轧空，您可能知道视频游戏和配件零售商游戏驿站（纽约证券交易所代码：GME）。</blockquote> On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.<blockquote>在<a href=\"https://laohu8.com/S/AONE.U\">一</a>另一方面，游戏驿站能够利用其最近的名气，通过出售股票为其正在进行的向数字游戏公司的转型筹集资金。这是一项急需的举措，此前电子商务销售额在2020财年增长了191%，在假期期间比去年同期增长了四倍多。</blockquote> However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.<blockquote>然而，这些融资并没有忽视前任管理团队让公司失望的事实。二十年来，实体游戏模式运行良好。然而，当游戏走向数字化时，坚持这种实体模式会让公司陷入不稳定的境地。如今，即使电子商务快速增长，游戏驿站仍在继续亏损，去年同店销售额下降了近10%。数字销售可能在增长，但随着游戏驿站关闭其实体店以降低成本，总收入将无处可去。</blockquote> GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.<blockquote>游戏驿站绝不是破产的候选者，我实际上可以看到几年后实现盈利的道路。但话虽如此，考虑到未来漫长的转型和运营亏损，所看到的收益毫无意义。</blockquote> Inovio Pharmaceuticals<blockquote>Inovio制药公司</blockquote> Biotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.<blockquote>生物科技股可以提供充足的机会，或者Inovio制药公司（纳斯达克：INO）案例，吸走长期投资者的命脉。</blockquote> Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.<blockquote>Inovio似乎是一家仅基于纸张的有趣公司。它的产品线目前包括十几种治疗癌症、传染病和人乳头瘤病毒的临床候选药物。最有前途的看起来是INO-4800，这是该公司的冠状病毒病2019（COVID-19）候选疫苗，已准备好进行3期研究。但如果你深入研究Inovio的临床表现，你会非常失望。</blockquote> For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.<blockquote>例如，INO-4800在美国已被部分临床搁置，而监管机构要求提供有关Inovio疫苗及其输送系统Cellectra的更多数据。最近，INO-4800的后期资金被美国政府取消，这就是为什么它现在正在为其COVID-19候选药物寻求国际研究。</blockquote> If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.<blockquote>如果你认为我不公平地指责Inovio在新冠肺炎的挣扎，那就更进一步吧。四十年来，Inovio一直未能获得FDA批准的药物。这并不是我希望Inovio发生不好的事情——这是现实，希望和结果很长一段时间都没有与这家公司保持一致。在Inovio在后期临床试验中证明自己之前，值得避免使用。</blockquote> AMC Entertainment<blockquote>AMC院线</blockquote> Finally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.<blockquote>最后，我不能忘记正在进行的抽水和转储计划AMC院线（纽约证券交易所代码：AMC）。尽管在AMC通过发行大量股票和高息债务自救后，散户投资者能够通过1月份的轧空来宣称胜利，但最近的上涨与轧空无关。相反，它主要基于炒作，在留言板上故意混淆具体的基本数据，以及广泛的，公然的错误信息。</blockquote> AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.<blockquote>AMC的散户投资者希望你相信基本面并不重要，但尝试驾驶一辆没有发动机的汽车，看看你能走多远。AMC正在应对行业票房收入连续19年下降的问题，并且随着电影制片厂依赖流媒体，其部分电影独家经营权正在消失。电影院将会有一席之地，但AMC的潜在市场逐年萎缩。</blockquote> AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.<blockquote>AMC的散户投资者还会让您相信该公司在筹集20亿美元资本后状况良好。尽管近期破产传闻已被搁置，但2027年债券价格远未接近面值。你会问，为什么？因为债券持有人不相信AMC会逃脱破产。</blockquote> I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.<blockquote>我一生中见过足够多的泵和转储活动来识别它们，并且AMC检查了所有的框。我的建议是不要做空AMC。我的建议是完全避免。所有的抽水和转储计划最终都会崩溃，AMC也不例外。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nThe motley fool2021-07-06 09:32\n\n</h4>\n</header>\n<article>\nFor the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&amp;P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.<blockquote>在过去的15个月里，华尔街和投资者享受了历史性的反弹。基准标普500自2020年3月23日触及熊市底部以来，已上涨超过90%。</blockquote> While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.<blockquote>虽然许多高质量和创新的企业引领了这场反弹，但它也让相当多糟糕的公司蓬勃发展。我建议像七月瘟疫一样避开以下五只超受欢迎的股票。</blockquote> Coinbase Global<blockquote>比特币基地全球</blockquote> First up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin&nbsp;andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.<blockquote>首先是加密货币交易所和生态系统比特币基地全球（纳斯达克：硬币）。Coinbase很受欢迎，因为投资者纷纷涌入Coinbase等公司，其第一季度收入和利润飙升得如此之快比特币和以太币.问题是有三种催化剂对Coinbase经纪模式不利。</blockquote> To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.<blockquote>首先，没有什么可以阻止竞争交易所降低Coinbase Global的费用。目前它可能具有经过验证的用户优势，但不要低估加密货币投资者为节省交易费用而跳槽的意愿。我们在传统券商中目睹了这一点，该行业最终实现了免佣金。</blockquote> Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.<blockquote>其次，加密货币有繁荣和萧条周期的历史。在过去十年中，比特币曾发生过三起独立的事件，其价值至少缩水80%。这是一项完全基于动量的投资，当上行动力枯竭时，Coinbase的交易收入也会枯竭。继2017年达到峰值后，Coinbase的收入在随后几年几乎减半。</blockquote> And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.<blockquote>第三，根据CoinShares数字资产基金流量周刊的数据，截至6月28日的过去四周内，加密货币资金流出量为2.573亿美元。这进一步证明，随着这些资产远低于高点，人们对加密货币的兴趣已经在下降。可以说，Coinbase并不是一只您未来想要拥有的股票。</blockquote> Cassava Sciences<blockquote>木薯科学</blockquote> Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).<blockquote>另一家风险回报比糟糕的超受欢迎公司是临床阶段的生物技术股票木薯科学（纳斯达克：萨瓦）。</blockquote> Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.<blockquote>Cassava在2月份宣布了simufilam治疗阿尔茨海默病的中期分析的积极临床数据，这理所当然地引起了轰动。这项开放标签试验显示，在六个月时认知和行为有所改善，最近允许Cassava概述其涉及其主要候选药物的3期试验计划。</blockquote> I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.<blockquote>我希望simufilam能够成功，但历史表明阿尔茨海默氏症是<a href=\"https://laohu8.com/S/AONE\">一</a>最难治疗的疾病。除了BiogenAduhelm获得了美国食品和药物管理局(FDA)的批准，但因缺乏明确的益处而受到严厉批评，十多年来，每种阿尔茨海默病药物都在后期研究中失败。投资者所要做的就是一项旨在招募100名患者的试验的早期开放标签数据。在大型3期阿尔茨海默病试验中，早期或中期的积极结果被粉碎的情况并不罕见。</blockquote> Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.<blockquote>尽管Cassava筹集了大量现金来继续其研究，但历史表明simufilam成功的机会非常渺茫。这使得木薯科学很容易避免。</blockquote> GameStop<blockquote>游戏驿站</blockquote> If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).<blockquote>如果您一直在关注零售贸易运动（即Reddit股票），散户投资者正在寻找大量卖空的公司并试图进行轧空，您可能知道视频游戏和配件零售商游戏驿站（纽约证券交易所代码：GME）。</blockquote> On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.<blockquote>在<a href=\"https://laohu8.com/S/AONE.U\">一</a>另一方面，游戏驿站能够利用其最近的名气，通过出售股票为其正在进行的向数字游戏公司的转型筹集资金。这是一项急需的举措，此前电子商务销售额在2020财年增长了191%，在假期期间比去年同期增长了四倍多。</blockquote> However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.<blockquote>然而，这些融资并没有忽视前任管理团队让公司失望的事实。二十年来，实体游戏模式运行良好。然而，当游戏走向数字化时，坚持这种实体模式会让公司陷入不稳定的境地。如今，即使电子商务快速增长，游戏驿站仍在继续亏损，去年同店销售额下降了近10%。数字销售可能在增长，但随着游戏驿站关闭其实体店以降低成本，总收入将无处可去。</blockquote> GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.<blockquote>游戏驿站绝不是破产的候选者，我实际上可以看到几年后实现盈利的道路。但话虽如此，考虑到未来漫长的转型和运营亏损，所看到的收益毫无意义。</blockquote> Inovio Pharmaceuticals<blockquote>Inovio制药公司</blockquote> Biotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.<blockquote>生物科技股可以提供充足的机会，或者Inovio制药公司（纳斯达克：INO）案例，吸走长期投资者的命脉。</blockquote> Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.<blockquote>Inovio似乎是一家仅基于纸张的有趣公司。它的产品线目前包括十几种治疗癌症、传染病和人乳头瘤病毒的临床候选药物。最有前途的看起来是INO-4800，这是该公司的冠状病毒病2019（COVID-19）候选疫苗，已准备好进行3期研究。但如果你深入研究Inovio的临床表现，你会非常失望。</blockquote> For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.<blockquote>例如，INO-4800在美国已被部分临床搁置，而监管机构要求提供有关Inovio疫苗及其输送系统Cellectra的更多数据。最近，INO-4800的后期资金被美国政府取消，这就是为什么它现在正在为其COVID-19候选药物寻求国际研究。</blockquote> If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.<blockquote>如果你认为我不公平地指责Inovio在新冠肺炎的挣扎，那就更进一步吧。四十年来，Inovio一直未能获得FDA批准的药物。这并不是我希望Inovio发生不好的事情——这是现实，希望和结果很长一段时间都没有与这家公司保持一致。在Inovio在后期临床试验中证明自己之前，值得避免使用。</blockquote> AMC Entertainment<blockquote>AMC院线</blockquote> Finally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.<blockquote>最后，我不能忘记正在进行的抽水和转储计划AMC院线（纽约证券交易所代码：AMC）。尽管在AMC通过发行大量股票和高息债务自救后，散户投资者能够通过1月份的轧空来宣称胜利，但最近的上涨与轧空无关。相反，它主要基于炒作，在留言板上故意混淆具体的基本数据，以及广泛的，公然的错误信息。</blockquote> AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.<blockquote>AMC的散户投资者希望你相信基本面并不重要，但尝试驾驶一辆没有发动机的汽车，看看你能走多远。AMC正在应对行业票房收入连续19年下降的问题，并且随着电影制片厂依赖流媒体，其部分电影独家经营权正在消失。电影院将会有一席之地，但AMC的潜在市场逐年萎缩。</blockquote> AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.<blockquote>AMC的散户投资者还会让您相信该公司在筹集20亿美元资本后状况良好。尽管近期破产传闻已被搁置，但2027年债券价格远未接近面值。你会问，为什么？因为债券持有人不相信AMC会逃脱破产。</blockquote> I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.<blockquote>我一生中见过足够多的泵和转储活动来识别它们，并且AMC检查了所有的框。我的建议是不要做空AMC。我的建议是完全避免。所有的抽水和转储计划最终都会崩溃，AMC也不例外。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/\">The motley fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GME":"游戏驿站","SAVA":"Cassava Sciences Inc","INO":"伊诺维奥制药","COIN":"Coinbase Global, Inc.","AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164348327","content_text":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.\nWhile a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.\nCoinbase Global\nFirst up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.\nTo start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.\nSecond,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.\nAnd third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.\nCassava Sciences\nAnother ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).\nCassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.\nI'd love for simufilam to be successful, but history has shown that Alzheimer's is one of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.\nAlthough Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.\nGameStop\nIf you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).\nOn one hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.\nHowever, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.\nGameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.\nInovio Pharmaceuticals\nBiotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.\nInovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.\nFor example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.\nIf you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.\nAMC Entertainment\nFinally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.\nAMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.\nAMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.\nI've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.","news_type":1,"symbols_score_info":{"SAVA":0.9,"INO":0.9,"GME":0.9,"COIN":0.9,"AMC":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":157001313,"gmtCreate":1625550203332,"gmtModify":1633939729514,"author":{"id":"3566293775093626","authorId":"3566293775093626","name":"Patek1975","avatar":"https://static.tigerbbs.com/a2e5f9a5d563704aaf5f2473be16f148","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3566293775093626","authorIdStr":"3566293775093626"},"htmlText":"Apes hold [Smile]&nbsp;","listText":"Apes hold [Smile]&nbsp;","text":"Apes hold [Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/157001313","repostId":1164348327,"repostType":2,"repost":{"id":"1164348327","kind":"news","pubTimestamp":1625535165,"share":"https://www.laohu8.com/m/news/1164348327?lang=zh_CN&edition=full","pubTime":"2021-07-06 09:32","market":"us","language":"en","title":"5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1164348327","media":"The motley fool","summary":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The ben","content":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&amp;P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.<blockquote>在过去的15个月里，华尔街和投资者享受了历史性的反弹。基准标普500自2020年3月23日触及熊市底部以来，已上涨超过90%。</blockquote> While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.<blockquote>虽然许多高质量和创新的企业引领了这场反弹，但它也让相当多糟糕的公司蓬勃发展。我建议像七月瘟疫一样避开以下五只超受欢迎的股票。</blockquote> Coinbase Global<blockquote>比特币基地全球</blockquote> First up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin&nbsp;andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.<blockquote>首先是加密货币交易所和生态系统比特币基地全球（纳斯达克：硬币）。Coinbase很受欢迎，因为投资者纷纷涌入Coinbase等公司，其第一季度收入和利润飙升得如此之快比特币和以太币.问题是有三种催化剂对Coinbase经纪模式不利。</blockquote> To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.<blockquote>首先，没有什么可以阻止竞争交易所降低Coinbase Global的费用。目前它可能具有经过验证的用户优势，但不要低估加密货币投资者为节省交易费用而跳槽的意愿。我们在传统券商中目睹了这一点，该行业最终实现了免佣金。</blockquote> Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.<blockquote>其次，加密货币有繁荣和萧条周期的历史。在过去十年中，比特币曾发生过三起独立的事件，其价值至少缩水80%。这是一项完全基于动量的投资，当上行动力枯竭时，Coinbase的交易收入也会枯竭。继2017年达到峰值后，Coinbase的收入在随后几年几乎减半。</blockquote> And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.<blockquote>第三，根据CoinShares数字资产基金流量周刊的数据，截至6月28日的过去四周内，加密货币资金流出量为2.573亿美元。这进一步证明，随着这些资产远低于高点，人们对加密货币的兴趣已经在下降。可以说，Coinbase并不是一只您未来想要拥有的股票。</blockquote> Cassava Sciences<blockquote>木薯科学</blockquote> Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).<blockquote>另一家风险回报比糟糕的超受欢迎公司是临床阶段的生物技术股票木薯科学（纳斯达克：萨瓦）。</blockquote> Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.<blockquote>Cassava在2月份宣布了simufilam治疗阿尔茨海默病的中期分析的积极临床数据，这理所当然地引起了轰动。这项开放标签试验显示，在六个月时认知和行为有所改善，最近允许Cassava概述其涉及其主要候选药物的3期试验计划。</blockquote> I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.<blockquote>我希望simufilam能够成功，但历史表明阿尔茨海默氏症是<a href=\"https://laohu8.com/S/AONE\">一</a>最难治疗的疾病。除了BiogenAduhelm获得了美国食品和药物管理局(FDA)的批准，但因缺乏明确的益处而受到严厉批评，十多年来，每种阿尔茨海默病药物都在后期研究中失败。投资者所要做的就是一项旨在招募100名患者的试验的早期开放标签数据。在大型3期阿尔茨海默病试验中，早期或中期的积极结果被粉碎的情况并不罕见。</blockquote> Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.<blockquote>尽管Cassava筹集了大量现金来继续其研究，但历史表明simufilam成功的机会非常渺茫。这使得木薯科学很容易避免。</blockquote> GameStop<blockquote>游戏驿站</blockquote> If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).<blockquote>如果您一直在关注零售贸易运动（即Reddit股票），散户投资者正在寻找大量卖空的公司并试图进行轧空，您可能知道视频游戏和配件零售商游戏驿站（纽约证券交易所代码：GME）。</blockquote> On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.<blockquote>在<a href=\"https://laohu8.com/S/AONE.U\">一</a>另一方面，游戏驿站能够利用其最近的名气，通过出售股票为其正在进行的向数字游戏公司的转型筹集资金。这是一项急需的举措，此前电子商务销售额在2020财年增长了191%，在假期期间比去年同期增长了四倍多。</blockquote> However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.<blockquote>然而，这些融资并没有忽视前任管理团队让公司失望的事实。二十年来，实体游戏模式运行良好。然而，当游戏走向数字化时，坚持这种实体模式会让公司陷入不稳定的境地。如今，即使电子商务快速增长，游戏驿站仍在继续亏损，去年同店销售额下降了近10%。数字销售可能在增长，但随着游戏驿站关闭其实体店以降低成本，总收入将无处可去。</blockquote> GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.<blockquote>游戏驿站绝不是破产的候选者，我实际上可以看到几年后实现盈利的道路。但话虽如此，考虑到未来漫长的转型和运营亏损，所看到的收益毫无意义。</blockquote> Inovio Pharmaceuticals<blockquote>Inovio制药公司</blockquote> Biotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.<blockquote>生物科技股可以提供充足的机会，或者Inovio制药公司（纳斯达克：INO）案例，吸走长期投资者的命脉。</blockquote> Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.<blockquote>Inovio似乎是一家仅基于纸张的有趣公司。它的产品线目前包括十几种治疗癌症、传染病和人乳头瘤病毒的临床候选药物。最有前途的看起来是INO-4800，这是该公司的冠状病毒病2019（COVID-19）候选疫苗，已准备好进行3期研究。但如果你深入研究Inovio的临床表现，你会非常失望。</blockquote> For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.<blockquote>例如，INO-4800在美国已被部分临床搁置，而监管机构要求提供有关Inovio疫苗及其输送系统Cellectra的更多数据。最近，INO-4800的后期资金被美国政府取消，这就是为什么它现在正在为其COVID-19候选药物寻求国际研究。</blockquote> If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.<blockquote>如果你认为我不公平地指责Inovio在新冠肺炎的挣扎，那就更进一步吧。四十年来，Inovio一直未能获得FDA批准的药物。这并不是我希望Inovio发生不好的事情——这是现实，希望和结果很长一段时间都没有与这家公司保持一致。在Inovio在后期临床试验中证明自己之前，值得避免使用。</blockquote> AMC Entertainment<blockquote>AMC院线</blockquote> Finally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.<blockquote>最后，我不能忘记正在进行的抽水和转储计划AMC院线（纽约证券交易所代码：AMC）。尽管在AMC通过发行大量股票和高息债务自救后，散户投资者能够通过1月份的轧空来宣称胜利，但最近的上涨与轧空无关。相反，它主要基于炒作，在留言板上故意混淆具体的基本数据，以及广泛的，公然的错误信息。</blockquote> AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.<blockquote>AMC的散户投资者希望你相信基本面并不重要，但尝试驾驶一辆没有发动机的汽车，看看你能走多远。AMC正在应对行业票房收入连续19年下降的问题，并且随着电影制片厂依赖流媒体，其部分电影独家经营权正在消失。电影院将会有一席之地，但AMC的潜在市场逐年萎缩。</blockquote> AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.<blockquote>AMC的散户投资者还会让您相信该公司在筹集20亿美元资本后状况良好。尽管近期破产传闻已被搁置，但2027年债券价格远未接近面值。你会问，为什么？因为债券持有人不相信AMC会逃脱破产。</blockquote> I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.<blockquote>我一生中见过足够多的泵和转储活动来识别它们，并且AMC检查了所有的框。我的建议是不要做空AMC。我的建议是完全避免。所有的抽水和转储计划最终都会崩溃，AMC也不例外。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nThe motley fool2021-07-06 09:32\n\n</h4>\n</header>\n<article>\nFor the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&amp;P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.<blockquote>在过去的15个月里，华尔街和投资者享受了历史性的反弹。基准标普500自2020年3月23日触及熊市底部以来，已上涨超过90%。</blockquote> While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.<blockquote>虽然许多高质量和创新的企业引领了这场反弹，但它也让相当多糟糕的公司蓬勃发展。我建议像七月瘟疫一样避开以下五只超受欢迎的股票。</blockquote> Coinbase Global<blockquote>比特币基地全球</blockquote> First up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin&nbsp;andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.<blockquote>首先是加密货币交易所和生态系统比特币基地全球（纳斯达克：硬币）。Coinbase很受欢迎，因为投资者纷纷涌入Coinbase等公司，其第一季度收入和利润飙升得如此之快比特币和以太币.问题是有三种催化剂对Coinbase经纪模式不利。</blockquote> To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.<blockquote>首先，没有什么可以阻止竞争交易所降低Coinbase Global的费用。目前它可能具有经过验证的用户优势，但不要低估加密货币投资者为节省交易费用而跳槽的意愿。我们在传统券商中目睹了这一点，该行业最终实现了免佣金。</blockquote> Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.<blockquote>其次，加密货币有繁荣和萧条周期的历史。在过去十年中，比特币曾发生过三起独立的事件，其价值至少缩水80%。这是一项完全基于动量的投资，当上行动力枯竭时，Coinbase的交易收入也会枯竭。继2017年达到峰值后，Coinbase的收入在随后几年几乎减半。</blockquote> And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.<blockquote>第三，根据CoinShares数字资产基金流量周刊的数据，截至6月28日的过去四周内，加密货币资金流出量为2.573亿美元。这进一步证明，随着这些资产远低于高点，人们对加密货币的兴趣已经在下降。可以说，Coinbase并不是一只您未来想要拥有的股票。</blockquote> Cassava Sciences<blockquote>木薯科学</blockquote> Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).<blockquote>另一家风险回报比糟糕的超受欢迎公司是临床阶段的生物技术股票木薯科学（纳斯达克：萨瓦）。</blockquote> Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.<blockquote>Cassava在2月份宣布了simufilam治疗阿尔茨海默病的中期分析的积极临床数据，这理所当然地引起了轰动。这项开放标签试验显示，在六个月时认知和行为有所改善，最近允许Cassava概述其涉及其主要候选药物的3期试验计划。</blockquote> I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.<blockquote>我希望simufilam能够成功，但历史表明阿尔茨海默氏症是<a href=\"https://laohu8.com/S/AONE\">一</a>最难治疗的疾病。除了BiogenAduhelm获得了美国食品和药物管理局(FDA)的批准，但因缺乏明确的益处而受到严厉批评，十多年来，每种阿尔茨海默病药物都在后期研究中失败。投资者所要做的就是一项旨在招募100名患者的试验的早期开放标签数据。在大型3期阿尔茨海默病试验中，早期或中期的积极结果被粉碎的情况并不罕见。</blockquote> Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.<blockquote>尽管Cassava筹集了大量现金来继续其研究，但历史表明simufilam成功的机会非常渺茫。这使得木薯科学很容易避免。</blockquote> GameStop<blockquote>游戏驿站</blockquote> If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).<blockquote>如果您一直在关注零售贸易运动（即Reddit股票），散户投资者正在寻找大量卖空的公司并试图进行轧空，您可能知道视频游戏和配件零售商游戏驿站（纽约证券交易所代码：GME）。</blockquote> On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.<blockquote>在<a href=\"https://laohu8.com/S/AONE.U\">一</a>另一方面，游戏驿站能够利用其最近的名气，通过出售股票为其正在进行的向数字游戏公司的转型筹集资金。这是一项急需的举措，此前电子商务销售额在2020财年增长了191%，在假期期间比去年同期增长了四倍多。</blockquote> However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.<blockquote>然而，这些融资并没有忽视前任管理团队让公司失望的事实。二十年来，实体游戏模式运行良好。然而，当游戏走向数字化时，坚持这种实体模式会让公司陷入不稳定的境地。如今，即使电子商务快速增长，游戏驿站仍在继续亏损，去年同店销售额下降了近10%。数字销售可能在增长，但随着游戏驿站关闭其实体店以降低成本，总收入将无处可去。</blockquote> GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.<blockquote>游戏驿站绝不是破产的候选者，我实际上可以看到几年后实现盈利的道路。但话虽如此，考虑到未来漫长的转型和运营亏损，所看到的收益毫无意义。</blockquote> Inovio Pharmaceuticals<blockquote>Inovio制药公司</blockquote> Biotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.<blockquote>生物科技股可以提供充足的机会，或者Inovio制药公司（纳斯达克：INO）案例，吸走长期投资者的命脉。</blockquote> Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.<blockquote>Inovio似乎是一家仅基于纸张的有趣公司。它的产品线目前包括十几种治疗癌症、传染病和人乳头瘤病毒的临床候选药物。最有前途的看起来是INO-4800，这是该公司的冠状病毒病2019（COVID-19）候选疫苗，已准备好进行3期研究。但如果你深入研究Inovio的临床表现，你会非常失望。</blockquote> For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.<blockquote>例如，INO-4800在美国已被部分临床搁置，而监管机构要求提供有关Inovio疫苗及其输送系统Cellectra的更多数据。最近，INO-4800的后期资金被美国政府取消，这就是为什么它现在正在为其COVID-19候选药物寻求国际研究。</blockquote> If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.<blockquote>如果你认为我不公平地指责Inovio在新冠肺炎的挣扎，那就更进一步吧。四十年来，Inovio一直未能获得FDA批准的药物。这并不是我希望Inovio发生不好的事情——这是现实，希望和结果很长一段时间都没有与这家公司保持一致。在Inovio在后期临床试验中证明自己之前，值得避免使用。</blockquote> AMC Entertainment<blockquote>AMC院线</blockquote> Finally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.<blockquote>最后，我不能忘记正在进行的抽水和转储计划AMC院线（纽约证券交易所代码：AMC）。尽管在AMC通过发行大量股票和高息债务自救后，散户投资者能够通过1月份的轧空来宣称胜利，但最近的上涨与轧空无关。相反，它主要基于炒作，在留言板上故意混淆具体的基本数据，以及广泛的，公然的错误信息。</blockquote> AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.<blockquote>AMC的散户投资者希望你相信基本面并不重要，但尝试驾驶一辆没有发动机的汽车，看看你能走多远。AMC正在应对行业票房收入连续19年下降的问题，并且随着电影制片厂依赖流媒体，其部分电影独家经营权正在消失。电影院将会有一席之地，但AMC的潜在市场逐年萎缩。</blockquote> AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.<blockquote>AMC的散户投资者还会让您相信该公司在筹集20亿美元资本后状况良好。尽管近期破产传闻已被搁置，但2027年债券价格远未接近面值。你会问，为什么？因为债券持有人不相信AMC会逃脱破产。</blockquote> I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.<blockquote>我一生中见过足够多的泵和转储活动来识别它们，并且AMC检查了所有的框。我的建议是不要做空AMC。我的建议是完全避免。所有的抽水和转储计划最终都会崩溃，AMC也不例外。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/\">The motley fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GME":"游戏驿站","SAVA":"Cassava Sciences Inc","INO":"伊诺维奥制药","COIN":"Coinbase Global, Inc.","AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164348327","content_text":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.\nWhile a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.\nCoinbase Global\nFirst up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.\nTo start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.\nSecond,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.\nAnd third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.\nCassava Sciences\nAnother ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).\nCassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.\nI'd love for simufilam to be successful, but history has shown that Alzheimer's is one of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.\nAlthough Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.\nGameStop\nIf you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).\nOn one hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.\nHowever, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.\nGameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.\nInovio Pharmaceuticals\nBiotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.\nInovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.\nFor example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.\nIf you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.\nAMC Entertainment\nFinally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.\nAMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.\nAMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.\nI've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.","news_type":1,"symbols_score_info":{"SAVA":0.9,"INO":0.9,"GME":0.9,"COIN":0.9,"AMC":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":154754276,"gmtCreate":1625548066895,"gmtModify":1633939746786,"author":{"id":"3583491361400942","authorId":"3583491361400942","name":"Xuehao","avatar":"https://static.tigerbbs.com/68f8f0968bdff0787e4a34cf6caf8f84","vip":1,"crmLevel":8,"crmLevelSwitch":0,"idStr":"3583491361400942","authorIdStr":"3583491361400942"},"htmlText":"Too the moonn,&nbsp; like n share tq","listText":"Too the moonn,&nbsp; like n share tq","text":"Too the moonn, like n share tq","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/154754276","repostId":1164348327,"repostType":4,"repost":{"id":"1164348327","kind":"news","pubTimestamp":1625535165,"share":"https://www.laohu8.com/m/news/1164348327?lang=zh_CN&edition=full","pubTime":"2021-07-06 09:32","market":"us","language":"en","title":"5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1164348327","media":"The motley fool","summary":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The ben","content":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&amp;P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.<blockquote>在过去的15个月里，华尔街和投资者享受了历史性的反弹。基准标普500自2020年3月23日触及熊市底部以来，已上涨超过90%。</blockquote> While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.<blockquote>虽然许多高质量和创新的企业引领了这场反弹，但它也让相当多糟糕的公司蓬勃发展。我建议像七月瘟疫一样避开以下五只超受欢迎的股票。</blockquote> Coinbase Global<blockquote>比特币基地全球</blockquote> First up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin&nbsp;andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.<blockquote>首先是加密货币交易所和生态系统比特币基地全球（纳斯达克：硬币）。Coinbase很受欢迎，因为投资者纷纷涌入Coinbase等公司，其第一季度收入和利润飙升得如此之快比特币和以太币.问题是有三种催化剂对Coinbase经纪模式不利。</blockquote> To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.<blockquote>首先，没有什么可以阻止竞争交易所降低Coinbase Global的费用。目前它可能具有经过验证的用户优势，但不要低估加密货币投资者为节省交易费用而跳槽的意愿。我们在传统券商中目睹了这一点，该行业最终实现了免佣金。</blockquote> Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.<blockquote>其次，加密货币有繁荣和萧条周期的历史。在过去十年中，比特币曾发生过三起独立的事件，其价值至少缩水80%。这是一项完全基于动量的投资，当上行动力枯竭时，Coinbase的交易收入也会枯竭。继2017年达到峰值后，Coinbase的收入在随后几年几乎减半。</blockquote> And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.<blockquote>第三，根据CoinShares数字资产基金流量周刊的数据，截至6月28日的过去四周内，加密货币资金流出量为2.573亿美元。这进一步证明，随着这些资产远低于高点，人们对加密货币的兴趣已经在下降。可以说，Coinbase并不是一只您未来想要拥有的股票。</blockquote> Cassava Sciences<blockquote>木薯科学</blockquote> Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).<blockquote>另一家风险回报比糟糕的超受欢迎公司是临床阶段的生物技术股票木薯科学（纳斯达克：萨瓦）。</blockquote> Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.<blockquote>Cassava在2月份宣布了simufilam治疗阿尔茨海默病的中期分析的积极临床数据，这理所当然地引起了轰动。这项开放标签试验显示，在六个月时认知和行为有所改善，最近允许Cassava概述其涉及其主要候选药物的3期试验计划。</blockquote> I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.<blockquote>我希望simufilam能够成功，但历史表明阿尔茨海默氏症是<a href=\"https://laohu8.com/S/AONE\">一</a>最难治疗的疾病。除了BiogenAduhelm获得了美国食品和药物管理局(FDA)的批准，但因缺乏明确的益处而受到严厉批评，十多年来，每种阿尔茨海默病药物都在后期研究中失败。投资者所要做的就是一项旨在招募100名患者的试验的早期开放标签数据。在大型3期阿尔茨海默病试验中，早期或中期的积极结果被粉碎的情况并不罕见。</blockquote> Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.<blockquote>尽管Cassava筹集了大量现金来继续其研究，但历史表明simufilam成功的机会非常渺茫。这使得木薯科学很容易避免。</blockquote> GameStop<blockquote>游戏驿站</blockquote> If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).<blockquote>如果您一直在关注零售贸易运动（即Reddit股票），散户投资者正在寻找大量卖空的公司并试图进行轧空，您可能知道视频游戏和配件零售商游戏驿站（纽约证券交易所代码：GME）。</blockquote> On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.<blockquote>在<a href=\"https://laohu8.com/S/AONE.U\">一</a>另一方面，游戏驿站能够利用其最近的名气，通过出售股票为其正在进行的向数字游戏公司的转型筹集资金。这是一项急需的举措，此前电子商务销售额在2020财年增长了191%，在假期期间比去年同期增长了四倍多。</blockquote> However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.<blockquote>然而，这些融资并没有忽视前任管理团队让公司失望的事实。二十年来，实体游戏模式运行良好。然而，当游戏走向数字化时，坚持这种实体模式会让公司陷入不稳定的境地。如今，即使电子商务快速增长，游戏驿站仍在继续亏损，去年同店销售额下降了近10%。数字销售可能在增长，但随着游戏驿站关闭其实体店以降低成本，总收入将无处可去。</blockquote> GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.<blockquote>游戏驿站绝不是破产的候选者，我实际上可以看到几年后实现盈利的道路。但话虽如此，考虑到未来漫长的转型和运营亏损，所看到的收益毫无意义。</blockquote> Inovio Pharmaceuticals<blockquote>Inovio制药公司</blockquote> Biotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.<blockquote>生物科技股可以提供充足的机会，或者Inovio制药公司（纳斯达克：INO）案例，吸走长期投资者的命脉。</blockquote> Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.<blockquote>Inovio似乎是一家仅基于纸张的有趣公司。它的产品线目前包括十几种治疗癌症、传染病和人乳头瘤病毒的临床候选药物。最有前途的看起来是INO-4800，这是该公司的冠状病毒病2019（COVID-19）候选疫苗，已准备好进行3期研究。但如果你深入研究Inovio的临床表现，你会非常失望。</blockquote> For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.<blockquote>例如，INO-4800在美国已被部分临床搁置，而监管机构要求提供有关Inovio疫苗及其输送系统Cellectra的更多数据。最近，INO-4800的后期资金被美国政府取消，这就是为什么它现在正在为其COVID-19候选药物寻求国际研究。</blockquote> If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.<blockquote>如果你认为我不公平地指责Inovio在新冠肺炎的挣扎，那就更进一步吧。四十年来，Inovio一直未能获得FDA批准的药物。这并不是我希望Inovio发生不好的事情——这是现实，希望和结果很长一段时间都没有与这家公司保持一致。在Inovio在后期临床试验中证明自己之前，值得避免使用。</blockquote> AMC Entertainment<blockquote>AMC院线</blockquote> Finally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.<blockquote>最后，我不能忘记正在进行的抽水和转储计划AMC院线（纽约证券交易所代码：AMC）。尽管在AMC通过发行大量股票和高息债务自救后，散户投资者能够通过1月份的轧空来宣称胜利，但最近的上涨与轧空无关。相反，它主要基于炒作，在留言板上故意混淆具体的基本数据，以及广泛的，公然的错误信息。</blockquote> AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.<blockquote>AMC的散户投资者希望你相信基本面并不重要，但尝试驾驶一辆没有发动机的汽车，看看你能走多远。AMC正在应对行业票房收入连续19年下降的问题，并且随着电影制片厂依赖流媒体，其部分电影独家经营权正在消失。电影院将会有一席之地，但AMC的潜在市场逐年萎缩。</blockquote> AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.<blockquote>AMC的散户投资者还会让您相信该公司在筹集20亿美元资本后状况良好。尽管近期破产传闻已被搁置，但2027年债券价格远未接近面值。你会问，为什么？因为债券持有人不相信AMC会逃脱破产。</blockquote> I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.<blockquote>我一生中见过足够多的泵和转储活动来识别它们，并且AMC检查了所有的框。我的建议是不要做空AMC。我的建议是完全避免。所有的抽水和转储计划最终都会崩溃，AMC也不例外。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nThe motley fool2021-07-06 09:32\n\n</h4>\n</header>\n<article>\nFor the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&amp;P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.<blockquote>在过去的15个月里，华尔街和投资者享受了历史性的反弹。基准标普500自2020年3月23日触及熊市底部以来，已上涨超过90%。</blockquote> While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.<blockquote>虽然许多高质量和创新的企业引领了这场反弹，但它也让相当多糟糕的公司蓬勃发展。我建议像七月瘟疫一样避开以下五只超受欢迎的股票。</blockquote> Coinbase Global<blockquote>比特币基地全球</blockquote> First up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin&nbsp;andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.<blockquote>首先是加密货币交易所和生态系统比特币基地全球（纳斯达克：硬币）。Coinbase很受欢迎，因为投资者纷纷涌入Coinbase等公司，其第一季度收入和利润飙升得如此之快比特币和以太币.问题是有三种催化剂对Coinbase经纪模式不利。</blockquote> To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.<blockquote>首先，没有什么可以阻止竞争交易所降低Coinbase Global的费用。目前它可能具有经过验证的用户优势，但不要低估加密货币投资者为节省交易费用而跳槽的意愿。我们在传统券商中目睹了这一点，该行业最终实现了免佣金。</blockquote> Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.<blockquote>其次，加密货币有繁荣和萧条周期的历史。在过去十年中，比特币曾发生过三起独立的事件，其价值至少缩水80%。这是一项完全基于动量的投资，当上行动力枯竭时，Coinbase的交易收入也会枯竭。继2017年达到峰值后，Coinbase的收入在随后几年几乎减半。</blockquote> And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.<blockquote>第三，根据CoinShares数字资产基金流量周刊的数据，截至6月28日的过去四周内，加密货币资金流出量为2.573亿美元。这进一步证明，随着这些资产远低于高点，人们对加密货币的兴趣已经在下降。可以说，Coinbase并不是一只您未来想要拥有的股票。</blockquote> Cassava Sciences<blockquote>木薯科学</blockquote> Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).<blockquote>另一家风险回报比糟糕的超受欢迎公司是临床阶段的生物技术股票木薯科学（纳斯达克：萨瓦）。</blockquote> Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.<blockquote>Cassava在2月份宣布了simufilam治疗阿尔茨海默病的中期分析的积极临床数据，这理所当然地引起了轰动。这项开放标签试验显示，在六个月时认知和行为有所改善，最近允许Cassava概述其涉及其主要候选药物的3期试验计划。</blockquote> I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.<blockquote>我希望simufilam能够成功，但历史表明阿尔茨海默氏症是<a href=\"https://laohu8.com/S/AONE\">一</a>最难治疗的疾病。除了BiogenAduhelm获得了美国食品和药物管理局(FDA)的批准，但因缺乏明确的益处而受到严厉批评，十多年来，每种阿尔茨海默病药物都在后期研究中失败。投资者所要做的就是一项旨在招募100名患者的试验的早期开放标签数据。在大型3期阿尔茨海默病试验中，早期或中期的积极结果被粉碎的情况并不罕见。</blockquote> Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.<blockquote>尽管Cassava筹集了大量现金来继续其研究，但历史表明simufilam成功的机会非常渺茫。这使得木薯科学很容易避免。</blockquote> GameStop<blockquote>游戏驿站</blockquote> If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).<blockquote>如果您一直在关注零售贸易运动（即Reddit股票），散户投资者正在寻找大量卖空的公司并试图进行轧空，您可能知道视频游戏和配件零售商游戏驿站（纽约证券交易所代码：GME）。</blockquote> On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.<blockquote>在<a href=\"https://laohu8.com/S/AONE.U\">一</a>另一方面，游戏驿站能够利用其最近的名气，通过出售股票为其正在进行的向数字游戏公司的转型筹集资金。这是一项急需的举措，此前电子商务销售额在2020财年增长了191%，在假期期间比去年同期增长了四倍多。</blockquote> However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.<blockquote>然而，这些融资并没有忽视前任管理团队让公司失望的事实。二十年来，实体游戏模式运行良好。然而，当游戏走向数字化时，坚持这种实体模式会让公司陷入不稳定的境地。如今，即使电子商务快速增长，游戏驿站仍在继续亏损，去年同店销售额下降了近10%。数字销售可能在增长，但随着游戏驿站关闭其实体店以降低成本，总收入将无处可去。</blockquote> GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.<blockquote>游戏驿站绝不是破产的候选者，我实际上可以看到几年后实现盈利的道路。但话虽如此，考虑到未来漫长的转型和运营亏损，所看到的收益毫无意义。</blockquote> Inovio Pharmaceuticals<blockquote>Inovio制药公司</blockquote> Biotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.<blockquote>生物科技股可以提供充足的机会，或者Inovio制药公司（纳斯达克：INO）案例，吸走长期投资者的命脉。</blockquote> Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.<blockquote>Inovio似乎是一家仅基于纸张的有趣公司。它的产品线目前包括十几种治疗癌症、传染病和人乳头瘤病毒的临床候选药物。最有前途的看起来是INO-4800，这是该公司的冠状病毒病2019（COVID-19）候选疫苗，已准备好进行3期研究。但如果你深入研究Inovio的临床表现，你会非常失望。</blockquote> For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.<blockquote>例如，INO-4800在美国已被部分临床搁置，而监管机构要求提供有关Inovio疫苗及其输送系统Cellectra的更多数据。最近，INO-4800的后期资金被美国政府取消，这就是为什么它现在正在为其COVID-19候选药物寻求国际研究。</blockquote> If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.<blockquote>如果你认为我不公平地指责Inovio在新冠肺炎的挣扎，那就更进一步吧。四十年来，Inovio一直未能获得FDA批准的药物。这并不是我希望Inovio发生不好的事情——这是现实，希望和结果很长一段时间都没有与这家公司保持一致。在Inovio在后期临床试验中证明自己之前，值得避免使用。</blockquote> AMC Entertainment<blockquote>AMC院线</blockquote> Finally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.<blockquote>最后，我不能忘记正在进行的抽水和转储计划AMC院线（纽约证券交易所代码：AMC）。尽管在AMC通过发行大量股票和高息债务自救后，散户投资者能够通过1月份的轧空来宣称胜利，但最近的上涨与轧空无关。相反，它主要基于炒作，在留言板上故意混淆具体的基本数据，以及广泛的，公然的错误信息。</blockquote> AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.<blockquote>AMC的散户投资者希望你相信基本面并不重要，但尝试驾驶一辆没有发动机的汽车，看看你能走多远。AMC正在应对行业票房收入连续19年下降的问题，并且随着电影制片厂依赖流媒体，其部分电影独家经营权正在消失。电影院将会有一席之地，但AMC的潜在市场逐年萎缩。</blockquote> AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.<blockquote>AMC的散户投资者还会让您相信该公司在筹集20亿美元资本后状况良好。尽管近期破产传闻已被搁置，但2027年债券价格远未接近面值。你会问，为什么？因为债券持有人不相信AMC会逃脱破产。</blockquote> I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.<blockquote>我一生中见过足够多的泵和转储活动来识别它们，并且AMC检查了所有的框。我的建议是不要做空AMC。我的建议是完全避免。所有的抽水和转储计划最终都会崩溃，AMC也不例外。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/\">The motley fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GME":"游戏驿站","SAVA":"Cassava Sciences Inc","INO":"伊诺维奥制药","COIN":"Coinbase Global, Inc.","AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164348327","content_text":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.\nWhile a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.\nCoinbase Global\nFirst up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.\nTo start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.\nSecond,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.\nAnd third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.\nCassava Sciences\nAnother ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).\nCassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.\nI'd love for simufilam to be successful, but history has shown that Alzheimer's is one of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.\nAlthough Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.\nGameStop\nIf you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).\nOn one hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.\nHowever, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.\nGameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.\nInovio Pharmaceuticals\nBiotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.\nInovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.\nFor example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.\nIf you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.\nAMC Entertainment\nFinally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.\nAMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.\nAMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.\nI've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.","news_type":1,"symbols_score_info":{"SAVA":0.9,"INO":0.9,"GME":0.9,"COIN":0.9,"AMC":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":154722394,"gmtCreate":1625547200418,"gmtModify":1631890163848,"author":{"id":"3569727470774557","authorId":"3569727470774557","name":"GohHW","avatar":"https://static.tigerbbs.com/6dec9efffb91ea367e5ecb140afa5a42","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3569727470774557","authorIdStr":"3569727470774557"},"htmlText":"Yes but highrisk high gain","listText":"Yes but highrisk high gain","text":"Yes but highrisk high gain","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/154722394","repostId":1164348327,"repostType":2,"repost":{"id":"1164348327","kind":"news","pubTimestamp":1625535165,"share":"https://www.laohu8.com/m/news/1164348327?lang=zh_CN&edition=full","pubTime":"2021-07-06 09:32","market":"us","language":"en","title":"5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1164348327","media":"The motley fool","summary":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The ben","content":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&amp;P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.<blockquote>在过去的15个月里，华尔街和投资者享受了历史性的反弹。基准标普500自2020年3月23日触及熊市底部以来，已上涨超过90%。</blockquote> While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.<blockquote>虽然许多高质量和创新的企业引领了这场反弹，但它也让相当多糟糕的公司蓬勃发展。我建议像七月瘟疫一样避开以下五只超受欢迎的股票。</blockquote> Coinbase Global<blockquote>比特币基地全球</blockquote> First up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin&nbsp;andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.<blockquote>首先是加密货币交易所和生态系统比特币基地全球（纳斯达克：硬币）。Coinbase很受欢迎，因为投资者纷纷涌入Coinbase等公司，其第一季度收入和利润飙升得如此之快比特币和以太币.问题是有三种催化剂对Coinbase经纪模式不利。</blockquote> To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.<blockquote>首先，没有什么可以阻止竞争交易所降低Coinbase Global的费用。目前它可能具有经过验证的用户优势，但不要低估加密货币投资者为节省交易费用而跳槽的意愿。我们在传统券商中目睹了这一点，该行业最终实现了免佣金。</blockquote> Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.<blockquote>其次，加密货币有繁荣和萧条周期的历史。在过去十年中，比特币曾发生过三起独立的事件，其价值至少缩水80%。这是一项完全基于动量的投资，当上行动力枯竭时，Coinbase的交易收入也会枯竭。继2017年达到峰值后，Coinbase的收入在随后几年几乎减半。</blockquote> And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.<blockquote>第三，根据CoinShares数字资产基金流量周刊的数据，截至6月28日的过去四周内，加密货币资金流出量为2.573亿美元。这进一步证明，随着这些资产远低于高点，人们对加密货币的兴趣已经在下降。可以说，Coinbase并不是一只您未来想要拥有的股票。</blockquote> Cassava Sciences<blockquote>木薯科学</blockquote> Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).<blockquote>另一家风险回报比糟糕的超受欢迎公司是临床阶段的生物技术股票木薯科学（纳斯达克：萨瓦）。</blockquote> Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.<blockquote>Cassava在2月份宣布了simufilam治疗阿尔茨海默病的中期分析的积极临床数据，这理所当然地引起了轰动。这项开放标签试验显示，在六个月时认知和行为有所改善，最近允许Cassava概述其涉及其主要候选药物的3期试验计划。</blockquote> I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.<blockquote>我希望simufilam能够成功，但历史表明阿尔茨海默氏症是<a href=\"https://laohu8.com/S/AONE\">一</a>最难治疗的疾病。除了BiogenAduhelm获得了美国食品和药物管理局(FDA)的批准，但因缺乏明确的益处而受到严厉批评，十多年来，每种阿尔茨海默病药物都在后期研究中失败。投资者所要做的就是一项旨在招募100名患者的试验的早期开放标签数据。在大型3期阿尔茨海默病试验中，早期或中期的积极结果被粉碎的情况并不罕见。</blockquote> Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.<blockquote>尽管Cassava筹集了大量现金来继续其研究，但历史表明simufilam成功的机会非常渺茫。这使得木薯科学很容易避免。</blockquote> GameStop<blockquote>游戏驿站</blockquote> If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).<blockquote>如果您一直在关注零售贸易运动（即Reddit股票），散户投资者正在寻找大量卖空的公司并试图进行轧空，您可能知道视频游戏和配件零售商游戏驿站（纽约证券交易所代码：GME）。</blockquote> On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.<blockquote>在<a href=\"https://laohu8.com/S/AONE.U\">一</a>另一方面，游戏驿站能够利用其最近的名气，通过出售股票为其正在进行的向数字游戏公司的转型筹集资金。这是一项急需的举措，此前电子商务销售额在2020财年增长了191%，在假期期间比去年同期增长了四倍多。</blockquote> However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.<blockquote>然而，这些融资并没有忽视前任管理团队让公司失望的事实。二十年来，实体游戏模式运行良好。然而，当游戏走向数字化时，坚持这种实体模式会让公司陷入不稳定的境地。如今，即使电子商务快速增长，游戏驿站仍在继续亏损，去年同店销售额下降了近10%。数字销售可能在增长，但随着游戏驿站关闭其实体店以降低成本，总收入将无处可去。</blockquote> GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.<blockquote>游戏驿站绝不是破产的候选者，我实际上可以看到几年后实现盈利的道路。但话虽如此，考虑到未来漫长的转型和运营亏损，所看到的收益毫无意义。</blockquote> Inovio Pharmaceuticals<blockquote>Inovio制药公司</blockquote> Biotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.<blockquote>生物科技股可以提供充足的机会，或者Inovio制药公司（纳斯达克：INO）案例，吸走长期投资者的命脉。</blockquote> Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.<blockquote>Inovio似乎是一家仅基于纸张的有趣公司。它的产品线目前包括十几种治疗癌症、传染病和人乳头瘤病毒的临床候选药物。最有前途的看起来是INO-4800，这是该公司的冠状病毒病2019（COVID-19）候选疫苗，已准备好进行3期研究。但如果你深入研究Inovio的临床表现，你会非常失望。</blockquote> For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.<blockquote>例如，INO-4800在美国已被部分临床搁置，而监管机构要求提供有关Inovio疫苗及其输送系统Cellectra的更多数据。最近，INO-4800的后期资金被美国政府取消，这就是为什么它现在正在为其COVID-19候选药物寻求国际研究。</blockquote> If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.<blockquote>如果你认为我不公平地指责Inovio在新冠肺炎的挣扎，那就更进一步吧。四十年来，Inovio一直未能获得FDA批准的药物。这并不是我希望Inovio发生不好的事情——这是现实，希望和结果很长一段时间都没有与这家公司保持一致。在Inovio在后期临床试验中证明自己之前，值得避免使用。</blockquote> AMC Entertainment<blockquote>AMC院线</blockquote> Finally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.<blockquote>最后，我不能忘记正在进行的抽水和转储计划AMC院线（纽约证券交易所代码：AMC）。尽管在AMC通过发行大量股票和高息债务自救后，散户投资者能够通过1月份的轧空来宣称胜利，但最近的上涨与轧空无关。相反，它主要基于炒作，在留言板上故意混淆具体的基本数据，以及广泛的，公然的错误信息。</blockquote> AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.<blockquote>AMC的散户投资者希望你相信基本面并不重要，但尝试驾驶一辆没有发动机的汽车，看看你能走多远。AMC正在应对行业票房收入连续19年下降的问题，并且随着电影制片厂依赖流媒体，其部分电影独家经营权正在消失。电影院将会有一席之地，但AMC的潜在市场逐年萎缩。</blockquote> AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.<blockquote>AMC的散户投资者还会让您相信该公司在筹集20亿美元资本后状况良好。尽管近期破产传闻已被搁置，但2027年债券价格远未接近面值。你会问，为什么？因为债券持有人不相信AMC会逃脱破产。</blockquote> I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.<blockquote>我一生中见过足够多的泵和转储活动来识别它们，并且AMC检查了所有的框。我的建议是不要做空AMC。我的建议是完全避免。所有的抽水和转储计划最终都会崩溃，AMC也不例外。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nThe motley fool2021-07-06 09:32\n\n</h4>\n</header>\n<article>\nFor the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&amp;P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.<blockquote>在过去的15个月里，华尔街和投资者享受了历史性的反弹。基准标普500自2020年3月23日触及熊市底部以来，已上涨超过90%。</blockquote> While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.<blockquote>虽然许多高质量和创新的企业引领了这场反弹，但它也让相当多糟糕的公司蓬勃发展。我建议像七月瘟疫一样避开以下五只超受欢迎的股票。</blockquote> Coinbase Global<blockquote>比特币基地全球</blockquote> First up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin&nbsp;andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.<blockquote>首先是加密货币交易所和生态系统比特币基地全球（纳斯达克：硬币）。Coinbase很受欢迎，因为投资者纷纷涌入Coinbase等公司，其第一季度收入和利润飙升得如此之快比特币和以太币.问题是有三种催化剂对Coinbase经纪模式不利。</blockquote> To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.<blockquote>首先，没有什么可以阻止竞争交易所降低Coinbase Global的费用。目前它可能具有经过验证的用户优势，但不要低估加密货币投资者为节省交易费用而跳槽的意愿。我们在传统券商中目睹了这一点，该行业最终实现了免佣金。</blockquote> Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.<blockquote>其次，加密货币有繁荣和萧条周期的历史。在过去十年中，比特币曾发生过三起独立的事件，其价值至少缩水80%。这是一项完全基于动量的投资，当上行动力枯竭时，Coinbase的交易收入也会枯竭。继2017年达到峰值后，Coinbase的收入在随后几年几乎减半。</blockquote> And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.<blockquote>第三，根据CoinShares数字资产基金流量周刊的数据，截至6月28日的过去四周内，加密货币资金流出量为2.573亿美元。这进一步证明，随着这些资产远低于高点，人们对加密货币的兴趣已经在下降。可以说，Coinbase并不是一只您未来想要拥有的股票。</blockquote> Cassava Sciences<blockquote>木薯科学</blockquote> Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).<blockquote>另一家风险回报比糟糕的超受欢迎公司是临床阶段的生物技术股票木薯科学（纳斯达克：萨瓦）。</blockquote> Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.<blockquote>Cassava在2月份宣布了simufilam治疗阿尔茨海默病的中期分析的积极临床数据，这理所当然地引起了轰动。这项开放标签试验显示，在六个月时认知和行为有所改善，最近允许Cassava概述其涉及其主要候选药物的3期试验计划。</blockquote> I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.<blockquote>我希望simufilam能够成功，但历史表明阿尔茨海默氏症是<a href=\"https://laohu8.com/S/AONE\">一</a>最难治疗的疾病。除了BiogenAduhelm获得了美国食品和药物管理局(FDA)的批准，但因缺乏明确的益处而受到严厉批评，十多年来，每种阿尔茨海默病药物都在后期研究中失败。投资者所要做的就是一项旨在招募100名患者的试验的早期开放标签数据。在大型3期阿尔茨海默病试验中，早期或中期的积极结果被粉碎的情况并不罕见。</blockquote> Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.<blockquote>尽管Cassava筹集了大量现金来继续其研究，但历史表明simufilam成功的机会非常渺茫。这使得木薯科学很容易避免。</blockquote> GameStop<blockquote>游戏驿站</blockquote> If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).<blockquote>如果您一直在关注零售贸易运动（即Reddit股票），散户投资者正在寻找大量卖空的公司并试图进行轧空，您可能知道视频游戏和配件零售商游戏驿站（纽约证券交易所代码：GME）。</blockquote> On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.<blockquote>在<a href=\"https://laohu8.com/S/AONE.U\">一</a>另一方面，游戏驿站能够利用其最近的名气，通过出售股票为其正在进行的向数字游戏公司的转型筹集资金。这是一项急需的举措，此前电子商务销售额在2020财年增长了191%，在假期期间比去年同期增长了四倍多。</blockquote> However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.<blockquote>然而，这些融资并没有忽视前任管理团队让公司失望的事实。二十年来，实体游戏模式运行良好。然而，当游戏走向数字化时，坚持这种实体模式会让公司陷入不稳定的境地。如今，即使电子商务快速增长，游戏驿站仍在继续亏损，去年同店销售额下降了近10%。数字销售可能在增长，但随着游戏驿站关闭其实体店以降低成本，总收入将无处可去。</blockquote> GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.<blockquote>游戏驿站绝不是破产的候选者，我实际上可以看到几年后实现盈利的道路。但话虽如此，考虑到未来漫长的转型和运营亏损，所看到的收益毫无意义。</blockquote> Inovio Pharmaceuticals<blockquote>Inovio制药公司</blockquote> Biotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.<blockquote>生物科技股可以提供充足的机会，或者Inovio制药公司（纳斯达克：INO）案例，吸走长期投资者的命脉。</blockquote> Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.<blockquote>Inovio似乎是一家仅基于纸张的有趣公司。它的产品线目前包括十几种治疗癌症、传染病和人乳头瘤病毒的临床候选药物。最有前途的看起来是INO-4800，这是该公司的冠状病毒病2019（COVID-19）候选疫苗，已准备好进行3期研究。但如果你深入研究Inovio的临床表现，你会非常失望。</blockquote> For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.<blockquote>例如，INO-4800在美国已被部分临床搁置，而监管机构要求提供有关Inovio疫苗及其输送系统Cellectra的更多数据。最近，INO-4800的后期资金被美国政府取消，这就是为什么它现在正在为其COVID-19候选药物寻求国际研究。</blockquote> If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.<blockquote>如果你认为我不公平地指责Inovio在新冠肺炎的挣扎，那就更进一步吧。四十年来，Inovio一直未能获得FDA批准的药物。这并不是我希望Inovio发生不好的事情——这是现实，希望和结果很长一段时间都没有与这家公司保持一致。在Inovio在后期临床试验中证明自己之前，值得避免使用。</blockquote> AMC Entertainment<blockquote>AMC院线</blockquote> Finally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.<blockquote>最后，我不能忘记正在进行的抽水和转储计划AMC院线（纽约证券交易所代码：AMC）。尽管在AMC通过发行大量股票和高息债务自救后，散户投资者能够通过1月份的轧空来宣称胜利，但最近的上涨与轧空无关。相反，它主要基于炒作，在留言板上故意混淆具体的基本数据，以及广泛的，公然的错误信息。</blockquote> AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.<blockquote>AMC的散户投资者希望你相信基本面并不重要，但尝试驾驶一辆没有发动机的汽车，看看你能走多远。AMC正在应对行业票房收入连续19年下降的问题，并且随着电影制片厂依赖流媒体，其部分电影独家经营权正在消失。电影院将会有一席之地，但AMC的潜在市场逐年萎缩。</blockquote> AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.<blockquote>AMC的散户投资者还会让您相信该公司在筹集20亿美元资本后状况良好。尽管近期破产传闻已被搁置，但2027年债券价格远未接近面值。你会问，为什么？因为债券持有人不相信AMC会逃脱破产。</blockquote> I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.<blockquote>我一生中见过足够多的泵和转储活动来识别它们，并且AMC检查了所有的框。我的建议是不要做空AMC。我的建议是完全避免。所有的抽水和转储计划最终都会崩溃，AMC也不例外。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/\">The motley fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GME":"游戏驿站","SAVA":"Cassava Sciences Inc","INO":"伊诺维奥制药","COIN":"Coinbase Global, Inc.","AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164348327","content_text":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.\nWhile a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.\nCoinbase Global\nFirst up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.\nTo start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.\nSecond,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.\nAnd third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.\nCassava Sciences\nAnother ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).\nCassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.\nI'd love for simufilam to be successful, but history has shown that Alzheimer's is one of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.\nAlthough Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.\nGameStop\nIf you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).\nOn one hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.\nHowever, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.\nGameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.\nInovio Pharmaceuticals\nBiotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.\nInovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.\nFor example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.\nIf you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.\nAMC Entertainment\nFinally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.\nAMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.\nAMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.\nI've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.","news_type":1,"symbols_score_info":{"SAVA":0.9,"INO":0.9,"GME":0.9,"COIN":0.9,"AMC":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5146153,"gmtCreate":1625633809584,"gmtModify":1631890163886,"authorId":3569727470774557,"author":{"id":3569727470774557,"idStr":"3569727470774557","authorId":3569727470774557,"name":"GohHW","avatar":"https://static.tigerbbs.com/6dec9efffb91ea367e5ecb140afa5a42","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":154722394,"type":1,"supId":0,"prevId":0,"content":"Great","text":"Great","html":"Great"},{"id":5134165,"gmtCreate":1625548077602,"gmtModify":1631890163877,"authorId":3583491361400942,"author":{"id":3583491361400942,"idStr":"3583491361400942","authorId":3583491361400942,"name":"Xuehao","avatar":"https://static.tigerbbs.com/68f8f0968bdff0787e4a34cf6caf8f84","vip":1,"crmLevel":8,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":3581670993895630,"repliedAuthor":{"id":3581670993895630,"idStr":"3581670993895630","authorId":3581670993895630,"name":"OpenSesame88","avatar":"https://static.tigerbbs.com/8acdaa8d911543916dedb8be1f245fd9","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"objectId":154722394,"type":1,"supId":5134079,"prevId":5134128,"content":"noted","text":"noted","html":"noted"},{"id":5134128,"gmtCreate":1625547696311,"gmtModify":1631890163867,"authorId":3581670993895630,"author":{"id":3581670993895630,"idStr":"3581670993895630","authorId":3581670993895630,"name":"OpenSesame88","avatar":"https://static.tigerbbs.com/8acdaa8d911543916dedb8be1f245fd9","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":154722394,"type":1,"supId":5134079,"prevId":0,"content":"yes","text":"yes","html":"yes"},{"id":5134079,"gmtCreate":1625547219322,"gmtModify":1631890163846,"authorId":3569727470774557,"author":{"id":3569727470774557,"idStr":"3569727470774557","authorId":3569727470774557,"name":"GohHW","avatar":"https://static.tigerbbs.com/6dec9efffb91ea367e5ecb140afa5a42","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":154722394,"type":1,"supId":0,"prevId":0,"content":"Yes","text":"Yes","html":"Yes"}],"langContent":"EN"},{"id":154728268,"gmtCreate":1625547095554,"gmtModify":1631883984453,"author":{"id":"3581985274026406","authorId":"3581985274026406","name":"Skai","avatar":"https://static.tigerbbs.com/77957397aed2feadade5874e503ea585","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3581985274026406","authorIdStr":"3581985274026406"},"htmlText":"The one news source to avoid is the fool. Thanks for the daily FUD.&nbsp;","listText":"The one news source to avoid is the fool. Thanks for the daily FUD.&nbsp;","text":"The one news source to avoid is the fool. Thanks for the daily FUD.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/154728268","repostId":1164348327,"repostType":2,"repost":{"id":"1164348327","kind":"news","pubTimestamp":1625535165,"share":"https://www.laohu8.com/m/news/1164348327?lang=zh_CN&edition=full","pubTime":"2021-07-06 09:32","market":"us","language":"en","title":"5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1164348327","media":"The motley fool","summary":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The ben","content":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&amp;P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.<blockquote>在过去的15个月里，华尔街和投资者享受了历史性的反弹。基准标普500自2020年3月23日触及熊市底部以来，已上涨超过90%。</blockquote> While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.<blockquote>虽然许多高质量和创新的企业引领了这场反弹，但它也让相当多糟糕的公司蓬勃发展。我建议像七月瘟疫一样避开以下五只超受欢迎的股票。</blockquote> Coinbase Global<blockquote>比特币基地全球</blockquote> First up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin&nbsp;andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.<blockquote>首先是加密货币交易所和生态系统比特币基地全球（纳斯达克：硬币）。Coinbase很受欢迎，因为投资者纷纷涌入Coinbase等公司，其第一季度收入和利润飙升得如此之快比特币和以太币.问题是有三种催化剂对Coinbase经纪模式不利。</blockquote> To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.<blockquote>首先，没有什么可以阻止竞争交易所降低Coinbase Global的费用。目前它可能具有经过验证的用户优势，但不要低估加密货币投资者为节省交易费用而跳槽的意愿。我们在传统券商中目睹了这一点，该行业最终实现了免佣金。</blockquote> Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.<blockquote>其次，加密货币有繁荣和萧条周期的历史。在过去十年中，比特币曾发生过三起独立的事件，其价值至少缩水80%。这是一项完全基于动量的投资，当上行动力枯竭时，Coinbase的交易收入也会枯竭。继2017年达到峰值后，Coinbase的收入在随后几年几乎减半。</blockquote> And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.<blockquote>第三，根据CoinShares数字资产基金流量周刊的数据，截至6月28日的过去四周内，加密货币资金流出量为2.573亿美元。这进一步证明，随着这些资产远低于高点，人们对加密货币的兴趣已经在下降。可以说，Coinbase并不是一只您未来想要拥有的股票。</blockquote> Cassava Sciences<blockquote>木薯科学</blockquote> Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).<blockquote>另一家风险回报比糟糕的超受欢迎公司是临床阶段的生物技术股票木薯科学（纳斯达克：萨瓦）。</blockquote> Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.<blockquote>Cassava在2月份宣布了simufilam治疗阿尔茨海默病的中期分析的积极临床数据，这理所当然地引起了轰动。这项开放标签试验显示，在六个月时认知和行为有所改善，最近允许Cassava概述其涉及其主要候选药物的3期试验计划。</blockquote> I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.<blockquote>我希望simufilam能够成功，但历史表明阿尔茨海默氏症是<a href=\"https://laohu8.com/S/AONE\">一</a>最难治疗的疾病。除了BiogenAduhelm获得了美国食品和药物管理局(FDA)的批准，但因缺乏明确的益处而受到严厉批评，十多年来，每种阿尔茨海默病药物都在后期研究中失败。投资者所要做的就是一项旨在招募100名患者的试验的早期开放标签数据。在大型3期阿尔茨海默病试验中，早期或中期的积极结果被粉碎的情况并不罕见。</blockquote> Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.<blockquote>尽管Cassava筹集了大量现金来继续其研究，但历史表明simufilam成功的机会非常渺茫。这使得木薯科学很容易避免。</blockquote> GameStop<blockquote>游戏驿站</blockquote> If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).<blockquote>如果您一直在关注零售贸易运动（即Reddit股票），散户投资者正在寻找大量卖空的公司并试图进行轧空，您可能知道视频游戏和配件零售商游戏驿站（纽约证券交易所代码：GME）。</blockquote> On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.<blockquote>在<a href=\"https://laohu8.com/S/AONE.U\">一</a>另一方面，游戏驿站能够利用其最近的名气，通过出售股票为其正在进行的向数字游戏公司的转型筹集资金。这是一项急需的举措，此前电子商务销售额在2020财年增长了191%，在假期期间比去年同期增长了四倍多。</blockquote> However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.<blockquote>然而，这些融资并没有忽视前任管理团队让公司失望的事实。二十年来，实体游戏模式运行良好。然而，当游戏走向数字化时，坚持这种实体模式会让公司陷入不稳定的境地。如今，即使电子商务快速增长，游戏驿站仍在继续亏损，去年同店销售额下降了近10%。数字销售可能在增长，但随着游戏驿站关闭其实体店以降低成本，总收入将无处可去。</blockquote> GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.<blockquote>游戏驿站绝不是破产的候选者，我实际上可以看到几年后实现盈利的道路。但话虽如此，考虑到未来漫长的转型和运营亏损，所看到的收益毫无意义。</blockquote> Inovio Pharmaceuticals<blockquote>Inovio制药公司</blockquote> Biotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.<blockquote>生物科技股可以提供充足的机会，或者Inovio制药公司（纳斯达克：INO）案例，吸走长期投资者的命脉。</blockquote> Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.<blockquote>Inovio似乎是一家仅基于纸张的有趣公司。它的产品线目前包括十几种治疗癌症、传染病和人乳头瘤病毒的临床候选药物。最有前途的看起来是INO-4800，这是该公司的冠状病毒病2019（COVID-19）候选疫苗，已准备好进行3期研究。但如果你深入研究Inovio的临床表现，你会非常失望。</blockquote> For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.<blockquote>例如，INO-4800在美国已被部分临床搁置，而监管机构要求提供有关Inovio疫苗及其输送系统Cellectra的更多数据。最近，INO-4800的后期资金被美国政府取消，这就是为什么它现在正在为其COVID-19候选药物寻求国际研究。</blockquote> If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.<blockquote>如果你认为我不公平地指责Inovio在新冠肺炎的挣扎，那就更进一步吧。四十年来，Inovio一直未能获得FDA批准的药物。这并不是我希望Inovio发生不好的事情——这是现实，希望和结果很长一段时间都没有与这家公司保持一致。在Inovio在后期临床试验中证明自己之前，值得避免使用。</blockquote> AMC Entertainment<blockquote>AMC院线</blockquote> Finally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.<blockquote>最后，我不能忘记正在进行的抽水和转储计划AMC院线（纽约证券交易所代码：AMC）。尽管在AMC通过发行大量股票和高息债务自救后，散户投资者能够通过1月份的轧空来宣称胜利，但最近的上涨与轧空无关。相反，它主要基于炒作，在留言板上故意混淆具体的基本数据，以及广泛的，公然的错误信息。</blockquote> AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.<blockquote>AMC的散户投资者希望你相信基本面并不重要，但尝试驾驶一辆没有发动机的汽车，看看你能走多远。AMC正在应对行业票房收入连续19年下降的问题，并且随着电影制片厂依赖流媒体，其部分电影独家经营权正在消失。电影院将会有一席之地，但AMC的潜在市场逐年萎缩。</blockquote> AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.<blockquote>AMC的散户投资者还会让您相信该公司在筹集20亿美元资本后状况良好。尽管近期破产传闻已被搁置，但2027年债券价格远未接近面值。你会问，为什么？因为债券持有人不相信AMC会逃脱破产。</blockquote> I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.<blockquote>我一生中见过足够多的泵和转储活动来识别它们，并且AMC检查了所有的框。我的建议是不要做空AMC。我的建议是完全避免。所有的抽水和转储计划最终都会崩溃，AMC也不例外。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nThe motley fool2021-07-06 09:32\n\n</h4>\n</header>\n<article>\nFor the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&amp;P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.<blockquote>在过去的15个月里，华尔街和投资者享受了历史性的反弹。基准标普500自2020年3月23日触及熊市底部以来，已上涨超过90%。</blockquote> While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.<blockquote>虽然许多高质量和创新的企业引领了这场反弹，但它也让相当多糟糕的公司蓬勃发展。我建议像七月瘟疫一样避开以下五只超受欢迎的股票。</blockquote> Coinbase Global<blockquote>比特币基地全球</blockquote> First up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin&nbsp;andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.<blockquote>首先是加密货币交易所和生态系统比特币基地全球（纳斯达克：硬币）。Coinbase很受欢迎，因为投资者纷纷涌入Coinbase等公司，其第一季度收入和利润飙升得如此之快比特币和以太币.问题是有三种催化剂对Coinbase经纪模式不利。</blockquote> To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.<blockquote>首先，没有什么可以阻止竞争交易所降低Coinbase Global的费用。目前它可能具有经过验证的用户优势，但不要低估加密货币投资者为节省交易费用而跳槽的意愿。我们在传统券商中目睹了这一点，该行业最终实现了免佣金。</blockquote> Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.<blockquote>其次，加密货币有繁荣和萧条周期的历史。在过去十年中，比特币曾发生过三起独立的事件，其价值至少缩水80%。这是一项完全基于动量的投资，当上行动力枯竭时，Coinbase的交易收入也会枯竭。继2017年达到峰值后，Coinbase的收入在随后几年几乎减半。</blockquote> And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.<blockquote>第三，根据CoinShares数字资产基金流量周刊的数据，截至6月28日的过去四周内，加密货币资金流出量为2.573亿美元。这进一步证明，随着这些资产远低于高点，人们对加密货币的兴趣已经在下降。可以说，Coinbase并不是一只您未来想要拥有的股票。</blockquote> Cassava Sciences<blockquote>木薯科学</blockquote> Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).<blockquote>另一家风险回报比糟糕的超受欢迎公司是临床阶段的生物技术股票木薯科学（纳斯达克：萨瓦）。</blockquote> Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.<blockquote>Cassava在2月份宣布了simufilam治疗阿尔茨海默病的中期分析的积极临床数据，这理所当然地引起了轰动。这项开放标签试验显示，在六个月时认知和行为有所改善，最近允许Cassava概述其涉及其主要候选药物的3期试验计划。</blockquote> I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.<blockquote>我希望simufilam能够成功，但历史表明阿尔茨海默氏症是<a href=\"https://laohu8.com/S/AONE\">一</a>最难治疗的疾病。除了BiogenAduhelm获得了美国食品和药物管理局(FDA)的批准，但因缺乏明确的益处而受到严厉批评，十多年来，每种阿尔茨海默病药物都在后期研究中失败。投资者所要做的就是一项旨在招募100名患者的试验的早期开放标签数据。在大型3期阿尔茨海默病试验中，早期或中期的积极结果被粉碎的情况并不罕见。</blockquote> Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.<blockquote>尽管Cassava筹集了大量现金来继续其研究，但历史表明simufilam成功的机会非常渺茫。这使得木薯科学很容易避免。</blockquote> GameStop<blockquote>游戏驿站</blockquote> If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).<blockquote>如果您一直在关注零售贸易运动（即Reddit股票），散户投资者正在寻找大量卖空的公司并试图进行轧空，您可能知道视频游戏和配件零售商游戏驿站（纽约证券交易所代码：GME）。</blockquote> On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.<blockquote>在<a href=\"https://laohu8.com/S/AONE.U\">一</a>另一方面，游戏驿站能够利用其最近的名气，通过出售股票为其正在进行的向数字游戏公司的转型筹集资金。这是一项急需的举措，此前电子商务销售额在2020财年增长了191%，在假期期间比去年同期增长了四倍多。</blockquote> However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.<blockquote>然而，这些融资并没有忽视前任管理团队让公司失望的事实。二十年来，实体游戏模式运行良好。然而，当游戏走向数字化时，坚持这种实体模式会让公司陷入不稳定的境地。如今，即使电子商务快速增长，游戏驿站仍在继续亏损，去年同店销售额下降了近10%。数字销售可能在增长，但随着游戏驿站关闭其实体店以降低成本，总收入将无处可去。</blockquote> GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.<blockquote>游戏驿站绝不是破产的候选者，我实际上可以看到几年后实现盈利的道路。但话虽如此，考虑到未来漫长的转型和运营亏损，所看到的收益毫无意义。</blockquote> Inovio Pharmaceuticals<blockquote>Inovio制药公司</blockquote> Biotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.<blockquote>生物科技股可以提供充足的机会，或者Inovio制药公司（纳斯达克：INO）案例，吸走长期投资者的命脉。</blockquote> Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.<blockquote>Inovio似乎是一家仅基于纸张的有趣公司。它的产品线目前包括十几种治疗癌症、传染病和人乳头瘤病毒的临床候选药物。最有前途的看起来是INO-4800，这是该公司的冠状病毒病2019（COVID-19）候选疫苗，已准备好进行3期研究。但如果你深入研究Inovio的临床表现，你会非常失望。</blockquote> For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.<blockquote>例如，INO-4800在美国已被部分临床搁置，而监管机构要求提供有关Inovio疫苗及其输送系统Cellectra的更多数据。最近，INO-4800的后期资金被美国政府取消，这就是为什么它现在正在为其COVID-19候选药物寻求国际研究。</blockquote> If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.<blockquote>如果你认为我不公平地指责Inovio在新冠肺炎的挣扎，那就更进一步吧。四十年来，Inovio一直未能获得FDA批准的药物。这并不是我希望Inovio发生不好的事情——这是现实，希望和结果很长一段时间都没有与这家公司保持一致。在Inovio在后期临床试验中证明自己之前，值得避免使用。</blockquote> AMC Entertainment<blockquote>AMC院线</blockquote> Finally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.<blockquote>最后，我不能忘记正在进行的抽水和转储计划AMC院线（纽约证券交易所代码：AMC）。尽管在AMC通过发行大量股票和高息债务自救后，散户投资者能够通过1月份的轧空来宣称胜利，但最近的上涨与轧空无关。相反，它主要基于炒作，在留言板上故意混淆具体的基本数据，以及广泛的，公然的错误信息。</blockquote> AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.<blockquote>AMC的散户投资者希望你相信基本面并不重要，但尝试驾驶一辆没有发动机的汽车，看看你能走多远。AMC正在应对行业票房收入连续19年下降的问题，并且随着电影制片厂依赖流媒体，其部分电影独家经营权正在消失。电影院将会有一席之地，但AMC的潜在市场逐年萎缩。</blockquote> AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.<blockquote>AMC的散户投资者还会让您相信该公司在筹集20亿美元资本后状况良好。尽管近期破产传闻已被搁置，但2027年债券价格远未接近面值。你会问，为什么？因为债券持有人不相信AMC会逃脱破产。</blockquote> I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.<blockquote>我一生中见过足够多的泵和转储活动来识别它们，并且AMC检查了所有的框。我的建议是不要做空AMC。我的建议是完全避免。所有的抽水和转储计划最终都会崩溃，AMC也不例外。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/\">The motley fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GME":"游戏驿站","SAVA":"Cassava Sciences Inc","INO":"伊诺维奥制药","COIN":"Coinbase Global, Inc.","AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164348327","content_text":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.\nWhile a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.\nCoinbase Global\nFirst up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.\nTo start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.\nSecond,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.\nAnd third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.\nCassava Sciences\nAnother ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).\nCassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.\nI'd love for simufilam to be successful, but history has shown that Alzheimer's is one of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.\nAlthough Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.\nGameStop\nIf you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).\nOn one hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.\nHowever, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.\nGameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.\nInovio Pharmaceuticals\nBiotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.\nInovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.\nFor example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.\nIf you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.\nAMC Entertainment\nFinally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.\nAMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.\nAMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.\nI've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.","news_type":1,"symbols_score_info":{"SAVA":0.9,"INO":0.9,"GME":0.9,"COIN":0.9,"AMC":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5134155,"gmtCreate":1625547979946,"gmtModify":1635236182935,"authorId":3573976216768090,"author":{"id":3573976216768090,"idStr":"3573976216768090","authorId":3573976216768090,"name":"3nn","avatar":"https://static.tigerbbs.com/303b8f037330070d95adf2f11d86d23a","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":154728268,"type":1,"supId":0,"prevId":0,"content":"good one lol","text":"good one lol","html":"good one lol"}],"langContent":"EN"},{"id":154765422,"gmtCreate":1625546775566,"gmtModify":1633939763846,"author":{"id":"3563672045211925","authorId":"3563672045211925","name":"balm","avatar":"https://static.tigerbbs.com/0b3156e053d7ec11324d42163b84c2d1","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3563672045211925","authorIdStr":"3563672045211925"},"htmlText":"Good reminder","listText":"Good reminder","text":"Good reminder","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/154765422","repostId":1164348327,"repostType":2,"repost":{"id":"1164348327","kind":"news","pubTimestamp":1625535165,"share":"https://www.laohu8.com/m/news/1164348327?lang=zh_CN&edition=full","pubTime":"2021-07-06 09:32","market":"us","language":"en","title":"5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1164348327","media":"The motley fool","summary":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The ben","content":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&amp;P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.<blockquote>在过去的15个月里，华尔街和投资者享受了历史性的反弹。基准标普500自2020年3月23日触及熊市底部以来，已上涨超过90%。</blockquote> While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.<blockquote>虽然许多高质量和创新的企业引领了这场反弹，但它也让相当多糟糕的公司蓬勃发展。我建议像七月瘟疫一样避开以下五只超受欢迎的股票。</blockquote> Coinbase Global<blockquote>比特币基地全球</blockquote> First up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin&nbsp;andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.<blockquote>首先是加密货币交易所和生态系统比特币基地全球（纳斯达克：硬币）。Coinbase很受欢迎，因为投资者纷纷涌入Coinbase等公司，其第一季度收入和利润飙升得如此之快比特币和以太币.问题是有三种催化剂对Coinbase经纪模式不利。</blockquote> To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.<blockquote>首先，没有什么可以阻止竞争交易所降低Coinbase Global的费用。目前它可能具有经过验证的用户优势，但不要低估加密货币投资者为节省交易费用而跳槽的意愿。我们在传统券商中目睹了这一点，该行业最终实现了免佣金。</blockquote> Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.<blockquote>其次，加密货币有繁荣和萧条周期的历史。在过去十年中，比特币曾发生过三起独立的事件，其价值至少缩水80%。这是一项完全基于动量的投资，当上行动力枯竭时，Coinbase的交易收入也会枯竭。继2017年达到峰值后，Coinbase的收入在随后几年几乎减半。</blockquote> And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.<blockquote>第三，根据CoinShares数字资产基金流量周刊的数据，截至6月28日的过去四周内，加密货币资金流出量为2.573亿美元。这进一步证明，随着这些资产远低于高点，人们对加密货币的兴趣已经在下降。可以说，Coinbase并不是一只您未来想要拥有的股票。</blockquote> Cassava Sciences<blockquote>木薯科学</blockquote> Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).<blockquote>另一家风险回报比糟糕的超受欢迎公司是临床阶段的生物技术股票木薯科学（纳斯达克：萨瓦）。</blockquote> Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.<blockquote>Cassava在2月份宣布了simufilam治疗阿尔茨海默病的中期分析的积极临床数据，这理所当然地引起了轰动。这项开放标签试验显示，在六个月时认知和行为有所改善，最近允许Cassava概述其涉及其主要候选药物的3期试验计划。</blockquote> I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.<blockquote>我希望simufilam能够成功，但历史表明阿尔茨海默氏症是<a href=\"https://laohu8.com/S/AONE\">一</a>最难治疗的疾病。除了BiogenAduhelm获得了美国食品和药物管理局(FDA)的批准，但因缺乏明确的益处而受到严厉批评，十多年来，每种阿尔茨海默病药物都在后期研究中失败。投资者所要做的就是一项旨在招募100名患者的试验的早期开放标签数据。在大型3期阿尔茨海默病试验中，早期或中期的积极结果被粉碎的情况并不罕见。</blockquote> Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.<blockquote>尽管Cassava筹集了大量现金来继续其研究，但历史表明simufilam成功的机会非常渺茫。这使得木薯科学很容易避免。</blockquote> GameStop<blockquote>游戏驿站</blockquote> If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).<blockquote>如果您一直在关注零售贸易运动（即Reddit股票），散户投资者正在寻找大量卖空的公司并试图进行轧空，您可能知道视频游戏和配件零售商游戏驿站（纽约证券交易所代码：GME）。</blockquote> On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.<blockquote>在<a href=\"https://laohu8.com/S/AONE.U\">一</a>另一方面，游戏驿站能够利用其最近的名气，通过出售股票为其正在进行的向数字游戏公司的转型筹集资金。这是一项急需的举措，此前电子商务销售额在2020财年增长了191%，在假期期间比去年同期增长了四倍多。</blockquote> However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.<blockquote>然而，这些融资并没有忽视前任管理团队让公司失望的事实。二十年来，实体游戏模式运行良好。然而，当游戏走向数字化时，坚持这种实体模式会让公司陷入不稳定的境地。如今，即使电子商务快速增长，游戏驿站仍在继续亏损，去年同店销售额下降了近10%。数字销售可能在增长，但随着游戏驿站关闭其实体店以降低成本，总收入将无处可去。</blockquote> GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.<blockquote>游戏驿站绝不是破产的候选者，我实际上可以看到几年后实现盈利的道路。但话虽如此，考虑到未来漫长的转型和运营亏损，所看到的收益毫无意义。</blockquote> Inovio Pharmaceuticals<blockquote>Inovio制药公司</blockquote> Biotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.<blockquote>生物科技股可以提供充足的机会，或者Inovio制药公司（纳斯达克：INO）案例，吸走长期投资者的命脉。</blockquote> Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.<blockquote>Inovio似乎是一家仅基于纸张的有趣公司。它的产品线目前包括十几种治疗癌症、传染病和人乳头瘤病毒的临床候选药物。最有前途的看起来是INO-4800，这是该公司的冠状病毒病2019（COVID-19）候选疫苗，已准备好进行3期研究。但如果你深入研究Inovio的临床表现，你会非常失望。</blockquote> For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.<blockquote>例如，INO-4800在美国已被部分临床搁置，而监管机构要求提供有关Inovio疫苗及其输送系统Cellectra的更多数据。最近，INO-4800的后期资金被美国政府取消，这就是为什么它现在正在为其COVID-19候选药物寻求国际研究。</blockquote> If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.<blockquote>如果你认为我不公平地指责Inovio在新冠肺炎的挣扎，那就更进一步吧。四十年来，Inovio一直未能获得FDA批准的药物。这并不是我希望Inovio发生不好的事情——这是现实，希望和结果很长一段时间都没有与这家公司保持一致。在Inovio在后期临床试验中证明自己之前，值得避免使用。</blockquote> AMC Entertainment<blockquote>AMC院线</blockquote> Finally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.<blockquote>最后，我不能忘记正在进行的抽水和转储计划AMC院线（纽约证券交易所代码：AMC）。尽管在AMC通过发行大量股票和高息债务自救后，散户投资者能够通过1月份的轧空来宣称胜利，但最近的上涨与轧空无关。相反，它主要基于炒作，在留言板上故意混淆具体的基本数据，以及广泛的，公然的错误信息。</blockquote> AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.<blockquote>AMC的散户投资者希望你相信基本面并不重要，但尝试驾驶一辆没有发动机的汽车，看看你能走多远。AMC正在应对行业票房收入连续19年下降的问题，并且随着电影制片厂依赖流媒体，其部分电影独家经营权正在消失。电影院将会有一席之地，但AMC的潜在市场逐年萎缩。</blockquote> AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.<blockquote>AMC的散户投资者还会让您相信该公司在筹集20亿美元资本后状况良好。尽管近期破产传闻已被搁置，但2027年债券价格远未接近面值。你会问，为什么？因为债券持有人不相信AMC会逃脱破产。</blockquote> I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.<blockquote>我一生中见过足够多的泵和转储活动来识别它们，并且AMC检查了所有的框。我的建议是不要做空AMC。我的建议是完全避免。所有的抽水和转储计划最终都会崩溃，AMC也不例外。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nThe motley fool2021-07-06 09:32\n\n</h4>\n</header>\n<article>\nFor the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&amp;P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.<blockquote>在过去的15个月里，华尔街和投资者享受了历史性的反弹。基准标普500自2020年3月23日触及熊市底部以来，已上涨超过90%。</blockquote> While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.<blockquote>虽然许多高质量和创新的企业引领了这场反弹，但它也让相当多糟糕的公司蓬勃发展。我建议像七月瘟疫一样避开以下五只超受欢迎的股票。</blockquote> Coinbase Global<blockquote>比特币基地全球</blockquote> First up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin&nbsp;andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.<blockquote>首先是加密货币交易所和生态系统比特币基地全球（纳斯达克：硬币）。Coinbase很受欢迎，因为投资者纷纷涌入Coinbase等公司，其第一季度收入和利润飙升得如此之快比特币和以太币.问题是有三种催化剂对Coinbase经纪模式不利。</blockquote> To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.<blockquote>首先，没有什么可以阻止竞争交易所降低Coinbase Global的费用。目前它可能具有经过验证的用户优势，但不要低估加密货币投资者为节省交易费用而跳槽的意愿。我们在传统券商中目睹了这一点，该行业最终实现了免佣金。</blockquote> Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.<blockquote>其次，加密货币有繁荣和萧条周期的历史。在过去十年中，比特币曾发生过三起独立的事件，其价值至少缩水80%。这是一项完全基于动量的投资，当上行动力枯竭时，Coinbase的交易收入也会枯竭。继2017年达到峰值后，Coinbase的收入在随后几年几乎减半。</blockquote> And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.<blockquote>第三，根据CoinShares数字资产基金流量周刊的数据，截至6月28日的过去四周内，加密货币资金流出量为2.573亿美元。这进一步证明，随着这些资产远低于高点，人们对加密货币的兴趣已经在下降。可以说，Coinbase并不是一只您未来想要拥有的股票。</blockquote> Cassava Sciences<blockquote>木薯科学</blockquote> Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).<blockquote>另一家风险回报比糟糕的超受欢迎公司是临床阶段的生物技术股票木薯科学（纳斯达克：萨瓦）。</blockquote> Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.<blockquote>Cassava在2月份宣布了simufilam治疗阿尔茨海默病的中期分析的积极临床数据，这理所当然地引起了轰动。这项开放标签试验显示，在六个月时认知和行为有所改善，最近允许Cassava概述其涉及其主要候选药物的3期试验计划。</blockquote> I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.<blockquote>我希望simufilam能够成功，但历史表明阿尔茨海默氏症是<a href=\"https://laohu8.com/S/AONE\">一</a>最难治疗的疾病。除了BiogenAduhelm获得了美国食品和药物管理局(FDA)的批准，但因缺乏明确的益处而受到严厉批评，十多年来，每种阿尔茨海默病药物都在后期研究中失败。投资者所要做的就是一项旨在招募100名患者的试验的早期开放标签数据。在大型3期阿尔茨海默病试验中，早期或中期的积极结果被粉碎的情况并不罕见。</blockquote> Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.<blockquote>尽管Cassava筹集了大量现金来继续其研究，但历史表明simufilam成功的机会非常渺茫。这使得木薯科学很容易避免。</blockquote> GameStop<blockquote>游戏驿站</blockquote> If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).<blockquote>如果您一直在关注零售贸易运动（即Reddit股票），散户投资者正在寻找大量卖空的公司并试图进行轧空，您可能知道视频游戏和配件零售商游戏驿站（纽约证券交易所代码：GME）。</blockquote> On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.<blockquote>在<a href=\"https://laohu8.com/S/AONE.U\">一</a>另一方面，游戏驿站能够利用其最近的名气，通过出售股票为其正在进行的向数字游戏公司的转型筹集资金。这是一项急需的举措，此前电子商务销售额在2020财年增长了191%，在假期期间比去年同期增长了四倍多。</blockquote> However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.<blockquote>然而，这些融资并没有忽视前任管理团队让公司失望的事实。二十年来，实体游戏模式运行良好。然而，当游戏走向数字化时，坚持这种实体模式会让公司陷入不稳定的境地。如今，即使电子商务快速增长，游戏驿站仍在继续亏损，去年同店销售额下降了近10%。数字销售可能在增长，但随着游戏驿站关闭其实体店以降低成本，总收入将无处可去。</blockquote> GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.<blockquote>游戏驿站绝不是破产的候选者，我实际上可以看到几年后实现盈利的道路。但话虽如此，考虑到未来漫长的转型和运营亏损，所看到的收益毫无意义。</blockquote> Inovio Pharmaceuticals<blockquote>Inovio制药公司</blockquote> Biotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.<blockquote>生物科技股可以提供充足的机会，或者Inovio制药公司（纳斯达克：INO）案例，吸走长期投资者的命脉。</blockquote> Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.<blockquote>Inovio似乎是一家仅基于纸张的有趣公司。它的产品线目前包括十几种治疗癌症、传染病和人乳头瘤病毒的临床候选药物。最有前途的看起来是INO-4800，这是该公司的冠状病毒病2019（COVID-19）候选疫苗，已准备好进行3期研究。但如果你深入研究Inovio的临床表现，你会非常失望。</blockquote> For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.<blockquote>例如，INO-4800在美国已被部分临床搁置，而监管机构要求提供有关Inovio疫苗及其输送系统Cellectra的更多数据。最近，INO-4800的后期资金被美国政府取消，这就是为什么它现在正在为其COVID-19候选药物寻求国际研究。</blockquote> If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.<blockquote>如果你认为我不公平地指责Inovio在新冠肺炎的挣扎，那就更进一步吧。四十年来，Inovio一直未能获得FDA批准的药物。这并不是我希望Inovio发生不好的事情——这是现实，希望和结果很长一段时间都没有与这家公司保持一致。在Inovio在后期临床试验中证明自己之前，值得避免使用。</blockquote> AMC Entertainment<blockquote>AMC院线</blockquote> Finally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.<blockquote>最后，我不能忘记正在进行的抽水和转储计划AMC院线（纽约证券交易所代码：AMC）。尽管在AMC通过发行大量股票和高息债务自救后，散户投资者能够通过1月份的轧空来宣称胜利，但最近的上涨与轧空无关。相反，它主要基于炒作，在留言板上故意混淆具体的基本数据，以及广泛的，公然的错误信息。</blockquote> AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.<blockquote>AMC的散户投资者希望你相信基本面并不重要，但尝试驾驶一辆没有发动机的汽车，看看你能走多远。AMC正在应对行业票房收入连续19年下降的问题，并且随着电影制片厂依赖流媒体，其部分电影独家经营权正在消失。电影院将会有一席之地，但AMC的潜在市场逐年萎缩。</blockquote> AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.<blockquote>AMC的散户投资者还会让您相信该公司在筹集20亿美元资本后状况良好。尽管近期破产传闻已被搁置，但2027年债券价格远未接近面值。你会问，为什么？因为债券持有人不相信AMC会逃脱破产。</blockquote> I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.<blockquote>我一生中见过足够多的泵和转储活动来识别它们，并且AMC检查了所有的框。我的建议是不要做空AMC。我的建议是完全避免。所有的抽水和转储计划最终都会崩溃，AMC也不例外。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/\">The motley fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GME":"游戏驿站","SAVA":"Cassava Sciences Inc","INO":"伊诺维奥制药","COIN":"Coinbase Global, Inc.","AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164348327","content_text":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.\nWhile a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.\nCoinbase Global\nFirst up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.\nTo start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.\nSecond,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.\nAnd third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.\nCassava Sciences\nAnother ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).\nCassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.\nI'd love for simufilam to be successful, but history has shown that Alzheimer's is one of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.\nAlthough Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.\nGameStop\nIf you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).\nOn one hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.\nHowever, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.\nGameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.\nInovio Pharmaceuticals\nBiotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.\nInovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.\nFor example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.\nIf you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.\nAMC Entertainment\nFinally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.\nAMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.\nAMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.\nI've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.","news_type":1,"symbols_score_info":{"SAVA":0.9,"INO":0.9,"GME":0.9,"COIN":0.9,"AMC":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":154706732,"gmtCreate":1625543236126,"gmtModify":1633939801468,"author":{"id":"4088394474156640","authorId":"4088394474156640","name":"JessHang","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4088394474156640","authorIdStr":"4088394474156640"},"htmlText":"Great advise 👍","listText":"Great advise 👍","text":"Great advise 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/154706732","repostId":1164348327,"repostType":4,"repost":{"id":"1164348327","kind":"news","pubTimestamp":1625535165,"share":"https://www.laohu8.com/m/news/1164348327?lang=zh_CN&edition=full","pubTime":"2021-07-06 09:32","market":"us","language":"en","title":"5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1164348327","media":"The motley fool","summary":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The ben","content":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&amp;P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.<blockquote>在过去的15个月里，华尔街和投资者享受了历史性的反弹。基准标普500自2020年3月23日触及熊市底部以来，已上涨超过90%。</blockquote> While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.<blockquote>虽然许多高质量和创新的企业引领了这场反弹，但它也让相当多糟糕的公司蓬勃发展。我建议像七月瘟疫一样避开以下五只超受欢迎的股票。</blockquote> Coinbase Global<blockquote>比特币基地全球</blockquote> First up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin&nbsp;andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.<blockquote>首先是加密货币交易所和生态系统比特币基地全球（纳斯达克：硬币）。Coinbase很受欢迎，因为投资者纷纷涌入Coinbase等公司，其第一季度收入和利润飙升得如此之快比特币和以太币.问题是有三种催化剂对Coinbase经纪模式不利。</blockquote> To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.<blockquote>首先，没有什么可以阻止竞争交易所降低Coinbase Global的费用。目前它可能具有经过验证的用户优势，但不要低估加密货币投资者为节省交易费用而跳槽的意愿。我们在传统券商中目睹了这一点，该行业最终实现了免佣金。</blockquote> Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.<blockquote>其次，加密货币有繁荣和萧条周期的历史。在过去十年中，比特币曾发生过三起独立的事件，其价值至少缩水80%。这是一项完全基于动量的投资，当上行动力枯竭时，Coinbase的交易收入也会枯竭。继2017年达到峰值后，Coinbase的收入在随后几年几乎减半。</blockquote> And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.<blockquote>第三，根据CoinShares数字资产基金流量周刊的数据，截至6月28日的过去四周内，加密货币资金流出量为2.573亿美元。这进一步证明，随着这些资产远低于高点，人们对加密货币的兴趣已经在下降。可以说，Coinbase并不是一只您未来想要拥有的股票。</blockquote> Cassava Sciences<blockquote>木薯科学</blockquote> Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).<blockquote>另一家风险回报比糟糕的超受欢迎公司是临床阶段的生物技术股票木薯科学（纳斯达克：萨瓦）。</blockquote> Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.<blockquote>Cassava在2月份宣布了simufilam治疗阿尔茨海默病的中期分析的积极临床数据，这理所当然地引起了轰动。这项开放标签试验显示，在六个月时认知和行为有所改善，最近允许Cassava概述其涉及其主要候选药物的3期试验计划。</blockquote> I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.<blockquote>我希望simufilam能够成功，但历史表明阿尔茨海默氏症是<a href=\"https://laohu8.com/S/AONE\">一</a>最难治疗的疾病。除了BiogenAduhelm获得了美国食品和药物管理局(FDA)的批准，但因缺乏明确的益处而受到严厉批评，十多年来，每种阿尔茨海默病药物都在后期研究中失败。投资者所要做的就是一项旨在招募100名患者的试验的早期开放标签数据。在大型3期阿尔茨海默病试验中，早期或中期的积极结果被粉碎的情况并不罕见。</blockquote> Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.<blockquote>尽管Cassava筹集了大量现金来继续其研究，但历史表明simufilam成功的机会非常渺茫。这使得木薯科学很容易避免。</blockquote> GameStop<blockquote>游戏驿站</blockquote> If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).<blockquote>如果您一直在关注零售贸易运动（即Reddit股票），散户投资者正在寻找大量卖空的公司并试图进行轧空，您可能知道视频游戏和配件零售商游戏驿站（纽约证券交易所代码：GME）。</blockquote> On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.<blockquote>在<a href=\"https://laohu8.com/S/AONE.U\">一</a>另一方面，游戏驿站能够利用其最近的名气，通过出售股票为其正在进行的向数字游戏公司的转型筹集资金。这是一项急需的举措，此前电子商务销售额在2020财年增长了191%，在假期期间比去年同期增长了四倍多。</blockquote> However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.<blockquote>然而，这些融资并没有忽视前任管理团队让公司失望的事实。二十年来，实体游戏模式运行良好。然而，当游戏走向数字化时，坚持这种实体模式会让公司陷入不稳定的境地。如今，即使电子商务快速增长，游戏驿站仍在继续亏损，去年同店销售额下降了近10%。数字销售可能在增长，但随着游戏驿站关闭其实体店以降低成本，总收入将无处可去。</blockquote> GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.<blockquote>游戏驿站绝不是破产的候选者，我实际上可以看到几年后实现盈利的道路。但话虽如此，考虑到未来漫长的转型和运营亏损，所看到的收益毫无意义。</blockquote> Inovio Pharmaceuticals<blockquote>Inovio制药公司</blockquote> Biotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.<blockquote>生物科技股可以提供充足的机会，或者Inovio制药公司（纳斯达克：INO）案例，吸走长期投资者的命脉。</blockquote> Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.<blockquote>Inovio似乎是一家仅基于纸张的有趣公司。它的产品线目前包括十几种治疗癌症、传染病和人乳头瘤病毒的临床候选药物。最有前途的看起来是INO-4800，这是该公司的冠状病毒病2019（COVID-19）候选疫苗，已准备好进行3期研究。但如果你深入研究Inovio的临床表现，你会非常失望。</blockquote> For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.<blockquote>例如，INO-4800在美国已被部分临床搁置，而监管机构要求提供有关Inovio疫苗及其输送系统Cellectra的更多数据。最近，INO-4800的后期资金被美国政府取消，这就是为什么它现在正在为其COVID-19候选药物寻求国际研究。</blockquote> If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.<blockquote>如果你认为我不公平地指责Inovio在新冠肺炎的挣扎，那就更进一步吧。四十年来，Inovio一直未能获得FDA批准的药物。这并不是我希望Inovio发生不好的事情——这是现实，希望和结果很长一段时间都没有与这家公司保持一致。在Inovio在后期临床试验中证明自己之前，值得避免使用。</blockquote> AMC Entertainment<blockquote>AMC院线</blockquote> Finally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.<blockquote>最后，我不能忘记正在进行的抽水和转储计划AMC院线（纽约证券交易所代码：AMC）。尽管在AMC通过发行大量股票和高息债务自救后，散户投资者能够通过1月份的轧空来宣称胜利，但最近的上涨与轧空无关。相反，它主要基于炒作，在留言板上故意混淆具体的基本数据，以及广泛的，公然的错误信息。</blockquote> AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.<blockquote>AMC的散户投资者希望你相信基本面并不重要，但尝试驾驶一辆没有发动机的汽车，看看你能走多远。AMC正在应对行业票房收入连续19年下降的问题，并且随着电影制片厂依赖流媒体，其部分电影独家经营权正在消失。电影院将会有一席之地，但AMC的潜在市场逐年萎缩。</blockquote> AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.<blockquote>AMC的散户投资者还会让您相信该公司在筹集20亿美元资本后状况良好。尽管近期破产传闻已被搁置，但2027年债券价格远未接近面值。你会问，为什么？因为债券持有人不相信AMC会逃脱破产。</blockquote> I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.<blockquote>我一生中见过足够多的泵和转储活动来识别它们，并且AMC检查了所有的框。我的建议是不要做空AMC。我的建议是完全避免。所有的抽水和转储计划最终都会崩溃，AMC也不例外。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nThe motley fool2021-07-06 09:32\n\n</h4>\n</header>\n<article>\nFor the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&amp;P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.<blockquote>在过去的15个月里，华尔街和投资者享受了历史性的反弹。基准标普500自2020年3月23日触及熊市底部以来，已上涨超过90%。</blockquote> While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.<blockquote>虽然许多高质量和创新的企业引领了这场反弹，但它也让相当多糟糕的公司蓬勃发展。我建议像七月瘟疫一样避开以下五只超受欢迎的股票。</blockquote> Coinbase Global<blockquote>比特币基地全球</blockquote> First up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin&nbsp;andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.<blockquote>首先是加密货币交易所和生态系统比特币基地全球（纳斯达克：硬币）。Coinbase很受欢迎，因为投资者纷纷涌入Coinbase等公司，其第一季度收入和利润飙升得如此之快比特币和以太币.问题是有三种催化剂对Coinbase经纪模式不利。</blockquote> To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.<blockquote>首先，没有什么可以阻止竞争交易所降低Coinbase Global的费用。目前它可能具有经过验证的用户优势，但不要低估加密货币投资者为节省交易费用而跳槽的意愿。我们在传统券商中目睹了这一点，该行业最终实现了免佣金。</blockquote> Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.<blockquote>其次，加密货币有繁荣和萧条周期的历史。在过去十年中，比特币曾发生过三起独立的事件，其价值至少缩水80%。这是一项完全基于动量的投资，当上行动力枯竭时，Coinbase的交易收入也会枯竭。继2017年达到峰值后，Coinbase的收入在随后几年几乎减半。</blockquote> And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.<blockquote>第三，根据CoinShares数字资产基金流量周刊的数据，截至6月28日的过去四周内，加密货币资金流出量为2.573亿美元。这进一步证明，随着这些资产远低于高点，人们对加密货币的兴趣已经在下降。可以说，Coinbase并不是一只您未来想要拥有的股票。</blockquote> Cassava Sciences<blockquote>木薯科学</blockquote> Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).<blockquote>另一家风险回报比糟糕的超受欢迎公司是临床阶段的生物技术股票木薯科学（纳斯达克：萨瓦）。</blockquote> Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.<blockquote>Cassava在2月份宣布了simufilam治疗阿尔茨海默病的中期分析的积极临床数据，这理所当然地引起了轰动。这项开放标签试验显示，在六个月时认知和行为有所改善，最近允许Cassava概述其涉及其主要候选药物的3期试验计划。</blockquote> I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.<blockquote>我希望simufilam能够成功，但历史表明阿尔茨海默氏症是<a href=\"https://laohu8.com/S/AONE\">一</a>最难治疗的疾病。除了BiogenAduhelm获得了美国食品和药物管理局(FDA)的批准，但因缺乏明确的益处而受到严厉批评，十多年来，每种阿尔茨海默病药物都在后期研究中失败。投资者所要做的就是一项旨在招募100名患者的试验的早期开放标签数据。在大型3期阿尔茨海默病试验中，早期或中期的积极结果被粉碎的情况并不罕见。</blockquote> Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.<blockquote>尽管Cassava筹集了大量现金来继续其研究，但历史表明simufilam成功的机会非常渺茫。这使得木薯科学很容易避免。</blockquote> GameStop<blockquote>游戏驿站</blockquote> If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).<blockquote>如果您一直在关注零售贸易运动（即Reddit股票），散户投资者正在寻找大量卖空的公司并试图进行轧空，您可能知道视频游戏和配件零售商游戏驿站（纽约证券交易所代码：GME）。</blockquote> On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.<blockquote>在<a href=\"https://laohu8.com/S/AONE.U\">一</a>另一方面，游戏驿站能够利用其最近的名气，通过出售股票为其正在进行的向数字游戏公司的转型筹集资金。这是一项急需的举措，此前电子商务销售额在2020财年增长了191%，在假期期间比去年同期增长了四倍多。</blockquote> However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.<blockquote>然而，这些融资并没有忽视前任管理团队让公司失望的事实。二十年来，实体游戏模式运行良好。然而，当游戏走向数字化时，坚持这种实体模式会让公司陷入不稳定的境地。如今，即使电子商务快速增长，游戏驿站仍在继续亏损，去年同店销售额下降了近10%。数字销售可能在增长，但随着游戏驿站关闭其实体店以降低成本，总收入将无处可去。</blockquote> GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.<blockquote>游戏驿站绝不是破产的候选者，我实际上可以看到几年后实现盈利的道路。但话虽如此，考虑到未来漫长的转型和运营亏损，所看到的收益毫无意义。</blockquote> Inovio Pharmaceuticals<blockquote>Inovio制药公司</blockquote> Biotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.<blockquote>生物科技股可以提供充足的机会，或者Inovio制药公司（纳斯达克：INO）案例，吸走长期投资者的命脉。</blockquote> Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.<blockquote>Inovio似乎是一家仅基于纸张的有趣公司。它的产品线目前包括十几种治疗癌症、传染病和人乳头瘤病毒的临床候选药物。最有前途的看起来是INO-4800，这是该公司的冠状病毒病2019（COVID-19）候选疫苗，已准备好进行3期研究。但如果你深入研究Inovio的临床表现，你会非常失望。</blockquote> For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.<blockquote>例如，INO-4800在美国已被部分临床搁置，而监管机构要求提供有关Inovio疫苗及其输送系统Cellectra的更多数据。最近，INO-4800的后期资金被美国政府取消，这就是为什么它现在正在为其COVID-19候选药物寻求国际研究。</blockquote> If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.<blockquote>如果你认为我不公平地指责Inovio在新冠肺炎的挣扎，那就更进一步吧。四十年来，Inovio一直未能获得FDA批准的药物。这并不是我希望Inovio发生不好的事情——这是现实，希望和结果很长一段时间都没有与这家公司保持一致。在Inovio在后期临床试验中证明自己之前，值得避免使用。</blockquote> AMC Entertainment<blockquote>AMC院线</blockquote> Finally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.<blockquote>最后，我不能忘记正在进行的抽水和转储计划AMC院线（纽约证券交易所代码：AMC）。尽管在AMC通过发行大量股票和高息债务自救后，散户投资者能够通过1月份的轧空来宣称胜利，但最近的上涨与轧空无关。相反，它主要基于炒作，在留言板上故意混淆具体的基本数据，以及广泛的，公然的错误信息。</blockquote> AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.<blockquote>AMC的散户投资者希望你相信基本面并不重要，但尝试驾驶一辆没有发动机的汽车，看看你能走多远。AMC正在应对行业票房收入连续19年下降的问题，并且随着电影制片厂依赖流媒体，其部分电影独家经营权正在消失。电影院将会有一席之地，但AMC的潜在市场逐年萎缩。</blockquote> AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.<blockquote>AMC的散户投资者还会让您相信该公司在筹集20亿美元资本后状况良好。尽管近期破产传闻已被搁置，但2027年债券价格远未接近面值。你会问，为什么？因为债券持有人不相信AMC会逃脱破产。</blockquote> I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.<blockquote>我一生中见过足够多的泵和转储活动来识别它们，并且AMC检查了所有的框。我的建议是不要做空AMC。我的建议是完全避免。所有的抽水和转储计划最终都会崩溃，AMC也不例外。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/\">The motley fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GME":"游戏驿站","SAVA":"Cassava Sciences Inc","INO":"伊诺维奥制药","COIN":"Coinbase Global, Inc.","AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164348327","content_text":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.\nWhile a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.\nCoinbase Global\nFirst up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.\nTo start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.\nSecond,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.\nAnd third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.\nCassava Sciences\nAnother ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).\nCassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.\nI'd love for simufilam to be successful, but history has shown that Alzheimer's is one of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.\nAlthough Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.\nGameStop\nIf you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).\nOn one hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.\nHowever, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.\nGameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.\nInovio Pharmaceuticals\nBiotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.\nInovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.\nFor example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.\nIf you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.\nAMC Entertainment\nFinally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.\nAMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.\nAMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.\nI've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.","news_type":1,"symbols_score_info":{"SAVA":0.9,"INO":0.9,"GME":0.9,"COIN":0.9,"AMC":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":154451676,"gmtCreate":1625540784495,"gmtModify":1631890443468,"author":{"id":"3581483267354246","authorId":"3581483267354246","name":"Zacific","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581483267354246","authorIdStr":"3581483267354246"},"htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/154451676","repostId":1164348327,"repostType":4,"repost":{"id":"1164348327","kind":"news","pubTimestamp":1625535165,"share":"https://www.laohu8.com/m/news/1164348327?lang=zh_CN&edition=full","pubTime":"2021-07-06 09:32","market":"us","language":"en","title":"5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1164348327","media":"The motley fool","summary":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The ben","content":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&amp;P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.<blockquote>在过去的15个月里，华尔街和投资者享受了历史性的反弹。基准标普500自2020年3月23日触及熊市底部以来，已上涨超过90%。</blockquote> While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.<blockquote>虽然许多高质量和创新的企业引领了这场反弹，但它也让相当多糟糕的公司蓬勃发展。我建议像七月瘟疫一样避开以下五只超受欢迎的股票。</blockquote> Coinbase Global<blockquote>比特币基地全球</blockquote> First up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin&nbsp;andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.<blockquote>首先是加密货币交易所和生态系统比特币基地全球（纳斯达克：硬币）。Coinbase很受欢迎，因为投资者纷纷涌入Coinbase等公司，其第一季度收入和利润飙升得如此之快比特币和以太币.问题是有三种催化剂对Coinbase经纪模式不利。</blockquote> To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.<blockquote>首先，没有什么可以阻止竞争交易所降低Coinbase Global的费用。目前它可能具有经过验证的用户优势，但不要低估加密货币投资者为节省交易费用而跳槽的意愿。我们在传统券商中目睹了这一点，该行业最终实现了免佣金。</blockquote> Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.<blockquote>其次，加密货币有繁荣和萧条周期的历史。在过去十年中，比特币曾发生过三起独立的事件，其价值至少缩水80%。这是一项完全基于动量的投资，当上行动力枯竭时，Coinbase的交易收入也会枯竭。继2017年达到峰值后，Coinbase的收入在随后几年几乎减半。</blockquote> And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.<blockquote>第三，根据CoinShares数字资产基金流量周刊的数据，截至6月28日的过去四周内，加密货币资金流出量为2.573亿美元。这进一步证明，随着这些资产远低于高点，人们对加密货币的兴趣已经在下降。可以说，Coinbase并不是一只您未来想要拥有的股票。</blockquote> Cassava Sciences<blockquote>木薯科学</blockquote> Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).<blockquote>另一家风险回报比糟糕的超受欢迎公司是临床阶段的生物技术股票木薯科学（纳斯达克：萨瓦）。</blockquote> Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.<blockquote>Cassava在2月份宣布了simufilam治疗阿尔茨海默病的中期分析的积极临床数据，这理所当然地引起了轰动。这项开放标签试验显示，在六个月时认知和行为有所改善，最近允许Cassava概述其涉及其主要候选药物的3期试验计划。</blockquote> I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.<blockquote>我希望simufilam能够成功，但历史表明阿尔茨海默氏症是<a href=\"https://laohu8.com/S/AONE\">一</a>最难治疗的疾病。除了BiogenAduhelm获得了美国食品和药物管理局(FDA)的批准，但因缺乏明确的益处而受到严厉批评，十多年来，每种阿尔茨海默病药物都在后期研究中失败。投资者所要做的就是一项旨在招募100名患者的试验的早期开放标签数据。在大型3期阿尔茨海默病试验中，早期或中期的积极结果被粉碎的情况并不罕见。</blockquote> Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.<blockquote>尽管Cassava筹集了大量现金来继续其研究，但历史表明simufilam成功的机会非常渺茫。这使得木薯科学很容易避免。</blockquote> GameStop<blockquote>游戏驿站</blockquote> If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).<blockquote>如果您一直在关注零售贸易运动（即Reddit股票），散户投资者正在寻找大量卖空的公司并试图进行轧空，您可能知道视频游戏和配件零售商游戏驿站（纽约证券交易所代码：GME）。</blockquote> On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.<blockquote>在<a href=\"https://laohu8.com/S/AONE.U\">一</a>另一方面，游戏驿站能够利用其最近的名气，通过出售股票为其正在进行的向数字游戏公司的转型筹集资金。这是一项急需的举措，此前电子商务销售额在2020财年增长了191%，在假期期间比去年同期增长了四倍多。</blockquote> However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.<blockquote>然而，这些融资并没有忽视前任管理团队让公司失望的事实。二十年来，实体游戏模式运行良好。然而，当游戏走向数字化时，坚持这种实体模式会让公司陷入不稳定的境地。如今，即使电子商务快速增长，游戏驿站仍在继续亏损，去年同店销售额下降了近10%。数字销售可能在增长，但随着游戏驿站关闭其实体店以降低成本，总收入将无处可去。</blockquote> GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.<blockquote>游戏驿站绝不是破产的候选者，我实际上可以看到几年后实现盈利的道路。但话虽如此，考虑到未来漫长的转型和运营亏损，所看到的收益毫无意义。</blockquote> Inovio Pharmaceuticals<blockquote>Inovio制药公司</blockquote> Biotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.<blockquote>生物科技股可以提供充足的机会，或者Inovio制药公司（纳斯达克：INO）案例，吸走长期投资者的命脉。</blockquote> Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.<blockquote>Inovio似乎是一家仅基于纸张的有趣公司。它的产品线目前包括十几种治疗癌症、传染病和人乳头瘤病毒的临床候选药物。最有前途的看起来是INO-4800，这是该公司的冠状病毒病2019（COVID-19）候选疫苗，已准备好进行3期研究。但如果你深入研究Inovio的临床表现，你会非常失望。</blockquote> For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.<blockquote>例如，INO-4800在美国已被部分临床搁置，而监管机构要求提供有关Inovio疫苗及其输送系统Cellectra的更多数据。最近，INO-4800的后期资金被美国政府取消，这就是为什么它现在正在为其COVID-19候选药物寻求国际研究。</blockquote> If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.<blockquote>如果你认为我不公平地指责Inovio在新冠肺炎的挣扎，那就更进一步吧。四十年来，Inovio一直未能获得FDA批准的药物。这并不是我希望Inovio发生不好的事情——这是现实，希望和结果很长一段时间都没有与这家公司保持一致。在Inovio在后期临床试验中证明自己之前，值得避免使用。</blockquote> AMC Entertainment<blockquote>AMC院线</blockquote> Finally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.<blockquote>最后，我不能忘记正在进行的抽水和转储计划AMC院线（纽约证券交易所代码：AMC）。尽管在AMC通过发行大量股票和高息债务自救后，散户投资者能够通过1月份的轧空来宣称胜利，但最近的上涨与轧空无关。相反，它主要基于炒作，在留言板上故意混淆具体的基本数据，以及广泛的，公然的错误信息。</blockquote> AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.<blockquote>AMC的散户投资者希望你相信基本面并不重要，但尝试驾驶一辆没有发动机的汽车，看看你能走多远。AMC正在应对行业票房收入连续19年下降的问题，并且随着电影制片厂依赖流媒体，其部分电影独家经营权正在消失。电影院将会有一席之地，但AMC的潜在市场逐年萎缩。</blockquote> AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.<blockquote>AMC的散户投资者还会让您相信该公司在筹集20亿美元资本后状况良好。尽管近期破产传闻已被搁置，但2027年债券价格远未接近面值。你会问，为什么？因为债券持有人不相信AMC会逃脱破产。</blockquote> I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.<blockquote>我一生中见过足够多的泵和转储活动来识别它们，并且AMC检查了所有的框。我的建议是不要做空AMC。我的建议是完全避免。所有的抽水和转储计划最终都会崩溃，AMC也不例外。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nThe motley fool2021-07-06 09:32\n\n</h4>\n</header>\n<article>\nFor the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&amp;P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.<blockquote>在过去的15个月里，华尔街和投资者享受了历史性的反弹。基准标普500自2020年3月23日触及熊市底部以来，已上涨超过90%。</blockquote> While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.<blockquote>虽然许多高质量和创新的企业引领了这场反弹，但它也让相当多糟糕的公司蓬勃发展。我建议像七月瘟疫一样避开以下五只超受欢迎的股票。</blockquote> Coinbase Global<blockquote>比特币基地全球</blockquote> First up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin&nbsp;andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.<blockquote>首先是加密货币交易所和生态系统比特币基地全球（纳斯达克：硬币）。Coinbase很受欢迎，因为投资者纷纷涌入Coinbase等公司，其第一季度收入和利润飙升得如此之快比特币和以太币.问题是有三种催化剂对Coinbase经纪模式不利。</blockquote> To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.<blockquote>首先，没有什么可以阻止竞争交易所降低Coinbase Global的费用。目前它可能具有经过验证的用户优势，但不要低估加密货币投资者为节省交易费用而跳槽的意愿。我们在传统券商中目睹了这一点，该行业最终实现了免佣金。</blockquote> Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.<blockquote>其次，加密货币有繁荣和萧条周期的历史。在过去十年中，比特币曾发生过三起独立的事件，其价值至少缩水80%。这是一项完全基于动量的投资，当上行动力枯竭时，Coinbase的交易收入也会枯竭。继2017年达到峰值后，Coinbase的收入在随后几年几乎减半。</blockquote> And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.<blockquote>第三，根据CoinShares数字资产基金流量周刊的数据，截至6月28日的过去四周内，加密货币资金流出量为2.573亿美元。这进一步证明，随着这些资产远低于高点，人们对加密货币的兴趣已经在下降。可以说，Coinbase并不是一只您未来想要拥有的股票。</blockquote> Cassava Sciences<blockquote>木薯科学</blockquote> Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).<blockquote>另一家风险回报比糟糕的超受欢迎公司是临床阶段的生物技术股票木薯科学（纳斯达克：萨瓦）。</blockquote> Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.<blockquote>Cassava在2月份宣布了simufilam治疗阿尔茨海默病的中期分析的积极临床数据，这理所当然地引起了轰动。这项开放标签试验显示，在六个月时认知和行为有所改善，最近允许Cassava概述其涉及其主要候选药物的3期试验计划。</blockquote> I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.<blockquote>我希望simufilam能够成功，但历史表明阿尔茨海默氏症是<a href=\"https://laohu8.com/S/AONE\">一</a>最难治疗的疾病。除了BiogenAduhelm获得了美国食品和药物管理局(FDA)的批准，但因缺乏明确的益处而受到严厉批评，十多年来，每种阿尔茨海默病药物都在后期研究中失败。投资者所要做的就是一项旨在招募100名患者的试验的早期开放标签数据。在大型3期阿尔茨海默病试验中，早期或中期的积极结果被粉碎的情况并不罕见。</blockquote> Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.<blockquote>尽管Cassava筹集了大量现金来继续其研究，但历史表明simufilam成功的机会非常渺茫。这使得木薯科学很容易避免。</blockquote> GameStop<blockquote>游戏驿站</blockquote> If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).<blockquote>如果您一直在关注零售贸易运动（即Reddit股票），散户投资者正在寻找大量卖空的公司并试图进行轧空，您可能知道视频游戏和配件零售商游戏驿站（纽约证券交易所代码：GME）。</blockquote> On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.<blockquote>在<a href=\"https://laohu8.com/S/AONE.U\">一</a>另一方面，游戏驿站能够利用其最近的名气，通过出售股票为其正在进行的向数字游戏公司的转型筹集资金。这是一项急需的举措，此前电子商务销售额在2020财年增长了191%，在假期期间比去年同期增长了四倍多。</blockquote> However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.<blockquote>然而，这些融资并没有忽视前任管理团队让公司失望的事实。二十年来，实体游戏模式运行良好。然而，当游戏走向数字化时，坚持这种实体模式会让公司陷入不稳定的境地。如今，即使电子商务快速增长，游戏驿站仍在继续亏损，去年同店销售额下降了近10%。数字销售可能在增长，但随着游戏驿站关闭其实体店以降低成本，总收入将无处可去。</blockquote> GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.<blockquote>游戏驿站绝不是破产的候选者，我实际上可以看到几年后实现盈利的道路。但话虽如此，考虑到未来漫长的转型和运营亏损，所看到的收益毫无意义。</blockquote> Inovio Pharmaceuticals<blockquote>Inovio制药公司</blockquote> Biotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.<blockquote>生物科技股可以提供充足的机会，或者Inovio制药公司（纳斯达克：INO）案例，吸走长期投资者的命脉。</blockquote> Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.<blockquote>Inovio似乎是一家仅基于纸张的有趣公司。它的产品线目前包括十几种治疗癌症、传染病和人乳头瘤病毒的临床候选药物。最有前途的看起来是INO-4800，这是该公司的冠状病毒病2019（COVID-19）候选疫苗，已准备好进行3期研究。但如果你深入研究Inovio的临床表现，你会非常失望。</blockquote> For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.<blockquote>例如，INO-4800在美国已被部分临床搁置，而监管机构要求提供有关Inovio疫苗及其输送系统Cellectra的更多数据。最近，INO-4800的后期资金被美国政府取消，这就是为什么它现在正在为其COVID-19候选药物寻求国际研究。</blockquote> If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.<blockquote>如果你认为我不公平地指责Inovio在新冠肺炎的挣扎，那就更进一步吧。四十年来，Inovio一直未能获得FDA批准的药物。这并不是我希望Inovio发生不好的事情——这是现实，希望和结果很长一段时间都没有与这家公司保持一致。在Inovio在后期临床试验中证明自己之前，值得避免使用。</blockquote> AMC Entertainment<blockquote>AMC院线</blockquote> Finally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.<blockquote>最后，我不能忘记正在进行的抽水和转储计划AMC院线（纽约证券交易所代码：AMC）。尽管在AMC通过发行大量股票和高息债务自救后，散户投资者能够通过1月份的轧空来宣称胜利，但最近的上涨与轧空无关。相反，它主要基于炒作，在留言板上故意混淆具体的基本数据，以及广泛的，公然的错误信息。</blockquote> AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.<blockquote>AMC的散户投资者希望你相信基本面并不重要，但尝试驾驶一辆没有发动机的汽车，看看你能走多远。AMC正在应对行业票房收入连续19年下降的问题，并且随着电影制片厂依赖流媒体，其部分电影独家经营权正在消失。电影院将会有一席之地，但AMC的潜在市场逐年萎缩。</blockquote> AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.<blockquote>AMC的散户投资者还会让您相信该公司在筹集20亿美元资本后状况良好。尽管近期破产传闻已被搁置，但2027年债券价格远未接近面值。你会问，为什么？因为债券持有人不相信AMC会逃脱破产。</blockquote> I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.<blockquote>我一生中见过足够多的泵和转储活动来识别它们，并且AMC检查了所有的框。我的建议是不要做空AMC。我的建议是完全避免。所有的抽水和转储计划最终都会崩溃，AMC也不例外。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/\">The motley fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GME":"游戏驿站","SAVA":"Cassava Sciences Inc","INO":"伊诺维奥制药","COIN":"Coinbase Global, Inc.","AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164348327","content_text":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.\nWhile a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.\nCoinbase Global\nFirst up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.\nTo start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.\nSecond,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.\nAnd third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.\nCassava Sciences\nAnother ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).\nCassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.\nI'd love for simufilam to be successful, but history has shown that Alzheimer's is one of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.\nAlthough Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.\nGameStop\nIf you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).\nOn one hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.\nHowever, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.\nGameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.\nInovio Pharmaceuticals\nBiotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.\nInovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.\nFor example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.\nIf you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.\nAMC Entertainment\nFinally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.\nAMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.\nAMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.\nI've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.","news_type":1,"symbols_score_info":{"SAVA":0.9,"INO":0.9,"GME":0.9,"COIN":0.9,"AMC":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5133807,"gmtCreate":1625545243920,"gmtModify":1631890443466,"authorId":3586829232043276,"author":{"id":3586829232043276,"idStr":"3586829232043276","authorId":3586829232043276,"name":"clingling","avatar":"https://static.tigerbbs.com/6ac8266443879ca0b9b00e68416a1244","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":154451676,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":154425643,"gmtCreate":1625540383282,"gmtModify":1633939824986,"author":{"id":"3555908735229300","authorId":"3555908735229300","name":"Vin309","avatar":"https://static.tigerbbs.com/9ca4de1ca05f1d625f1bcdbc1d790726","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3555908735229300","authorIdStr":"3555908735229300"},"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/154425643","repostId":1164348327,"repostType":4,"repost":{"id":"1164348327","kind":"news","pubTimestamp":1625535165,"share":"https://www.laohu8.com/m/news/1164348327?lang=zh_CN&edition=full","pubTime":"2021-07-06 09:32","market":"us","language":"en","title":"5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1164348327","media":"The motley fool","summary":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The ben","content":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&amp;P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.<blockquote>在过去的15个月里，华尔街和投资者享受了历史性的反弹。基准标普500自2020年3月23日触及熊市底部以来，已上涨超过90%。</blockquote> While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.<blockquote>虽然许多高质量和创新的企业引领了这场反弹，但它也让相当多糟糕的公司蓬勃发展。我建议像七月瘟疫一样避开以下五只超受欢迎的股票。</blockquote> Coinbase Global<blockquote>比特币基地全球</blockquote> First up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin&nbsp;andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.<blockquote>首先是加密货币交易所和生态系统比特币基地全球（纳斯达克：硬币）。Coinbase很受欢迎，因为投资者纷纷涌入Coinbase等公司，其第一季度收入和利润飙升得如此之快比特币和以太币.问题是有三种催化剂对Coinbase经纪模式不利。</blockquote> To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.<blockquote>首先，没有什么可以阻止竞争交易所降低Coinbase Global的费用。目前它可能具有经过验证的用户优势，但不要低估加密货币投资者为节省交易费用而跳槽的意愿。我们在传统券商中目睹了这一点，该行业最终实现了免佣金。</blockquote> Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.<blockquote>其次，加密货币有繁荣和萧条周期的历史。在过去十年中，比特币曾发生过三起独立的事件，其价值至少缩水80%。这是一项完全基于动量的投资，当上行动力枯竭时，Coinbase的交易收入也会枯竭。继2017年达到峰值后，Coinbase的收入在随后几年几乎减半。</blockquote> And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.<blockquote>第三，根据CoinShares数字资产基金流量周刊的数据，截至6月28日的过去四周内，加密货币资金流出量为2.573亿美元。这进一步证明，随着这些资产远低于高点，人们对加密货币的兴趣已经在下降。可以说，Coinbase并不是一只您未来想要拥有的股票。</blockquote> Cassava Sciences<blockquote>木薯科学</blockquote> Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).<blockquote>另一家风险回报比糟糕的超受欢迎公司是临床阶段的生物技术股票木薯科学（纳斯达克：萨瓦）。</blockquote> Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.<blockquote>Cassava在2月份宣布了simufilam治疗阿尔茨海默病的中期分析的积极临床数据，这理所当然地引起了轰动。这项开放标签试验显示，在六个月时认知和行为有所改善，最近允许Cassava概述其涉及其主要候选药物的3期试验计划。</blockquote> I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.<blockquote>我希望simufilam能够成功，但历史表明阿尔茨海默氏症是<a href=\"https://laohu8.com/S/AONE\">一</a>最难治疗的疾病。除了BiogenAduhelm获得了美国食品和药物管理局(FDA)的批准，但因缺乏明确的益处而受到严厉批评，十多年来，每种阿尔茨海默病药物都在后期研究中失败。投资者所要做的就是一项旨在招募100名患者的试验的早期开放标签数据。在大型3期阿尔茨海默病试验中，早期或中期的积极结果被粉碎的情况并不罕见。</blockquote> Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.<blockquote>尽管Cassava筹集了大量现金来继续其研究，但历史表明simufilam成功的机会非常渺茫。这使得木薯科学很容易避免。</blockquote> GameStop<blockquote>游戏驿站</blockquote> If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).<blockquote>如果您一直在关注零售贸易运动（即Reddit股票），散户投资者正在寻找大量卖空的公司并试图进行轧空，您可能知道视频游戏和配件零售商游戏驿站（纽约证券交易所代码：GME）。</blockquote> On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.<blockquote>在<a href=\"https://laohu8.com/S/AONE.U\">一</a>另一方面，游戏驿站能够利用其最近的名气，通过出售股票为其正在进行的向数字游戏公司的转型筹集资金。这是一项急需的举措，此前电子商务销售额在2020财年增长了191%，在假期期间比去年同期增长了四倍多。</blockquote> However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.<blockquote>然而，这些融资并没有忽视前任管理团队让公司失望的事实。二十年来，实体游戏模式运行良好。然而，当游戏走向数字化时，坚持这种实体模式会让公司陷入不稳定的境地。如今，即使电子商务快速增长，游戏驿站仍在继续亏损，去年同店销售额下降了近10%。数字销售可能在增长，但随着游戏驿站关闭其实体店以降低成本，总收入将无处可去。</blockquote> GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.<blockquote>游戏驿站绝不是破产的候选者，我实际上可以看到几年后实现盈利的道路。但话虽如此，考虑到未来漫长的转型和运营亏损，所看到的收益毫无意义。</blockquote> Inovio Pharmaceuticals<blockquote>Inovio制药公司</blockquote> Biotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.<blockquote>生物科技股可以提供充足的机会，或者Inovio制药公司（纳斯达克：INO）案例，吸走长期投资者的命脉。</blockquote> Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.<blockquote>Inovio似乎是一家仅基于纸张的有趣公司。它的产品线目前包括十几种治疗癌症、传染病和人乳头瘤病毒的临床候选药物。最有前途的看起来是INO-4800，这是该公司的冠状病毒病2019（COVID-19）候选疫苗，已准备好进行3期研究。但如果你深入研究Inovio的临床表现，你会非常失望。</blockquote> For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.<blockquote>例如，INO-4800在美国已被部分临床搁置，而监管机构要求提供有关Inovio疫苗及其输送系统Cellectra的更多数据。最近，INO-4800的后期资金被美国政府取消，这就是为什么它现在正在为其COVID-19候选药物寻求国际研究。</blockquote> If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.<blockquote>如果你认为我不公平地指责Inovio在新冠肺炎的挣扎，那就更进一步吧。四十年来，Inovio一直未能获得FDA批准的药物。这并不是我希望Inovio发生不好的事情——这是现实，希望和结果很长一段时间都没有与这家公司保持一致。在Inovio在后期临床试验中证明自己之前，值得避免使用。</blockquote> AMC Entertainment<blockquote>AMC院线</blockquote> Finally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.<blockquote>最后，我不能忘记正在进行的抽水和转储计划AMC院线（纽约证券交易所代码：AMC）。尽管在AMC通过发行大量股票和高息债务自救后，散户投资者能够通过1月份的轧空来宣称胜利，但最近的上涨与轧空无关。相反，它主要基于炒作，在留言板上故意混淆具体的基本数据，以及广泛的，公然的错误信息。</blockquote> AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.<blockquote>AMC的散户投资者希望你相信基本面并不重要，但尝试驾驶一辆没有发动机的汽车，看看你能走多远。AMC正在应对行业票房收入连续19年下降的问题，并且随着电影制片厂依赖流媒体，其部分电影独家经营权正在消失。电影院将会有一席之地，但AMC的潜在市场逐年萎缩。</blockquote> AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.<blockquote>AMC的散户投资者还会让您相信该公司在筹集20亿美元资本后状况良好。尽管近期破产传闻已被搁置，但2027年债券价格远未接近面值。你会问，为什么？因为债券持有人不相信AMC会逃脱破产。</blockquote> I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.<blockquote>我一生中见过足够多的泵和转储活动来识别它们，并且AMC检查了所有的框。我的建议是不要做空AMC。我的建议是完全避免。所有的抽水和转储计划最终都会崩溃，AMC也不例外。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nThe motley fool2021-07-06 09:32\n\n</h4>\n</header>\n<article>\nFor the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&amp;P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.<blockquote>在过去的15个月里，华尔街和投资者享受了历史性的反弹。基准标普500自2020年3月23日触及熊市底部以来，已上涨超过90%。</blockquote> While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.<blockquote>虽然许多高质量和创新的企业引领了这场反弹，但它也让相当多糟糕的公司蓬勃发展。我建议像七月瘟疫一样避开以下五只超受欢迎的股票。</blockquote> Coinbase Global<blockquote>比特币基地全球</blockquote> First up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin&nbsp;andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.<blockquote>首先是加密货币交易所和生态系统比特币基地全球（纳斯达克：硬币）。Coinbase很受欢迎，因为投资者纷纷涌入Coinbase等公司，其第一季度收入和利润飙升得如此之快比特币和以太币.问题是有三种催化剂对Coinbase经纪模式不利。</blockquote> To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.<blockquote>首先，没有什么可以阻止竞争交易所降低Coinbase Global的费用。目前它可能具有经过验证的用户优势，但不要低估加密货币投资者为节省交易费用而跳槽的意愿。我们在传统券商中目睹了这一点，该行业最终实现了免佣金。</blockquote> Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.<blockquote>其次，加密货币有繁荣和萧条周期的历史。在过去十年中，比特币曾发生过三起独立的事件，其价值至少缩水80%。这是一项完全基于动量的投资，当上行动力枯竭时，Coinbase的交易收入也会枯竭。继2017年达到峰值后，Coinbase的收入在随后几年几乎减半。</blockquote> And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.<blockquote>第三，根据CoinShares数字资产基金流量周刊的数据，截至6月28日的过去四周内，加密货币资金流出量为2.573亿美元。这进一步证明，随着这些资产远低于高点，人们对加密货币的兴趣已经在下降。可以说，Coinbase并不是一只您未来想要拥有的股票。</blockquote> Cassava Sciences<blockquote>木薯科学</blockquote> Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).<blockquote>另一家风险回报比糟糕的超受欢迎公司是临床阶段的生物技术股票木薯科学（纳斯达克：萨瓦）。</blockquote> Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.<blockquote>Cassava在2月份宣布了simufilam治疗阿尔茨海默病的中期分析的积极临床数据，这理所当然地引起了轰动。这项开放标签试验显示，在六个月时认知和行为有所改善，最近允许Cassava概述其涉及其主要候选药物的3期试验计划。</blockquote> I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.<blockquote>我希望simufilam能够成功，但历史表明阿尔茨海默氏症是<a href=\"https://laohu8.com/S/AONE\">一</a>最难治疗的疾病。除了BiogenAduhelm获得了美国食品和药物管理局(FDA)的批准，但因缺乏明确的益处而受到严厉批评，十多年来，每种阿尔茨海默病药物都在后期研究中失败。投资者所要做的就是一项旨在招募100名患者的试验的早期开放标签数据。在大型3期阿尔茨海默病试验中，早期或中期的积极结果被粉碎的情况并不罕见。</blockquote> Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.<blockquote>尽管Cassava筹集了大量现金来继续其研究，但历史表明simufilam成功的机会非常渺茫。这使得木薯科学很容易避免。</blockquote> GameStop<blockquote>游戏驿站</blockquote> If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).<blockquote>如果您一直在关注零售贸易运动（即Reddit股票），散户投资者正在寻找大量卖空的公司并试图进行轧空，您可能知道视频游戏和配件零售商游戏驿站（纽约证券交易所代码：GME）。</blockquote> On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.<blockquote>在<a href=\"https://laohu8.com/S/AONE.U\">一</a>另一方面，游戏驿站能够利用其最近的名气，通过出售股票为其正在进行的向数字游戏公司的转型筹集资金。这是一项急需的举措，此前电子商务销售额在2020财年增长了191%，在假期期间比去年同期增长了四倍多。</blockquote> However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.<blockquote>然而，这些融资并没有忽视前任管理团队让公司失望的事实。二十年来，实体游戏模式运行良好。然而，当游戏走向数字化时，坚持这种实体模式会让公司陷入不稳定的境地。如今，即使电子商务快速增长，游戏驿站仍在继续亏损，去年同店销售额下降了近10%。数字销售可能在增长，但随着游戏驿站关闭其实体店以降低成本，总收入将无处可去。</blockquote> GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.<blockquote>游戏驿站绝不是破产的候选者，我实际上可以看到几年后实现盈利的道路。但话虽如此，考虑到未来漫长的转型和运营亏损，所看到的收益毫无意义。</blockquote> Inovio Pharmaceuticals<blockquote>Inovio制药公司</blockquote> Biotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.<blockquote>生物科技股可以提供充足的机会，或者Inovio制药公司（纳斯达克：INO）案例，吸走长期投资者的命脉。</blockquote> Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.<blockquote>Inovio似乎是一家仅基于纸张的有趣公司。它的产品线目前包括十几种治疗癌症、传染病和人乳头瘤病毒的临床候选药物。最有前途的看起来是INO-4800，这是该公司的冠状病毒病2019（COVID-19）候选疫苗，已准备好进行3期研究。但如果你深入研究Inovio的临床表现，你会非常失望。</blockquote> For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.<blockquote>例如，INO-4800在美国已被部分临床搁置，而监管机构要求提供有关Inovio疫苗及其输送系统Cellectra的更多数据。最近，INO-4800的后期资金被美国政府取消，这就是为什么它现在正在为其COVID-19候选药物寻求国际研究。</blockquote> If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.<blockquote>如果你认为我不公平地指责Inovio在新冠肺炎的挣扎，那就更进一步吧。四十年来，Inovio一直未能获得FDA批准的药物。这并不是我希望Inovio发生不好的事情——这是现实，希望和结果很长一段时间都没有与这家公司保持一致。在Inovio在后期临床试验中证明自己之前，值得避免使用。</blockquote> AMC Entertainment<blockquote>AMC院线</blockquote> Finally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.<blockquote>最后，我不能忘记正在进行的抽水和转储计划AMC院线（纽约证券交易所代码：AMC）。尽管在AMC通过发行大量股票和高息债务自救后，散户投资者能够通过1月份的轧空来宣称胜利，但最近的上涨与轧空无关。相反，它主要基于炒作，在留言板上故意混淆具体的基本数据，以及广泛的，公然的错误信息。</blockquote> AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.<blockquote>AMC的散户投资者希望你相信基本面并不重要，但尝试驾驶一辆没有发动机的汽车，看看你能走多远。AMC正在应对行业票房收入连续19年下降的问题，并且随着电影制片厂依赖流媒体，其部分电影独家经营权正在消失。电影院将会有一席之地，但AMC的潜在市场逐年萎缩。</blockquote> AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.<blockquote>AMC的散户投资者还会让您相信该公司在筹集20亿美元资本后状况良好。尽管近期破产传闻已被搁置，但2027年债券价格远未接近面值。你会问，为什么？因为债券持有人不相信AMC会逃脱破产。</blockquote> I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.<blockquote>我一生中见过足够多的泵和转储活动来识别它们，并且AMC检查了所有的框。我的建议是不要做空AMC。我的建议是完全避免。所有的抽水和转储计划最终都会崩溃，AMC也不例外。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/\">The motley fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GME":"游戏驿站","SAVA":"Cassava Sciences Inc","INO":"伊诺维奥制药","COIN":"Coinbase Global, Inc.","AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164348327","content_text":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.\nWhile a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.\nCoinbase Global\nFirst up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.\nTo start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.\nSecond,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.\nAnd third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.\nCassava Sciences\nAnother ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).\nCassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.\nI'd love for simufilam to be successful, but history has shown that Alzheimer's is one of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.\nAlthough Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.\nGameStop\nIf you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).\nOn one hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.\nHowever, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.\nGameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.\nInovio Pharmaceuticals\nBiotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.\nInovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.\nFor example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.\nIf you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.\nAMC Entertainment\nFinally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.\nAMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.\nAMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.\nI've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.","news_type":1,"symbols_score_info":{"SAVA":0.9,"INO":0.9,"GME":0.9,"COIN":0.9,"AMC":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5133456,"gmtCreate":1625542741686,"gmtModify":1635236245015,"authorId":3574921814752173,"author":{"id":3574921814752173,"idStr":"3574921814752173","authorId":3574921814752173,"name":"loti","avatar":"https://static.tigerbbs.com/8cca1ef20b63a0869e29787e48188b21","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":154425643,"type":1,"supId":0,"prevId":0,"content":"ok","text":"ok","html":"ok"}],"langContent":"EN"},{"id":154421439,"gmtCreate":1625540211921,"gmtModify":1631891132161,"author":{"id":"3581916650287080","authorId":"3581916650287080","name":"Edylc","avatar":"https://static.tigerbbs.com/d47ae9801294e297e6bdb82900a5efb6","vip":1,"crmLevel":12,"crmLevelSwitch":0,"idStr":"3581916650287080","authorIdStr":"3581916650287080"},"htmlText":"Buy stocks u like","listText":"Buy stocks u like","text":"Buy stocks u like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/154421439","repostId":1164348327,"repostType":4,"repost":{"id":"1164348327","kind":"news","pubTimestamp":1625535165,"share":"https://www.laohu8.com/m/news/1164348327?lang=zh_CN&edition=full","pubTime":"2021-07-06 09:32","market":"us","language":"en","title":"5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1164348327","media":"The motley fool","summary":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The ben","content":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&amp;P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.<blockquote>在过去的15个月里，华尔街和投资者享受了历史性的反弹。基准标普500自2020年3月23日触及熊市底部以来，已上涨超过90%。</blockquote> While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.<blockquote>虽然许多高质量和创新的企业引领了这场反弹，但它也让相当多糟糕的公司蓬勃发展。我建议像七月瘟疫一样避开以下五只超受欢迎的股票。</blockquote> Coinbase Global<blockquote>比特币基地全球</blockquote> First up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin&nbsp;andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.<blockquote>首先是加密货币交易所和生态系统比特币基地全球（纳斯达克：硬币）。Coinbase很受欢迎，因为投资者纷纷涌入Coinbase等公司，其第一季度收入和利润飙升得如此之快比特币和以太币.问题是有三种催化剂对Coinbase经纪模式不利。</blockquote> To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.<blockquote>首先，没有什么可以阻止竞争交易所降低Coinbase Global的费用。目前它可能具有经过验证的用户优势，但不要低估加密货币投资者为节省交易费用而跳槽的意愿。我们在传统券商中目睹了这一点，该行业最终实现了免佣金。</blockquote> Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.<blockquote>其次，加密货币有繁荣和萧条周期的历史。在过去十年中，比特币曾发生过三起独立的事件，其价值至少缩水80%。这是一项完全基于动量的投资，当上行动力枯竭时，Coinbase的交易收入也会枯竭。继2017年达到峰值后，Coinbase的收入在随后几年几乎减半。</blockquote> And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.<blockquote>第三，根据CoinShares数字资产基金流量周刊的数据，截至6月28日的过去四周内，加密货币资金流出量为2.573亿美元。这进一步证明，随着这些资产远低于高点，人们对加密货币的兴趣已经在下降。可以说，Coinbase并不是一只您未来想要拥有的股票。</blockquote> Cassava Sciences<blockquote>木薯科学</blockquote> Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).<blockquote>另一家风险回报比糟糕的超受欢迎公司是临床阶段的生物技术股票木薯科学（纳斯达克：萨瓦）。</blockquote> Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.<blockquote>Cassava在2月份宣布了simufilam治疗阿尔茨海默病的中期分析的积极临床数据，这理所当然地引起了轰动。这项开放标签试验显示，在六个月时认知和行为有所改善，最近允许Cassava概述其涉及其主要候选药物的3期试验计划。</blockquote> I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.<blockquote>我希望simufilam能够成功，但历史表明阿尔茨海默氏症是<a href=\"https://laohu8.com/S/AONE\">一</a>最难治疗的疾病。除了BiogenAduhelm获得了美国食品和药物管理局(FDA)的批准，但因缺乏明确的益处而受到严厉批评，十多年来，每种阿尔茨海默病药物都在后期研究中失败。投资者所要做的就是一项旨在招募100名患者的试验的早期开放标签数据。在大型3期阿尔茨海默病试验中，早期或中期的积极结果被粉碎的情况并不罕见。</blockquote> Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.<blockquote>尽管Cassava筹集了大量现金来继续其研究，但历史表明simufilam成功的机会非常渺茫。这使得木薯科学很容易避免。</blockquote> GameStop<blockquote>游戏驿站</blockquote> If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).<blockquote>如果您一直在关注零售贸易运动（即Reddit股票），散户投资者正在寻找大量卖空的公司并试图进行轧空，您可能知道视频游戏和配件零售商游戏驿站（纽约证券交易所代码：GME）。</blockquote> On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.<blockquote>在<a href=\"https://laohu8.com/S/AONE.U\">一</a>另一方面，游戏驿站能够利用其最近的名气，通过出售股票为其正在进行的向数字游戏公司的转型筹集资金。这是一项急需的举措，此前电子商务销售额在2020财年增长了191%，在假期期间比去年同期增长了四倍多。</blockquote> However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.<blockquote>然而，这些融资并没有忽视前任管理团队让公司失望的事实。二十年来，实体游戏模式运行良好。然而，当游戏走向数字化时，坚持这种实体模式会让公司陷入不稳定的境地。如今，即使电子商务快速增长，游戏驿站仍在继续亏损，去年同店销售额下降了近10%。数字销售可能在增长，但随着游戏驿站关闭其实体店以降低成本，总收入将无处可去。</blockquote> GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.<blockquote>游戏驿站绝不是破产的候选者，我实际上可以看到几年后实现盈利的道路。但话虽如此，考虑到未来漫长的转型和运营亏损，所看到的收益毫无意义。</blockquote> Inovio Pharmaceuticals<blockquote>Inovio制药公司</blockquote> Biotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.<blockquote>生物科技股可以提供充足的机会，或者Inovio制药公司（纳斯达克：INO）案例，吸走长期投资者的命脉。</blockquote> Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.<blockquote>Inovio似乎是一家仅基于纸张的有趣公司。它的产品线目前包括十几种治疗癌症、传染病和人乳头瘤病毒的临床候选药物。最有前途的看起来是INO-4800，这是该公司的冠状病毒病2019（COVID-19）候选疫苗，已准备好进行3期研究。但如果你深入研究Inovio的临床表现，你会非常失望。</blockquote> For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.<blockquote>例如，INO-4800在美国已被部分临床搁置，而监管机构要求提供有关Inovio疫苗及其输送系统Cellectra的更多数据。最近，INO-4800的后期资金被美国政府取消，这就是为什么它现在正在为其COVID-19候选药物寻求国际研究。</blockquote> If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.<blockquote>如果你认为我不公平地指责Inovio在新冠肺炎的挣扎，那就更进一步吧。四十年来，Inovio一直未能获得FDA批准的药物。这并不是我希望Inovio发生不好的事情——这是现实，希望和结果很长一段时间都没有与这家公司保持一致。在Inovio在后期临床试验中证明自己之前，值得避免使用。</blockquote> AMC Entertainment<blockquote>AMC院线</blockquote> Finally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.<blockquote>最后，我不能忘记正在进行的抽水和转储计划AMC院线（纽约证券交易所代码：AMC）。尽管在AMC通过发行大量股票和高息债务自救后，散户投资者能够通过1月份的轧空来宣称胜利，但最近的上涨与轧空无关。相反，它主要基于炒作，在留言板上故意混淆具体的基本数据，以及广泛的，公然的错误信息。</blockquote> AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.<blockquote>AMC的散户投资者希望你相信基本面并不重要，但尝试驾驶一辆没有发动机的汽车，看看你能走多远。AMC正在应对行业票房收入连续19年下降的问题，并且随着电影制片厂依赖流媒体，其部分电影独家经营权正在消失。电影院将会有一席之地，但AMC的潜在市场逐年萎缩。</blockquote> AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.<blockquote>AMC的散户投资者还会让您相信该公司在筹集20亿美元资本后状况良好。尽管近期破产传闻已被搁置，但2027年债券价格远未接近面值。你会问，为什么？因为债券持有人不相信AMC会逃脱破产。</blockquote> I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.<blockquote>我一生中见过足够多的泵和转储活动来识别它们，并且AMC检查了所有的框。我的建议是不要做空AMC。我的建议是完全避免。所有的抽水和转储计划最终都会崩溃，AMC也不例外。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nThe motley fool2021-07-06 09:32\n\n</h4>\n</header>\n<article>\nFor the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&amp;P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.<blockquote>在过去的15个月里，华尔街和投资者享受了历史性的反弹。基准标普500自2020年3月23日触及熊市底部以来，已上涨超过90%。</blockquote> While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.<blockquote>虽然许多高质量和创新的企业引领了这场反弹，但它也让相当多糟糕的公司蓬勃发展。我建议像七月瘟疫一样避开以下五只超受欢迎的股票。</blockquote> Coinbase Global<blockquote>比特币基地全球</blockquote> First up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin&nbsp;andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.<blockquote>首先是加密货币交易所和生态系统比特币基地全球（纳斯达克：硬币）。Coinbase很受欢迎，因为投资者纷纷涌入Coinbase等公司，其第一季度收入和利润飙升得如此之快比特币和以太币.问题是有三种催化剂对Coinbase经纪模式不利。</blockquote> To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.<blockquote>首先，没有什么可以阻止竞争交易所降低Coinbase Global的费用。目前它可能具有经过验证的用户优势，但不要低估加密货币投资者为节省交易费用而跳槽的意愿。我们在传统券商中目睹了这一点，该行业最终实现了免佣金。</blockquote> Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.<blockquote>其次，加密货币有繁荣和萧条周期的历史。在过去十年中，比特币曾发生过三起独立的事件，其价值至少缩水80%。这是一项完全基于动量的投资，当上行动力枯竭时，Coinbase的交易收入也会枯竭。继2017年达到峰值后，Coinbase的收入在随后几年几乎减半。</blockquote> And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.<blockquote>第三，根据CoinShares数字资产基金流量周刊的数据，截至6月28日的过去四周内，加密货币资金流出量为2.573亿美元。这进一步证明，随着这些资产远低于高点，人们对加密货币的兴趣已经在下降。可以说，Coinbase并不是一只您未来想要拥有的股票。</blockquote> Cassava Sciences<blockquote>木薯科学</blockquote> Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).<blockquote>另一家风险回报比糟糕的超受欢迎公司是临床阶段的生物技术股票木薯科学（纳斯达克：萨瓦）。</blockquote> Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.<blockquote>Cassava在2月份宣布了simufilam治疗阿尔茨海默病的中期分析的积极临床数据，这理所当然地引起了轰动。这项开放标签试验显示，在六个月时认知和行为有所改善，最近允许Cassava概述其涉及其主要候选药物的3期试验计划。</blockquote> I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.<blockquote>我希望simufilam能够成功，但历史表明阿尔茨海默氏症是<a href=\"https://laohu8.com/S/AONE\">一</a>最难治疗的疾病。除了BiogenAduhelm获得了美国食品和药物管理局(FDA)的批准，但因缺乏明确的益处而受到严厉批评，十多年来，每种阿尔茨海默病药物都在后期研究中失败。投资者所要做的就是一项旨在招募100名患者的试验的早期开放标签数据。在大型3期阿尔茨海默病试验中，早期或中期的积极结果被粉碎的情况并不罕见。</blockquote> Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.<blockquote>尽管Cassava筹集了大量现金来继续其研究，但历史表明simufilam成功的机会非常渺茫。这使得木薯科学很容易避免。</blockquote> GameStop<blockquote>游戏驿站</blockquote> If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).<blockquote>如果您一直在关注零售贸易运动（即Reddit股票），散户投资者正在寻找大量卖空的公司并试图进行轧空，您可能知道视频游戏和配件零售商游戏驿站（纽约证券交易所代码：GME）。</blockquote> On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.<blockquote>在<a href=\"https://laohu8.com/S/AONE.U\">一</a>另一方面，游戏驿站能够利用其最近的名气，通过出售股票为其正在进行的向数字游戏公司的转型筹集资金。这是一项急需的举措，此前电子商务销售额在2020财年增长了191%，在假期期间比去年同期增长了四倍多。</blockquote> However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.<blockquote>然而，这些融资并没有忽视前任管理团队让公司失望的事实。二十年来，实体游戏模式运行良好。然而，当游戏走向数字化时，坚持这种实体模式会让公司陷入不稳定的境地。如今，即使电子商务快速增长，游戏驿站仍在继续亏损，去年同店销售额下降了近10%。数字销售可能在增长，但随着游戏驿站关闭其实体店以降低成本，总收入将无处可去。</blockquote> GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.<blockquote>游戏驿站绝不是破产的候选者，我实际上可以看到几年后实现盈利的道路。但话虽如此，考虑到未来漫长的转型和运营亏损，所看到的收益毫无意义。</blockquote> Inovio Pharmaceuticals<blockquote>Inovio制药公司</blockquote> Biotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.<blockquote>生物科技股可以提供充足的机会，或者Inovio制药公司（纳斯达克：INO）案例，吸走长期投资者的命脉。</blockquote> Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.<blockquote>Inovio似乎是一家仅基于纸张的有趣公司。它的产品线目前包括十几种治疗癌症、传染病和人乳头瘤病毒的临床候选药物。最有前途的看起来是INO-4800，这是该公司的冠状病毒病2019（COVID-19）候选疫苗，已准备好进行3期研究。但如果你深入研究Inovio的临床表现，你会非常失望。</blockquote> For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.<blockquote>例如，INO-4800在美国已被部分临床搁置，而监管机构要求提供有关Inovio疫苗及其输送系统Cellectra的更多数据。最近，INO-4800的后期资金被美国政府取消，这就是为什么它现在正在为其COVID-19候选药物寻求国际研究。</blockquote> If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.<blockquote>如果你认为我不公平地指责Inovio在新冠肺炎的挣扎，那就更进一步吧。四十年来，Inovio一直未能获得FDA批准的药物。这并不是我希望Inovio发生不好的事情——这是现实，希望和结果很长一段时间都没有与这家公司保持一致。在Inovio在后期临床试验中证明自己之前，值得避免使用。</blockquote> AMC Entertainment<blockquote>AMC院线</blockquote> Finally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.<blockquote>最后，我不能忘记正在进行的抽水和转储计划AMC院线（纽约证券交易所代码：AMC）。尽管在AMC通过发行大量股票和高息债务自救后，散户投资者能够通过1月份的轧空来宣称胜利，但最近的上涨与轧空无关。相反，它主要基于炒作，在留言板上故意混淆具体的基本数据，以及广泛的，公然的错误信息。</blockquote> AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.<blockquote>AMC的散户投资者希望你相信基本面并不重要，但尝试驾驶一辆没有发动机的汽车，看看你能走多远。AMC正在应对行业票房收入连续19年下降的问题，并且随着电影制片厂依赖流媒体，其部分电影独家经营权正在消失。电影院将会有一席之地，但AMC的潜在市场逐年萎缩。</blockquote> AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.<blockquote>AMC的散户投资者还会让您相信该公司在筹集20亿美元资本后状况良好。尽管近期破产传闻已被搁置，但2027年债券价格远未接近面值。你会问，为什么？因为债券持有人不相信AMC会逃脱破产。</blockquote> I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.<blockquote>我一生中见过足够多的泵和转储活动来识别它们，并且AMC检查了所有的框。我的建议是不要做空AMC。我的建议是完全避免。所有的抽水和转储计划最终都会崩溃，AMC也不例外。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/\">The motley fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GME":"游戏驿站","SAVA":"Cassava Sciences Inc","INO":"伊诺维奥制药","COIN":"Coinbase Global, Inc.","AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164348327","content_text":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.\nWhile a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.\nCoinbase Global\nFirst up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.\nTo start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.\nSecond,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.\nAnd third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.\nCassava Sciences\nAnother ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).\nCassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.\nI'd love for simufilam to be successful, but history has shown that Alzheimer's is one of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.\nAlthough Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.\nGameStop\nIf you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).\nOn one hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.\nHowever, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.\nGameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.\nInovio Pharmaceuticals\nBiotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.\nInovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.\nFor example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.\nIf you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.\nAMC Entertainment\nFinally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.\nAMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.\nAMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.\nI've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.","news_type":1,"symbols_score_info":{"SAVA":0.9,"INO":0.9,"GME":0.9,"COIN":0.9,"AMC":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":154423205,"gmtCreate":1625540105207,"gmtModify":1633939828989,"author":{"id":"3575423014243315","authorId":"3575423014243315","name":"Jaminwu","avatar":"https://static.tigerbbs.com/e406a9629077a6d66bf3ea9d74b7b538","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3575423014243315","authorIdStr":"3575423014243315"},"htmlText":"yes","listText":"yes","text":"yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/154423205","repostId":1164348327,"repostType":4,"repost":{"id":"1164348327","kind":"news","pubTimestamp":1625535165,"share":"https://www.laohu8.com/m/news/1164348327?lang=zh_CN&edition=full","pubTime":"2021-07-06 09:32","market":"us","language":"en","title":"5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1164348327","media":"The motley fool","summary":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The ben","content":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&amp;P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.<blockquote>在过去的15个月里，华尔街和投资者享受了历史性的反弹。基准标普500自2020年3月23日触及熊市底部以来，已上涨超过90%。</blockquote> While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.<blockquote>虽然许多高质量和创新的企业引领了这场反弹，但它也让相当多糟糕的公司蓬勃发展。我建议像七月瘟疫一样避开以下五只超受欢迎的股票。</blockquote> Coinbase Global<blockquote>比特币基地全球</blockquote> First up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin&nbsp;andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.<blockquote>首先是加密货币交易所和生态系统比特币基地全球（纳斯达克：硬币）。Coinbase很受欢迎，因为投资者纷纷涌入Coinbase等公司，其第一季度收入和利润飙升得如此之快比特币和以太币.问题是有三种催化剂对Coinbase经纪模式不利。</blockquote> To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.<blockquote>首先，没有什么可以阻止竞争交易所降低Coinbase Global的费用。目前它可能具有经过验证的用户优势，但不要低估加密货币投资者为节省交易费用而跳槽的意愿。我们在传统券商中目睹了这一点，该行业最终实现了免佣金。</blockquote> Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.<blockquote>其次，加密货币有繁荣和萧条周期的历史。在过去十年中，比特币曾发生过三起独立的事件，其价值至少缩水80%。这是一项完全基于动量的投资，当上行动力枯竭时，Coinbase的交易收入也会枯竭。继2017年达到峰值后，Coinbase的收入在随后几年几乎减半。</blockquote> And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.<blockquote>第三，根据CoinShares数字资产基金流量周刊的数据，截至6月28日的过去四周内，加密货币资金流出量为2.573亿美元。这进一步证明，随着这些资产远低于高点，人们对加密货币的兴趣已经在下降。可以说，Coinbase并不是一只您未来想要拥有的股票。</blockquote> Cassava Sciences<blockquote>木薯科学</blockquote> Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).<blockquote>另一家风险回报比糟糕的超受欢迎公司是临床阶段的生物技术股票木薯科学（纳斯达克：萨瓦）。</blockquote> Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.<blockquote>Cassava在2月份宣布了simufilam治疗阿尔茨海默病的中期分析的积极临床数据，这理所当然地引起了轰动。这项开放标签试验显示，在六个月时认知和行为有所改善，最近允许Cassava概述其涉及其主要候选药物的3期试验计划。</blockquote> I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.<blockquote>我希望simufilam能够成功，但历史表明阿尔茨海默氏症是<a href=\"https://laohu8.com/S/AONE\">一</a>最难治疗的疾病。除了BiogenAduhelm获得了美国食品和药物管理局(FDA)的批准，但因缺乏明确的益处而受到严厉批评，十多年来，每种阿尔茨海默病药物都在后期研究中失败。投资者所要做的就是一项旨在招募100名患者的试验的早期开放标签数据。在大型3期阿尔茨海默病试验中，早期或中期的积极结果被粉碎的情况并不罕见。</blockquote> Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.<blockquote>尽管Cassava筹集了大量现金来继续其研究，但历史表明simufilam成功的机会非常渺茫。这使得木薯科学很容易避免。</blockquote> GameStop<blockquote>游戏驿站</blockquote> If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).<blockquote>如果您一直在关注零售贸易运动（即Reddit股票），散户投资者正在寻找大量卖空的公司并试图进行轧空，您可能知道视频游戏和配件零售商游戏驿站（纽约证券交易所代码：GME）。</blockquote> On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.<blockquote>在<a href=\"https://laohu8.com/S/AONE.U\">一</a>另一方面，游戏驿站能够利用其最近的名气，通过出售股票为其正在进行的向数字游戏公司的转型筹集资金。这是一项急需的举措，此前电子商务销售额在2020财年增长了191%，在假期期间比去年同期增长了四倍多。</blockquote> However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.<blockquote>然而，这些融资并没有忽视前任管理团队让公司失望的事实。二十年来，实体游戏模式运行良好。然而，当游戏走向数字化时，坚持这种实体模式会让公司陷入不稳定的境地。如今，即使电子商务快速增长，游戏驿站仍在继续亏损，去年同店销售额下降了近10%。数字销售可能在增长，但随着游戏驿站关闭其实体店以降低成本，总收入将无处可去。</blockquote> GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.<blockquote>游戏驿站绝不是破产的候选者，我实际上可以看到几年后实现盈利的道路。但话虽如此，考虑到未来漫长的转型和运营亏损，所看到的收益毫无意义。</blockquote> Inovio Pharmaceuticals<blockquote>Inovio制药公司</blockquote> Biotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.<blockquote>生物科技股可以提供充足的机会，或者Inovio制药公司（纳斯达克：INO）案例，吸走长期投资者的命脉。</blockquote> Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.<blockquote>Inovio似乎是一家仅基于纸张的有趣公司。它的产品线目前包括十几种治疗癌症、传染病和人乳头瘤病毒的临床候选药物。最有前途的看起来是INO-4800，这是该公司的冠状病毒病2019（COVID-19）候选疫苗，已准备好进行3期研究。但如果你深入研究Inovio的临床表现，你会非常失望。</blockquote> For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.<blockquote>例如，INO-4800在美国已被部分临床搁置，而监管机构要求提供有关Inovio疫苗及其输送系统Cellectra的更多数据。最近，INO-4800的后期资金被美国政府取消，这就是为什么它现在正在为其COVID-19候选药物寻求国际研究。</blockquote> If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.<blockquote>如果你认为我不公平地指责Inovio在新冠肺炎的挣扎，那就更进一步吧。四十年来，Inovio一直未能获得FDA批准的药物。这并不是我希望Inovio发生不好的事情——这是现实，希望和结果很长一段时间都没有与这家公司保持一致。在Inovio在后期临床试验中证明自己之前，值得避免使用。</blockquote> AMC Entertainment<blockquote>AMC院线</blockquote> Finally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.<blockquote>最后，我不能忘记正在进行的抽水和转储计划AMC院线（纽约证券交易所代码：AMC）。尽管在AMC通过发行大量股票和高息债务自救后，散户投资者能够通过1月份的轧空来宣称胜利，但最近的上涨与轧空无关。相反，它主要基于炒作，在留言板上故意混淆具体的基本数据，以及广泛的，公然的错误信息。</blockquote> AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.<blockquote>AMC的散户投资者希望你相信基本面并不重要，但尝试驾驶一辆没有发动机的汽车，看看你能走多远。AMC正在应对行业票房收入连续19年下降的问题，并且随着电影制片厂依赖流媒体，其部分电影独家经营权正在消失。电影院将会有一席之地，但AMC的潜在市场逐年萎缩。</blockquote> AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.<blockquote>AMC的散户投资者还会让您相信该公司在筹集20亿美元资本后状况良好。尽管近期破产传闻已被搁置，但2027年债券价格远未接近面值。你会问，为什么？因为债券持有人不相信AMC会逃脱破产。</blockquote> I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.<blockquote>我一生中见过足够多的泵和转储活动来识别它们，并且AMC检查了所有的框。我的建议是不要做空AMC。我的建议是完全避免。所有的抽水和转储计划最终都会崩溃，AMC也不例外。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nThe motley fool2021-07-06 09:32\n\n</h4>\n</header>\n<article>\nFor the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&amp;P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.<blockquote>在过去的15个月里，华尔街和投资者享受了历史性的反弹。基准标普500自2020年3月23日触及熊市底部以来，已上涨超过90%。</blockquote> While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.<blockquote>虽然许多高质量和创新的企业引领了这场反弹，但它也让相当多糟糕的公司蓬勃发展。我建议像七月瘟疫一样避开以下五只超受欢迎的股票。</blockquote> Coinbase Global<blockquote>比特币基地全球</blockquote> First up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin&nbsp;andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.<blockquote>首先是加密货币交易所和生态系统比特币基地全球（纳斯达克：硬币）。Coinbase很受欢迎，因为投资者纷纷涌入Coinbase等公司，其第一季度收入和利润飙升得如此之快比特币和以太币.问题是有三种催化剂对Coinbase经纪模式不利。</blockquote> To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.<blockquote>首先，没有什么可以阻止竞争交易所降低Coinbase Global的费用。目前它可能具有经过验证的用户优势，但不要低估加密货币投资者为节省交易费用而跳槽的意愿。我们在传统券商中目睹了这一点，该行业最终实现了免佣金。</blockquote> Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.<blockquote>其次，加密货币有繁荣和萧条周期的历史。在过去十年中，比特币曾发生过三起独立的事件，其价值至少缩水80%。这是一项完全基于动量的投资，当上行动力枯竭时，Coinbase的交易收入也会枯竭。继2017年达到峰值后，Coinbase的收入在随后几年几乎减半。</blockquote> And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.<blockquote>第三，根据CoinShares数字资产基金流量周刊的数据，截至6月28日的过去四周内，加密货币资金流出量为2.573亿美元。这进一步证明，随着这些资产远低于高点，人们对加密货币的兴趣已经在下降。可以说，Coinbase并不是一只您未来想要拥有的股票。</blockquote> Cassava Sciences<blockquote>木薯科学</blockquote> Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).<blockquote>另一家风险回报比糟糕的超受欢迎公司是临床阶段的生物技术股票木薯科学（纳斯达克：萨瓦）。</blockquote> Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.<blockquote>Cassava在2月份宣布了simufilam治疗阿尔茨海默病的中期分析的积极临床数据，这理所当然地引起了轰动。这项开放标签试验显示，在六个月时认知和行为有所改善，最近允许Cassava概述其涉及其主要候选药物的3期试验计划。</blockquote> I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.<blockquote>我希望simufilam能够成功，但历史表明阿尔茨海默氏症是<a href=\"https://laohu8.com/S/AONE\">一</a>最难治疗的疾病。除了BiogenAduhelm获得了美国食品和药物管理局(FDA)的批准，但因缺乏明确的益处而受到严厉批评，十多年来，每种阿尔茨海默病药物都在后期研究中失败。投资者所要做的就是一项旨在招募100名患者的试验的早期开放标签数据。在大型3期阿尔茨海默病试验中，早期或中期的积极结果被粉碎的情况并不罕见。</blockquote> Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.<blockquote>尽管Cassava筹集了大量现金来继续其研究，但历史表明simufilam成功的机会非常渺茫。这使得木薯科学很容易避免。</blockquote> GameStop<blockquote>游戏驿站</blockquote> If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).<blockquote>如果您一直在关注零售贸易运动（即Reddit股票），散户投资者正在寻找大量卖空的公司并试图进行轧空，您可能知道视频游戏和配件零售商游戏驿站（纽约证券交易所代码：GME）。</blockquote> On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.<blockquote>在<a href=\"https://laohu8.com/S/AONE.U\">一</a>另一方面，游戏驿站能够利用其最近的名气，通过出售股票为其正在进行的向数字游戏公司的转型筹集资金。这是一项急需的举措，此前电子商务销售额在2020财年增长了191%，在假期期间比去年同期增长了四倍多。</blockquote> However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.<blockquote>然而，这些融资并没有忽视前任管理团队让公司失望的事实。二十年来，实体游戏模式运行良好。然而，当游戏走向数字化时，坚持这种实体模式会让公司陷入不稳定的境地。如今，即使电子商务快速增长，游戏驿站仍在继续亏损，去年同店销售额下降了近10%。数字销售可能在增长，但随着游戏驿站关闭其实体店以降低成本，总收入将无处可去。</blockquote> GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.<blockquote>游戏驿站绝不是破产的候选者，我实际上可以看到几年后实现盈利的道路。但话虽如此，考虑到未来漫长的转型和运营亏损，所看到的收益毫无意义。</blockquote> Inovio Pharmaceuticals<blockquote>Inovio制药公司</blockquote> Biotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.<blockquote>生物科技股可以提供充足的机会，或者Inovio制药公司（纳斯达克：INO）案例，吸走长期投资者的命脉。</blockquote> Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.<blockquote>Inovio似乎是一家仅基于纸张的有趣公司。它的产品线目前包括十几种治疗癌症、传染病和人乳头瘤病毒的临床候选药物。最有前途的看起来是INO-4800，这是该公司的冠状病毒病2019（COVID-19）候选疫苗，已准备好进行3期研究。但如果你深入研究Inovio的临床表现，你会非常失望。</blockquote> For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.<blockquote>例如，INO-4800在美国已被部分临床搁置，而监管机构要求提供有关Inovio疫苗及其输送系统Cellectra的更多数据。最近，INO-4800的后期资金被美国政府取消，这就是为什么它现在正在为其COVID-19候选药物寻求国际研究。</blockquote> If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.<blockquote>如果你认为我不公平地指责Inovio在新冠肺炎的挣扎，那就更进一步吧。四十年来，Inovio一直未能获得FDA批准的药物。这并不是我希望Inovio发生不好的事情——这是现实，希望和结果很长一段时间都没有与这家公司保持一致。在Inovio在后期临床试验中证明自己之前，值得避免使用。</blockquote> AMC Entertainment<blockquote>AMC院线</blockquote> Finally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.<blockquote>最后，我不能忘记正在进行的抽水和转储计划AMC院线（纽约证券交易所代码：AMC）。尽管在AMC通过发行大量股票和高息债务自救后，散户投资者能够通过1月份的轧空来宣称胜利，但最近的上涨与轧空无关。相反，它主要基于炒作，在留言板上故意混淆具体的基本数据，以及广泛的，公然的错误信息。</blockquote> AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.<blockquote>AMC的散户投资者希望你相信基本面并不重要，但尝试驾驶一辆没有发动机的汽车，看看你能走多远。AMC正在应对行业票房收入连续19年下降的问题，并且随着电影制片厂依赖流媒体，其部分电影独家经营权正在消失。电影院将会有一席之地，但AMC的潜在市场逐年萎缩。</blockquote> AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.<blockquote>AMC的散户投资者还会让您相信该公司在筹集20亿美元资本后状况良好。尽管近期破产传闻已被搁置，但2027年债券价格远未接近面值。你会问，为什么？因为债券持有人不相信AMC会逃脱破产。</blockquote> I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.<blockquote>我一生中见过足够多的泵和转储活动来识别它们，并且AMC检查了所有的框。我的建议是不要做空AMC。我的建议是完全避免。所有的抽水和转储计划最终都会崩溃，AMC也不例外。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/\">The motley fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GME":"游戏驿站","SAVA":"Cassava Sciences Inc","INO":"伊诺维奥制药","COIN":"Coinbase Global, Inc.","AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164348327","content_text":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.\nWhile a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.\nCoinbase Global\nFirst up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.\nTo start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.\nSecond,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.\nAnd third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.\nCassava Sciences\nAnother ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).\nCassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.\nI'd love for simufilam to be successful, but history has shown that Alzheimer's is one of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.\nAlthough Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.\nGameStop\nIf you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).\nOn one hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.\nHowever, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.\nGameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.\nInovio Pharmaceuticals\nBiotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.\nInovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.\nFor example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.\nIf you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.\nAMC Entertainment\nFinally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.\nAMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.\nAMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.\nI've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.","news_type":1,"symbols_score_info":{"SAVA":0.9,"INO":0.9,"GME":0.9,"COIN":0.9,"AMC":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":154467397,"gmtCreate":1625539970719,"gmtModify":1633939832249,"author":{"id":"3570938362108330","authorId":"3570938362108330","name":"KVCGTan","avatar":"https://static.tigerbbs.com/2126be6bc046089345232547cb51d38a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3570938362108330","authorIdStr":"3570938362108330"},"htmlText":"Interesting&nbsp;","listText":"Interesting&nbsp;","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/154467397","repostId":1164348327,"repostType":4,"repost":{"id":"1164348327","kind":"news","pubTimestamp":1625535165,"share":"https://www.laohu8.com/m/news/1164348327?lang=zh_CN&edition=full","pubTime":"2021-07-06 09:32","market":"us","language":"en","title":"5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1164348327","media":"The motley fool","summary":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The ben","content":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&amp;P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.<blockquote>在过去的15个月里，华尔街和投资者享受了历史性的反弹。基准标普500自2020年3月23日触及熊市底部以来，已上涨超过90%。</blockquote> While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.<blockquote>虽然许多高质量和创新的企业引领了这场反弹，但它也让相当多糟糕的公司蓬勃发展。我建议像七月瘟疫一样避开以下五只超受欢迎的股票。</blockquote> Coinbase Global<blockquote>比特币基地全球</blockquote> First up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin&nbsp;andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.<blockquote>首先是加密货币交易所和生态系统比特币基地全球（纳斯达克：硬币）。Coinbase很受欢迎，因为投资者纷纷涌入Coinbase等公司，其第一季度收入和利润飙升得如此之快比特币和以太币.问题是有三种催化剂对Coinbase经纪模式不利。</blockquote> To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.<blockquote>首先，没有什么可以阻止竞争交易所降低Coinbase Global的费用。目前它可能具有经过验证的用户优势，但不要低估加密货币投资者为节省交易费用而跳槽的意愿。我们在传统券商中目睹了这一点，该行业最终实现了免佣金。</blockquote> Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.<blockquote>其次，加密货币有繁荣和萧条周期的历史。在过去十年中，比特币曾发生过三起独立的事件，其价值至少缩水80%。这是一项完全基于动量的投资，当上行动力枯竭时，Coinbase的交易收入也会枯竭。继2017年达到峰值后，Coinbase的收入在随后几年几乎减半。</blockquote> And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.<blockquote>第三，根据CoinShares数字资产基金流量周刊的数据，截至6月28日的过去四周内，加密货币资金流出量为2.573亿美元。这进一步证明，随着这些资产远低于高点，人们对加密货币的兴趣已经在下降。可以说，Coinbase并不是一只您未来想要拥有的股票。</blockquote> Cassava Sciences<blockquote>木薯科学</blockquote> Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).<blockquote>另一家风险回报比糟糕的超受欢迎公司是临床阶段的生物技术股票木薯科学（纳斯达克：萨瓦）。</blockquote> Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.<blockquote>Cassava在2月份宣布了simufilam治疗阿尔茨海默病的中期分析的积极临床数据，这理所当然地引起了轰动。这项开放标签试验显示，在六个月时认知和行为有所改善，最近允许Cassava概述其涉及其主要候选药物的3期试验计划。</blockquote> I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.<blockquote>我希望simufilam能够成功，但历史表明阿尔茨海默氏症是<a href=\"https://laohu8.com/S/AONE\">一</a>最难治疗的疾病。除了BiogenAduhelm获得了美国食品和药物管理局(FDA)的批准，但因缺乏明确的益处而受到严厉批评，十多年来，每种阿尔茨海默病药物都在后期研究中失败。投资者所要做的就是一项旨在招募100名患者的试验的早期开放标签数据。在大型3期阿尔茨海默病试验中，早期或中期的积极结果被粉碎的情况并不罕见。</blockquote> Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.<blockquote>尽管Cassava筹集了大量现金来继续其研究，但历史表明simufilam成功的机会非常渺茫。这使得木薯科学很容易避免。</blockquote> GameStop<blockquote>游戏驿站</blockquote> If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).<blockquote>如果您一直在关注零售贸易运动（即Reddit股票），散户投资者正在寻找大量卖空的公司并试图进行轧空，您可能知道视频游戏和配件零售商游戏驿站（纽约证券交易所代码：GME）。</blockquote> On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.<blockquote>在<a href=\"https://laohu8.com/S/AONE.U\">一</a>另一方面，游戏驿站能够利用其最近的名气，通过出售股票为其正在进行的向数字游戏公司的转型筹集资金。这是一项急需的举措，此前电子商务销售额在2020财年增长了191%，在假期期间比去年同期增长了四倍多。</blockquote> However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.<blockquote>然而，这些融资并没有忽视前任管理团队让公司失望的事实。二十年来，实体游戏模式运行良好。然而，当游戏走向数字化时，坚持这种实体模式会让公司陷入不稳定的境地。如今，即使电子商务快速增长，游戏驿站仍在继续亏损，去年同店销售额下降了近10%。数字销售可能在增长，但随着游戏驿站关闭其实体店以降低成本，总收入将无处可去。</blockquote> GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.<blockquote>游戏驿站绝不是破产的候选者，我实际上可以看到几年后实现盈利的道路。但话虽如此，考虑到未来漫长的转型和运营亏损，所看到的收益毫无意义。</blockquote> Inovio Pharmaceuticals<blockquote>Inovio制药公司</blockquote> Biotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.<blockquote>生物科技股可以提供充足的机会，或者Inovio制药公司（纳斯达克：INO）案例，吸走长期投资者的命脉。</blockquote> Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.<blockquote>Inovio似乎是一家仅基于纸张的有趣公司。它的产品线目前包括十几种治疗癌症、传染病和人乳头瘤病毒的临床候选药物。最有前途的看起来是INO-4800，这是该公司的冠状病毒病2019（COVID-19）候选疫苗，已准备好进行3期研究。但如果你深入研究Inovio的临床表现，你会非常失望。</blockquote> For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.<blockquote>例如，INO-4800在美国已被部分临床搁置，而监管机构要求提供有关Inovio疫苗及其输送系统Cellectra的更多数据。最近，INO-4800的后期资金被美国政府取消，这就是为什么它现在正在为其COVID-19候选药物寻求国际研究。</blockquote> If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.<blockquote>如果你认为我不公平地指责Inovio在新冠肺炎的挣扎，那就更进一步吧。四十年来，Inovio一直未能获得FDA批准的药物。这并不是我希望Inovio发生不好的事情——这是现实，希望和结果很长一段时间都没有与这家公司保持一致。在Inovio在后期临床试验中证明自己之前，值得避免使用。</blockquote> AMC Entertainment<blockquote>AMC院线</blockquote> Finally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.<blockquote>最后，我不能忘记正在进行的抽水和转储计划AMC院线（纽约证券交易所代码：AMC）。尽管在AMC通过发行大量股票和高息债务自救后，散户投资者能够通过1月份的轧空来宣称胜利，但最近的上涨与轧空无关。相反，它主要基于炒作，在留言板上故意混淆具体的基本数据，以及广泛的，公然的错误信息。</blockquote> AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.<blockquote>AMC的散户投资者希望你相信基本面并不重要，但尝试驾驶一辆没有发动机的汽车，看看你能走多远。AMC正在应对行业票房收入连续19年下降的问题，并且随着电影制片厂依赖流媒体，其部分电影独家经营权正在消失。电影院将会有一席之地，但AMC的潜在市场逐年萎缩。</blockquote> AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.<blockquote>AMC的散户投资者还会让您相信该公司在筹集20亿美元资本后状况良好。尽管近期破产传闻已被搁置，但2027年债券价格远未接近面值。你会问，为什么？因为债券持有人不相信AMC会逃脱破产。</blockquote> I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.<blockquote>我一生中见过足够多的泵和转储活动来识别它们，并且AMC检查了所有的框。我的建议是不要做空AMC。我的建议是完全避免。所有的抽水和转储计划最终都会崩溃，AMC也不例外。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nThe motley fool2021-07-06 09:32\n\n</h4>\n</header>\n<article>\nFor the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&amp;P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.<blockquote>在过去的15个月里，华尔街和投资者享受了历史性的反弹。基准标普500自2020年3月23日触及熊市底部以来，已上涨超过90%。</blockquote> While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.<blockquote>虽然许多高质量和创新的企业引领了这场反弹，但它也让相当多糟糕的公司蓬勃发展。我建议像七月瘟疫一样避开以下五只超受欢迎的股票。</blockquote> Coinbase Global<blockquote>比特币基地全球</blockquote> First up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin&nbsp;andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.<blockquote>首先是加密货币交易所和生态系统比特币基地全球（纳斯达克：硬币）。Coinbase很受欢迎，因为投资者纷纷涌入Coinbase等公司，其第一季度收入和利润飙升得如此之快比特币和以太币.问题是有三种催化剂对Coinbase经纪模式不利。</blockquote> To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.<blockquote>首先，没有什么可以阻止竞争交易所降低Coinbase Global的费用。目前它可能具有经过验证的用户优势，但不要低估加密货币投资者为节省交易费用而跳槽的意愿。我们在传统券商中目睹了这一点，该行业最终实现了免佣金。</blockquote> Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.<blockquote>其次，加密货币有繁荣和萧条周期的历史。在过去十年中，比特币曾发生过三起独立的事件，其价值至少缩水80%。这是一项完全基于动量的投资，当上行动力枯竭时，Coinbase的交易收入也会枯竭。继2017年达到峰值后，Coinbase的收入在随后几年几乎减半。</blockquote> And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.<blockquote>第三，根据CoinShares数字资产基金流量周刊的数据，截至6月28日的过去四周内，加密货币资金流出量为2.573亿美元。这进一步证明，随着这些资产远低于高点，人们对加密货币的兴趣已经在下降。可以说，Coinbase并不是一只您未来想要拥有的股票。</blockquote> Cassava Sciences<blockquote>木薯科学</blockquote> Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).<blockquote>另一家风险回报比糟糕的超受欢迎公司是临床阶段的生物技术股票木薯科学（纳斯达克：萨瓦）。</blockquote> Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.<blockquote>Cassava在2月份宣布了simufilam治疗阿尔茨海默病的中期分析的积极临床数据，这理所当然地引起了轰动。这项开放标签试验显示，在六个月时认知和行为有所改善，最近允许Cassava概述其涉及其主要候选药物的3期试验计划。</blockquote> I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.<blockquote>我希望simufilam能够成功，但历史表明阿尔茨海默氏症是<a href=\"https://laohu8.com/S/AONE\">一</a>最难治疗的疾病。除了BiogenAduhelm获得了美国食品和药物管理局(FDA)的批准，但因缺乏明确的益处而受到严厉批评，十多年来，每种阿尔茨海默病药物都在后期研究中失败。投资者所要做的就是一项旨在招募100名患者的试验的早期开放标签数据。在大型3期阿尔茨海默病试验中，早期或中期的积极结果被粉碎的情况并不罕见。</blockquote> Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.<blockquote>尽管Cassava筹集了大量现金来继续其研究，但历史表明simufilam成功的机会非常渺茫。这使得木薯科学很容易避免。</blockquote> GameStop<blockquote>游戏驿站</blockquote> If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).<blockquote>如果您一直在关注零售贸易运动（即Reddit股票），散户投资者正在寻找大量卖空的公司并试图进行轧空，您可能知道视频游戏和配件零售商游戏驿站（纽约证券交易所代码：GME）。</blockquote> On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.<blockquote>在<a href=\"https://laohu8.com/S/AONE.U\">一</a>另一方面，游戏驿站能够利用其最近的名气，通过出售股票为其正在进行的向数字游戏公司的转型筹集资金。这是一项急需的举措，此前电子商务销售额在2020财年增长了191%，在假期期间比去年同期增长了四倍多。</blockquote> However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.<blockquote>然而，这些融资并没有忽视前任管理团队让公司失望的事实。二十年来，实体游戏模式运行良好。然而，当游戏走向数字化时，坚持这种实体模式会让公司陷入不稳定的境地。如今，即使电子商务快速增长，游戏驿站仍在继续亏损，去年同店销售额下降了近10%。数字销售可能在增长，但随着游戏驿站关闭其实体店以降低成本，总收入将无处可去。</blockquote> GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.<blockquote>游戏驿站绝不是破产的候选者，我实际上可以看到几年后实现盈利的道路。但话虽如此，考虑到未来漫长的转型和运营亏损，所看到的收益毫无意义。</blockquote> Inovio Pharmaceuticals<blockquote>Inovio制药公司</blockquote> Biotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.<blockquote>生物科技股可以提供充足的机会，或者Inovio制药公司（纳斯达克：INO）案例，吸走长期投资者的命脉。</blockquote> Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.<blockquote>Inovio似乎是一家仅基于纸张的有趣公司。它的产品线目前包括十几种治疗癌症、传染病和人乳头瘤病毒的临床候选药物。最有前途的看起来是INO-4800，这是该公司的冠状病毒病2019（COVID-19）候选疫苗，已准备好进行3期研究。但如果你深入研究Inovio的临床表现，你会非常失望。</blockquote> For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.<blockquote>例如，INO-4800在美国已被部分临床搁置，而监管机构要求提供有关Inovio疫苗及其输送系统Cellectra的更多数据。最近，INO-4800的后期资金被美国政府取消，这就是为什么它现在正在为其COVID-19候选药物寻求国际研究。</blockquote> If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.<blockquote>如果你认为我不公平地指责Inovio在新冠肺炎的挣扎，那就更进一步吧。四十年来，Inovio一直未能获得FDA批准的药物。这并不是我希望Inovio发生不好的事情——这是现实，希望和结果很长一段时间都没有与这家公司保持一致。在Inovio在后期临床试验中证明自己之前，值得避免使用。</blockquote> AMC Entertainment<blockquote>AMC院线</blockquote> Finally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.<blockquote>最后，我不能忘记正在进行的抽水和转储计划AMC院线（纽约证券交易所代码：AMC）。尽管在AMC通过发行大量股票和高息债务自救后，散户投资者能够通过1月份的轧空来宣称胜利，但最近的上涨与轧空无关。相反，它主要基于炒作，在留言板上故意混淆具体的基本数据，以及广泛的，公然的错误信息。</blockquote> AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.<blockquote>AMC的散户投资者希望你相信基本面并不重要，但尝试驾驶一辆没有发动机的汽车，看看你能走多远。AMC正在应对行业票房收入连续19年下降的问题，并且随着电影制片厂依赖流媒体，其部分电影独家经营权正在消失。电影院将会有一席之地，但AMC的潜在市场逐年萎缩。</blockquote> AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.<blockquote>AMC的散户投资者还会让您相信该公司在筹集20亿美元资本后状况良好。尽管近期破产传闻已被搁置，但2027年债券价格远未接近面值。你会问，为什么？因为债券持有人不相信AMC会逃脱破产。</blockquote> I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.<blockquote>我一生中见过足够多的泵和转储活动来识别它们，并且AMC检查了所有的框。我的建议是不要做空AMC。我的建议是完全避免。所有的抽水和转储计划最终都会崩溃，AMC也不例外。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/\">The motley fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GME":"游戏驿站","SAVA":"Cassava Sciences Inc","INO":"伊诺维奥制药","COIN":"Coinbase Global, Inc.","AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164348327","content_text":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.\nWhile a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.\nCoinbase Global\nFirst up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.\nTo start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.\nSecond,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.\nAnd third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.\nCassava Sciences\nAnother ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).\nCassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.\nI'd love for simufilam to be successful, but history has shown that Alzheimer's is one of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.\nAlthough Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.\nGameStop\nIf you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).\nOn one hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.\nHowever, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.\nGameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.\nInovio Pharmaceuticals\nBiotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.\nInovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.\nFor example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.\nIf you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.\nAMC Entertainment\nFinally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.\nAMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.\nAMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.\nI've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.","news_type":1,"symbols_score_info":{"SAVA":0.9,"INO":0.9,"GME":0.9,"COIN":0.9,"AMC":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5133114,"gmtCreate":1625540210266,"gmtModify":1635236274407,"authorId":3559859558754319,"author":{"id":3559859558754319,"idStr":"3559859558754319","authorId":3559859558754319,"name":"Bodoh","avatar":"https://static.tigerbbs.com/349218ea2852130ca86ce660b4aa2d59","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":154467397,"type":1,"supId":0,"prevId":0,"content":"Yes","text":"Yes","html":"Yes"}],"langContent":"EN"},{"id":154481285,"gmtCreate":1625538951247,"gmtModify":1633939842379,"author":{"id":"3566111551860327","authorId":"3566111551860327","name":"Jo5tarz","avatar":"https://static.tigerbbs.com/8cdaa131f223c2f17b3669bce62cc05e","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3566111551860327","authorIdStr":"3566111551860327"},"htmlText":"FUD news by the same fools yet again[捂脸]&nbsp;","listText":"FUD news by the same fools yet again[捂脸]&nbsp;","text":"FUD news by the same fools yet again[捂脸]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/154481285","repostId":1164348327,"repostType":4,"repost":{"id":"1164348327","kind":"news","pubTimestamp":1625535165,"share":"https://www.laohu8.com/m/news/1164348327?lang=zh_CN&edition=full","pubTime":"2021-07-06 09:32","market":"us","language":"en","title":"5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1164348327","media":"The motley fool","summary":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The ben","content":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&amp;P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.<blockquote>在过去的15个月里，华尔街和投资者享受了历史性的反弹。基准标普500自2020年3月23日触及熊市底部以来，已上涨超过90%。</blockquote> While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.<blockquote>虽然许多高质量和创新的企业引领了这场反弹，但它也让相当多糟糕的公司蓬勃发展。我建议像七月瘟疫一样避开以下五只超受欢迎的股票。</blockquote> Coinbase Global<blockquote>比特币基地全球</blockquote> First up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin&nbsp;andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.<blockquote>首先是加密货币交易所和生态系统比特币基地全球（纳斯达克：硬币）。Coinbase很受欢迎，因为投资者纷纷涌入Coinbase等公司，其第一季度收入和利润飙升得如此之快比特币和以太币.问题是有三种催化剂对Coinbase经纪模式不利。</blockquote> To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.<blockquote>首先，没有什么可以阻止竞争交易所降低Coinbase Global的费用。目前它可能具有经过验证的用户优势，但不要低估加密货币投资者为节省交易费用而跳槽的意愿。我们在传统券商中目睹了这一点，该行业最终实现了免佣金。</blockquote> Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.<blockquote>其次，加密货币有繁荣和萧条周期的历史。在过去十年中，比特币曾发生过三起独立的事件，其价值至少缩水80%。这是一项完全基于动量的投资，当上行动力枯竭时，Coinbase的交易收入也会枯竭。继2017年达到峰值后，Coinbase的收入在随后几年几乎减半。</blockquote> And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.<blockquote>第三，根据CoinShares数字资产基金流量周刊的数据，截至6月28日的过去四周内，加密货币资金流出量为2.573亿美元。这进一步证明，随着这些资产远低于高点，人们对加密货币的兴趣已经在下降。可以说，Coinbase并不是一只您未来想要拥有的股票。</blockquote> Cassava Sciences<blockquote>木薯科学</blockquote> Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).<blockquote>另一家风险回报比糟糕的超受欢迎公司是临床阶段的生物技术股票木薯科学（纳斯达克：萨瓦）。</blockquote> Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.<blockquote>Cassava在2月份宣布了simufilam治疗阿尔茨海默病的中期分析的积极临床数据，这理所当然地引起了轰动。这项开放标签试验显示，在六个月时认知和行为有所改善，最近允许Cassava概述其涉及其主要候选药物的3期试验计划。</blockquote> I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.<blockquote>我希望simufilam能够成功，但历史表明阿尔茨海默氏症是<a href=\"https://laohu8.com/S/AONE\">一</a>最难治疗的疾病。除了BiogenAduhelm获得了美国食品和药物管理局(FDA)的批准，但因缺乏明确的益处而受到严厉批评，十多年来，每种阿尔茨海默病药物都在后期研究中失败。投资者所要做的就是一项旨在招募100名患者的试验的早期开放标签数据。在大型3期阿尔茨海默病试验中，早期或中期的积极结果被粉碎的情况并不罕见。</blockquote> Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.<blockquote>尽管Cassava筹集了大量现金来继续其研究，但历史表明simufilam成功的机会非常渺茫。这使得木薯科学很容易避免。</blockquote> GameStop<blockquote>游戏驿站</blockquote> If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).<blockquote>如果您一直在关注零售贸易运动（即Reddit股票），散户投资者正在寻找大量卖空的公司并试图进行轧空，您可能知道视频游戏和配件零售商游戏驿站（纽约证券交易所代码：GME）。</blockquote> On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.<blockquote>在<a href=\"https://laohu8.com/S/AONE.U\">一</a>另一方面，游戏驿站能够利用其最近的名气，通过出售股票为其正在进行的向数字游戏公司的转型筹集资金。这是一项急需的举措，此前电子商务销售额在2020财年增长了191%，在假期期间比去年同期增长了四倍多。</blockquote> However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.<blockquote>然而，这些融资并没有忽视前任管理团队让公司失望的事实。二十年来，实体游戏模式运行良好。然而，当游戏走向数字化时，坚持这种实体模式会让公司陷入不稳定的境地。如今，即使电子商务快速增长，游戏驿站仍在继续亏损，去年同店销售额下降了近10%。数字销售可能在增长，但随着游戏驿站关闭其实体店以降低成本，总收入将无处可去。</blockquote> GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.<blockquote>游戏驿站绝不是破产的候选者，我实际上可以看到几年后实现盈利的道路。但话虽如此，考虑到未来漫长的转型和运营亏损，所看到的收益毫无意义。</blockquote> Inovio Pharmaceuticals<blockquote>Inovio制药公司</blockquote> Biotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.<blockquote>生物科技股可以提供充足的机会，或者Inovio制药公司（纳斯达克：INO）案例，吸走长期投资者的命脉。</blockquote> Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.<blockquote>Inovio似乎是一家仅基于纸张的有趣公司。它的产品线目前包括十几种治疗癌症、传染病和人乳头瘤病毒的临床候选药物。最有前途的看起来是INO-4800，这是该公司的冠状病毒病2019（COVID-19）候选疫苗，已准备好进行3期研究。但如果你深入研究Inovio的临床表现，你会非常失望。</blockquote> For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.<blockquote>例如，INO-4800在美国已被部分临床搁置，而监管机构要求提供有关Inovio疫苗及其输送系统Cellectra的更多数据。最近，INO-4800的后期资金被美国政府取消，这就是为什么它现在正在为其COVID-19候选药物寻求国际研究。</blockquote> If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.<blockquote>如果你认为我不公平地指责Inovio在新冠肺炎的挣扎，那就更进一步吧。四十年来，Inovio一直未能获得FDA批准的药物。这并不是我希望Inovio发生不好的事情——这是现实，希望和结果很长一段时间都没有与这家公司保持一致。在Inovio在后期临床试验中证明自己之前，值得避免使用。</blockquote> AMC Entertainment<blockquote>AMC院线</blockquote> Finally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.<blockquote>最后，我不能忘记正在进行的抽水和转储计划AMC院线（纽约证券交易所代码：AMC）。尽管在AMC通过发行大量股票和高息债务自救后，散户投资者能够通过1月份的轧空来宣称胜利，但最近的上涨与轧空无关。相反，它主要基于炒作，在留言板上故意混淆具体的基本数据，以及广泛的，公然的错误信息。</blockquote> AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.<blockquote>AMC的散户投资者希望你相信基本面并不重要，但尝试驾驶一辆没有发动机的汽车，看看你能走多远。AMC正在应对行业票房收入连续19年下降的问题，并且随着电影制片厂依赖流媒体，其部分电影独家经营权正在消失。电影院将会有一席之地，但AMC的潜在市场逐年萎缩。</blockquote> AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.<blockquote>AMC的散户投资者还会让您相信该公司在筹集20亿美元资本后状况良好。尽管近期破产传闻已被搁置，但2027年债券价格远未接近面值。你会问，为什么？因为债券持有人不相信AMC会逃脱破产。</blockquote> I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.<blockquote>我一生中见过足够多的泵和转储活动来识别它们，并且AMC检查了所有的框。我的建议是不要做空AMC。我的建议是完全避免。所有的抽水和转储计划最终都会崩溃，AMC也不例外。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nThe motley fool2021-07-06 09:32\n\n</h4>\n</header>\n<article>\nFor the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&amp;P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.<blockquote>在过去的15个月里，华尔街和投资者享受了历史性的反弹。基准标普500自2020年3月23日触及熊市底部以来，已上涨超过90%。</blockquote> While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.<blockquote>虽然许多高质量和创新的企业引领了这场反弹，但它也让相当多糟糕的公司蓬勃发展。我建议像七月瘟疫一样避开以下五只超受欢迎的股票。</blockquote> Coinbase Global<blockquote>比特币基地全球</blockquote> First up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin&nbsp;andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.<blockquote>首先是加密货币交易所和生态系统比特币基地全球（纳斯达克：硬币）。Coinbase很受欢迎，因为投资者纷纷涌入Coinbase等公司，其第一季度收入和利润飙升得如此之快比特币和以太币.问题是有三种催化剂对Coinbase经纪模式不利。</blockquote> To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.<blockquote>首先，没有什么可以阻止竞争交易所降低Coinbase Global的费用。目前它可能具有经过验证的用户优势，但不要低估加密货币投资者为节省交易费用而跳槽的意愿。我们在传统券商中目睹了这一点，该行业最终实现了免佣金。</blockquote> Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.<blockquote>其次，加密货币有繁荣和萧条周期的历史。在过去十年中，比特币曾发生过三起独立的事件，其价值至少缩水80%。这是一项完全基于动量的投资，当上行动力枯竭时，Coinbase的交易收入也会枯竭。继2017年达到峰值后，Coinbase的收入在随后几年几乎减半。</blockquote> And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.<blockquote>第三，根据CoinShares数字资产基金流量周刊的数据，截至6月28日的过去四周内，加密货币资金流出量为2.573亿美元。这进一步证明，随着这些资产远低于高点，人们对加密货币的兴趣已经在下降。可以说，Coinbase并不是一只您未来想要拥有的股票。</blockquote> Cassava Sciences<blockquote>木薯科学</blockquote> Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).<blockquote>另一家风险回报比糟糕的超受欢迎公司是临床阶段的生物技术股票木薯科学（纳斯达克：萨瓦）。</blockquote> Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.<blockquote>Cassava在2月份宣布了simufilam治疗阿尔茨海默病的中期分析的积极临床数据，这理所当然地引起了轰动。这项开放标签试验显示，在六个月时认知和行为有所改善，最近允许Cassava概述其涉及其主要候选药物的3期试验计划。</blockquote> I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.<blockquote>我希望simufilam能够成功，但历史表明阿尔茨海默氏症是<a href=\"https://laohu8.com/S/AONE\">一</a>最难治疗的疾病。除了BiogenAduhelm获得了美国食品和药物管理局(FDA)的批准，但因缺乏明确的益处而受到严厉批评，十多年来，每种阿尔茨海默病药物都在后期研究中失败。投资者所要做的就是一项旨在招募100名患者的试验的早期开放标签数据。在大型3期阿尔茨海默病试验中，早期或中期的积极结果被粉碎的情况并不罕见。</blockquote> Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.<blockquote>尽管Cassava筹集了大量现金来继续其研究，但历史表明simufilam成功的机会非常渺茫。这使得木薯科学很容易避免。</blockquote> GameStop<blockquote>游戏驿站</blockquote> If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).<blockquote>如果您一直在关注零售贸易运动（即Reddit股票），散户投资者正在寻找大量卖空的公司并试图进行轧空，您可能知道视频游戏和配件零售商游戏驿站（纽约证券交易所代码：GME）。</blockquote> On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.<blockquote>在<a href=\"https://laohu8.com/S/AONE.U\">一</a>另一方面，游戏驿站能够利用其最近的名气，通过出售股票为其正在进行的向数字游戏公司的转型筹集资金。这是一项急需的举措，此前电子商务销售额在2020财年增长了191%，在假期期间比去年同期增长了四倍多。</blockquote> However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.<blockquote>然而，这些融资并没有忽视前任管理团队让公司失望的事实。二十年来，实体游戏模式运行良好。然而，当游戏走向数字化时，坚持这种实体模式会让公司陷入不稳定的境地。如今，即使电子商务快速增长，游戏驿站仍在继续亏损，去年同店销售额下降了近10%。数字销售可能在增长，但随着游戏驿站关闭其实体店以降低成本，总收入将无处可去。</blockquote> GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.<blockquote>游戏驿站绝不是破产的候选者，我实际上可以看到几年后实现盈利的道路。但话虽如此，考虑到未来漫长的转型和运营亏损，所看到的收益毫无意义。</blockquote> Inovio Pharmaceuticals<blockquote>Inovio制药公司</blockquote> Biotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.<blockquote>生物科技股可以提供充足的机会，或者Inovio制药公司（纳斯达克：INO）案例，吸走长期投资者的命脉。</blockquote> Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.<blockquote>Inovio似乎是一家仅基于纸张的有趣公司。它的产品线目前包括十几种治疗癌症、传染病和人乳头瘤病毒的临床候选药物。最有前途的看起来是INO-4800，这是该公司的冠状病毒病2019（COVID-19）候选疫苗，已准备好进行3期研究。但如果你深入研究Inovio的临床表现，你会非常失望。</blockquote> For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.<blockquote>例如，INO-4800在美国已被部分临床搁置，而监管机构要求提供有关Inovio疫苗及其输送系统Cellectra的更多数据。最近，INO-4800的后期资金被美国政府取消，这就是为什么它现在正在为其COVID-19候选药物寻求国际研究。</blockquote> If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.<blockquote>如果你认为我不公平地指责Inovio在新冠肺炎的挣扎，那就更进一步吧。四十年来，Inovio一直未能获得FDA批准的药物。这并不是我希望Inovio发生不好的事情——这是现实，希望和结果很长一段时间都没有与这家公司保持一致。在Inovio在后期临床试验中证明自己之前，值得避免使用。</blockquote> AMC Entertainment<blockquote>AMC院线</blockquote> Finally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.<blockquote>最后，我不能忘记正在进行的抽水和转储计划AMC院线（纽约证券交易所代码：AMC）。尽管在AMC通过发行大量股票和高息债务自救后，散户投资者能够通过1月份的轧空来宣称胜利，但最近的上涨与轧空无关。相反，它主要基于炒作，在留言板上故意混淆具体的基本数据，以及广泛的，公然的错误信息。</blockquote> AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.<blockquote>AMC的散户投资者希望你相信基本面并不重要，但尝试驾驶一辆没有发动机的汽车，看看你能走多远。AMC正在应对行业票房收入连续19年下降的问题，并且随着电影制片厂依赖流媒体，其部分电影独家经营权正在消失。电影院将会有一席之地，但AMC的潜在市场逐年萎缩。</blockquote> AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.<blockquote>AMC的散户投资者还会让您相信该公司在筹集20亿美元资本后状况良好。尽管近期破产传闻已被搁置，但2027年债券价格远未接近面值。你会问，为什么？因为债券持有人不相信AMC会逃脱破产。</blockquote> I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.<blockquote>我一生中见过足够多的泵和转储活动来识别它们，并且AMC检查了所有的框。我的建议是不要做空AMC。我的建议是完全避免。所有的抽水和转储计划最终都会崩溃，AMC也不例外。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/\">The motley fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GME":"游戏驿站","SAVA":"Cassava Sciences Inc","INO":"伊诺维奥制药","COIN":"Coinbase Global, Inc.","AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164348327","content_text":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.\nWhile a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.\nCoinbase Global\nFirst up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.\nTo start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.\nSecond,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.\nAnd third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.\nCassava Sciences\nAnother ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).\nCassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.\nI'd love for simufilam to be successful, but history has shown that Alzheimer's is one of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.\nAlthough Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.\nGameStop\nIf you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).\nOn one hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.\nHowever, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.\nGameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.\nInovio Pharmaceuticals\nBiotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.\nInovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.\nFor example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.\nIf you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.\nAMC Entertainment\nFinally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.\nAMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.\nAMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.\nI've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.","news_type":1,"symbols_score_info":{"SAVA":0.9,"INO":0.9,"GME":0.9,"COIN":0.9,"AMC":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5133094,"gmtCreate":1625540116372,"gmtModify":1635236276387,"authorId":3575423014243315,"author":{"id":3575423014243315,"idStr":"3575423014243315","authorId":3575423014243315,"name":"Jaminwu","avatar":"https://static.tigerbbs.com/e406a9629077a6d66bf3ea9d74b7b538","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":154481285,"type":1,"supId":0,"prevId":0,"content":"yes","text":"yes","html":"yes"},{"id":5134082,"gmtCreate":1625547258628,"gmtModify":1635236189995,"authorId":3581985274026406,"author":{"id":3581985274026406,"idStr":"3581985274026406","authorId":3581985274026406,"name":"Skai","avatar":"https://static.tigerbbs.com/77957397aed2feadade5874e503ea585","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":154481285,"type":1,"supId":0,"prevId":0,"content":"They write all sorts of articles with the goal of targeting AMC and GME daily. Lousy news source.","text":"They write all sorts of articles with the goal of targeting AMC and GME daily. Lousy news source.","html":"They write all sorts of articles with the goal of targeting AMC and GME daily. Lousy news source."}],"langContent":"CN"},{"id":154414968,"gmtCreate":1625538624054,"gmtModify":1633939845280,"author":{"id":"3570598542159923","authorId":"3570598542159923","name":"ShawnKoh1","avatar":"https://static.tigerbbs.com/0045c4894f8a2755b17a9e8518df4d5e","vip":1,"crmLevel":12,"crmLevelSwitch":0,"idStr":"3570598542159923","authorIdStr":"3570598542159923"},"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/154414968","repostId":1164348327,"repostType":4,"repost":{"id":"1164348327","kind":"news","pubTimestamp":1625535165,"share":"https://www.laohu8.com/m/news/1164348327?lang=zh_CN&edition=full","pubTime":"2021-07-06 09:32","market":"us","language":"en","title":"5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1164348327","media":"The motley fool","summary":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The ben","content":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&amp;P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.<blockquote>在过去的15个月里，华尔街和投资者享受了历史性的反弹。基准标普500自2020年3月23日触及熊市底部以来，已上涨超过90%。</blockquote> While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.<blockquote>虽然许多高质量和创新的企业引领了这场反弹，但它也让相当多糟糕的公司蓬勃发展。我建议像七月瘟疫一样避开以下五只超受欢迎的股票。</blockquote> Coinbase Global<blockquote>比特币基地全球</blockquote> First up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin&nbsp;andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.<blockquote>首先是加密货币交易所和生态系统比特币基地全球（纳斯达克：硬币）。Coinbase很受欢迎，因为投资者纷纷涌入Coinbase等公司，其第一季度收入和利润飙升得如此之快比特币和以太币.问题是有三种催化剂对Coinbase经纪模式不利。</blockquote> To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.<blockquote>首先，没有什么可以阻止竞争交易所降低Coinbase Global的费用。目前它可能具有经过验证的用户优势，但不要低估加密货币投资者为节省交易费用而跳槽的意愿。我们在传统券商中目睹了这一点，该行业最终实现了免佣金。</blockquote> Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.<blockquote>其次，加密货币有繁荣和萧条周期的历史。在过去十年中，比特币曾发生过三起独立的事件，其价值至少缩水80%。这是一项完全基于动量的投资，当上行动力枯竭时，Coinbase的交易收入也会枯竭。继2017年达到峰值后，Coinbase的收入在随后几年几乎减半。</blockquote> And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.<blockquote>第三，根据CoinShares数字资产基金流量周刊的数据，截至6月28日的过去四周内，加密货币资金流出量为2.573亿美元。这进一步证明，随着这些资产远低于高点，人们对加密货币的兴趣已经在下降。可以说，Coinbase并不是一只您未来想要拥有的股票。</blockquote> Cassava Sciences<blockquote>木薯科学</blockquote> Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).<blockquote>另一家风险回报比糟糕的超受欢迎公司是临床阶段的生物技术股票木薯科学（纳斯达克：萨瓦）。</blockquote> Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.<blockquote>Cassava在2月份宣布了simufilam治疗阿尔茨海默病的中期分析的积极临床数据，这理所当然地引起了轰动。这项开放标签试验显示，在六个月时认知和行为有所改善，最近允许Cassava概述其涉及其主要候选药物的3期试验计划。</blockquote> I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.<blockquote>我希望simufilam能够成功，但历史表明阿尔茨海默氏症是<a href=\"https://laohu8.com/S/AONE\">一</a>最难治疗的疾病。除了BiogenAduhelm获得了美国食品和药物管理局(FDA)的批准，但因缺乏明确的益处而受到严厉批评，十多年来，每种阿尔茨海默病药物都在后期研究中失败。投资者所要做的就是一项旨在招募100名患者的试验的早期开放标签数据。在大型3期阿尔茨海默病试验中，早期或中期的积极结果被粉碎的情况并不罕见。</blockquote> Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.<blockquote>尽管Cassava筹集了大量现金来继续其研究，但历史表明simufilam成功的机会非常渺茫。这使得木薯科学很容易避免。</blockquote> GameStop<blockquote>游戏驿站</blockquote> If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).<blockquote>如果您一直在关注零售贸易运动（即Reddit股票），散户投资者正在寻找大量卖空的公司并试图进行轧空，您可能知道视频游戏和配件零售商游戏驿站（纽约证券交易所代码：GME）。</blockquote> On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.<blockquote>在<a href=\"https://laohu8.com/S/AONE.U\">一</a>另一方面，游戏驿站能够利用其最近的名气，通过出售股票为其正在进行的向数字游戏公司的转型筹集资金。这是一项急需的举措，此前电子商务销售额在2020财年增长了191%，在假期期间比去年同期增长了四倍多。</blockquote> However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.<blockquote>然而，这些融资并没有忽视前任管理团队让公司失望的事实。二十年来，实体游戏模式运行良好。然而，当游戏走向数字化时，坚持这种实体模式会让公司陷入不稳定的境地。如今，即使电子商务快速增长，游戏驿站仍在继续亏损，去年同店销售额下降了近10%。数字销售可能在增长，但随着游戏驿站关闭其实体店以降低成本，总收入将无处可去。</blockquote> GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.<blockquote>游戏驿站绝不是破产的候选者，我实际上可以看到几年后实现盈利的道路。但话虽如此，考虑到未来漫长的转型和运营亏损，所看到的收益毫无意义。</blockquote> Inovio Pharmaceuticals<blockquote>Inovio制药公司</blockquote> Biotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.<blockquote>生物科技股可以提供充足的机会，或者Inovio制药公司（纳斯达克：INO）案例，吸走长期投资者的命脉。</blockquote> Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.<blockquote>Inovio似乎是一家仅基于纸张的有趣公司。它的产品线目前包括十几种治疗癌症、传染病和人乳头瘤病毒的临床候选药物。最有前途的看起来是INO-4800，这是该公司的冠状病毒病2019（COVID-19）候选疫苗，已准备好进行3期研究。但如果你深入研究Inovio的临床表现，你会非常失望。</blockquote> For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.<blockquote>例如，INO-4800在美国已被部分临床搁置，而监管机构要求提供有关Inovio疫苗及其输送系统Cellectra的更多数据。最近，INO-4800的后期资金被美国政府取消，这就是为什么它现在正在为其COVID-19候选药物寻求国际研究。</blockquote> If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.<blockquote>如果你认为我不公平地指责Inovio在新冠肺炎的挣扎，那就更进一步吧。四十年来，Inovio一直未能获得FDA批准的药物。这并不是我希望Inovio发生不好的事情——这是现实，希望和结果很长一段时间都没有与这家公司保持一致。在Inovio在后期临床试验中证明自己之前，值得避免使用。</blockquote> AMC Entertainment<blockquote>AMC院线</blockquote> Finally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.<blockquote>最后，我不能忘记正在进行的抽水和转储计划AMC院线（纽约证券交易所代码：AMC）。尽管在AMC通过发行大量股票和高息债务自救后，散户投资者能够通过1月份的轧空来宣称胜利，但最近的上涨与轧空无关。相反，它主要基于炒作，在留言板上故意混淆具体的基本数据，以及广泛的，公然的错误信息。</blockquote> AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.<blockquote>AMC的散户投资者希望你相信基本面并不重要，但尝试驾驶一辆没有发动机的汽车，看看你能走多远。AMC正在应对行业票房收入连续19年下降的问题，并且随着电影制片厂依赖流媒体，其部分电影独家经营权正在消失。电影院将会有一席之地，但AMC的潜在市场逐年萎缩。</blockquote> AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.<blockquote>AMC的散户投资者还会让您相信该公司在筹集20亿美元资本后状况良好。尽管近期破产传闻已被搁置，但2027年债券价格远未接近面值。你会问，为什么？因为债券持有人不相信AMC会逃脱破产。</blockquote> I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.<blockquote>我一生中见过足够多的泵和转储活动来识别它们，并且AMC检查了所有的框。我的建议是不要做空AMC。我的建议是完全避免。所有的抽水和转储计划最终都会崩溃，AMC也不例外。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nThe motley fool2021-07-06 09:32\n\n</h4>\n</header>\n<article>\nFor the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&amp;P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.<blockquote>在过去的15个月里，华尔街和投资者享受了历史性的反弹。基准标普500自2020年3月23日触及熊市底部以来，已上涨超过90%。</blockquote> While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.<blockquote>虽然许多高质量和创新的企业引领了这场反弹，但它也让相当多糟糕的公司蓬勃发展。我建议像七月瘟疫一样避开以下五只超受欢迎的股票。</blockquote> Coinbase Global<blockquote>比特币基地全球</blockquote> First up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin&nbsp;andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.<blockquote>首先是加密货币交易所和生态系统比特币基地全球（纳斯达克：硬币）。Coinbase很受欢迎，因为投资者纷纷涌入Coinbase等公司，其第一季度收入和利润飙升得如此之快比特币和以太币.问题是有三种催化剂对Coinbase经纪模式不利。</blockquote> To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.<blockquote>首先，没有什么可以阻止竞争交易所降低Coinbase Global的费用。目前它可能具有经过验证的用户优势，但不要低估加密货币投资者为节省交易费用而跳槽的意愿。我们在传统券商中目睹了这一点，该行业最终实现了免佣金。</blockquote> Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.<blockquote>其次，加密货币有繁荣和萧条周期的历史。在过去十年中，比特币曾发生过三起独立的事件，其价值至少缩水80%。这是一项完全基于动量的投资，当上行动力枯竭时，Coinbase的交易收入也会枯竭。继2017年达到峰值后，Coinbase的收入在随后几年几乎减半。</blockquote> And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.<blockquote>第三，根据CoinShares数字资产基金流量周刊的数据，截至6月28日的过去四周内，加密货币资金流出量为2.573亿美元。这进一步证明，随着这些资产远低于高点，人们对加密货币的兴趣已经在下降。可以说，Coinbase并不是一只您未来想要拥有的股票。</blockquote> Cassava Sciences<blockquote>木薯科学</blockquote> Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).<blockquote>另一家风险回报比糟糕的超受欢迎公司是临床阶段的生物技术股票木薯科学（纳斯达克：萨瓦）。</blockquote> Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.<blockquote>Cassava在2月份宣布了simufilam治疗阿尔茨海默病的中期分析的积极临床数据，这理所当然地引起了轰动。这项开放标签试验显示，在六个月时认知和行为有所改善，最近允许Cassava概述其涉及其主要候选药物的3期试验计划。</blockquote> I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.<blockquote>我希望simufilam能够成功，但历史表明阿尔茨海默氏症是<a href=\"https://laohu8.com/S/AONE\">一</a>最难治疗的疾病。除了BiogenAduhelm获得了美国食品和药物管理局(FDA)的批准，但因缺乏明确的益处而受到严厉批评，十多年来，每种阿尔茨海默病药物都在后期研究中失败。投资者所要做的就是一项旨在招募100名患者的试验的早期开放标签数据。在大型3期阿尔茨海默病试验中，早期或中期的积极结果被粉碎的情况并不罕见。</blockquote> Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.<blockquote>尽管Cassava筹集了大量现金来继续其研究，但历史表明simufilam成功的机会非常渺茫。这使得木薯科学很容易避免。</blockquote> GameStop<blockquote>游戏驿站</blockquote> If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).<blockquote>如果您一直在关注零售贸易运动（即Reddit股票），散户投资者正在寻找大量卖空的公司并试图进行轧空，您可能知道视频游戏和配件零售商游戏驿站（纽约证券交易所代码：GME）。</blockquote> On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.<blockquote>在<a href=\"https://laohu8.com/S/AONE.U\">一</a>另一方面，游戏驿站能够利用其最近的名气，通过出售股票为其正在进行的向数字游戏公司的转型筹集资金。这是一项急需的举措，此前电子商务销售额在2020财年增长了191%，在假期期间比去年同期增长了四倍多。</blockquote> However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.<blockquote>然而，这些融资并没有忽视前任管理团队让公司失望的事实。二十年来，实体游戏模式运行良好。然而，当游戏走向数字化时，坚持这种实体模式会让公司陷入不稳定的境地。如今，即使电子商务快速增长，游戏驿站仍在继续亏损，去年同店销售额下降了近10%。数字销售可能在增长，但随着游戏驿站关闭其实体店以降低成本，总收入将无处可去。</blockquote> GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.<blockquote>游戏驿站绝不是破产的候选者，我实际上可以看到几年后实现盈利的道路。但话虽如此，考虑到未来漫长的转型和运营亏损，所看到的收益毫无意义。</blockquote> Inovio Pharmaceuticals<blockquote>Inovio制药公司</blockquote> Biotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.<blockquote>生物科技股可以提供充足的机会，或者Inovio制药公司（纳斯达克：INO）案例，吸走长期投资者的命脉。</blockquote> Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.<blockquote>Inovio似乎是一家仅基于纸张的有趣公司。它的产品线目前包括十几种治疗癌症、传染病和人乳头瘤病毒的临床候选药物。最有前途的看起来是INO-4800，这是该公司的冠状病毒病2019（COVID-19）候选疫苗，已准备好进行3期研究。但如果你深入研究Inovio的临床表现，你会非常失望。</blockquote> For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.<blockquote>例如，INO-4800在美国已被部分临床搁置，而监管机构要求提供有关Inovio疫苗及其输送系统Cellectra的更多数据。最近，INO-4800的后期资金被美国政府取消，这就是为什么它现在正在为其COVID-19候选药物寻求国际研究。</blockquote> If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.<blockquote>如果你认为我不公平地指责Inovio在新冠肺炎的挣扎，那就更进一步吧。四十年来，Inovio一直未能获得FDA批准的药物。这并不是我希望Inovio发生不好的事情——这是现实，希望和结果很长一段时间都没有与这家公司保持一致。在Inovio在后期临床试验中证明自己之前，值得避免使用。</blockquote> AMC Entertainment<blockquote>AMC院线</blockquote> Finally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.<blockquote>最后，我不能忘记正在进行的抽水和转储计划AMC院线（纽约证券交易所代码：AMC）。尽管在AMC通过发行大量股票和高息债务自救后，散户投资者能够通过1月份的轧空来宣称胜利，但最近的上涨与轧空无关。相反，它主要基于炒作，在留言板上故意混淆具体的基本数据，以及广泛的，公然的错误信息。</blockquote> AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.<blockquote>AMC的散户投资者希望你相信基本面并不重要，但尝试驾驶一辆没有发动机的汽车，看看你能走多远。AMC正在应对行业票房收入连续19年下降的问题，并且随着电影制片厂依赖流媒体，其部分电影独家经营权正在消失。电影院将会有一席之地，但AMC的潜在市场逐年萎缩。</blockquote> AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.<blockquote>AMC的散户投资者还会让您相信该公司在筹集20亿美元资本后状况良好。尽管近期破产传闻已被搁置，但2027年债券价格远未接近面值。你会问，为什么？因为债券持有人不相信AMC会逃脱破产。</blockquote> I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.<blockquote>我一生中见过足够多的泵和转储活动来识别它们，并且AMC检查了所有的框。我的建议是不要做空AMC。我的建议是完全避免。所有的抽水和转储计划最终都会崩溃，AMC也不例外。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/\">The motley fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GME":"游戏驿站","SAVA":"Cassava Sciences Inc","INO":"伊诺维奥制药","COIN":"Coinbase Global, Inc.","AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164348327","content_text":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.\nWhile a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.\nCoinbase Global\nFirst up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.\nTo start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.\nSecond,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.\nAnd third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.\nCassava Sciences\nAnother ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).\nCassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.\nI'd love for simufilam to be successful, but history has shown that Alzheimer's is one of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.\nAlthough Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.\nGameStop\nIf you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).\nOn one hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.\nHowever, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.\nGameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.\nInovio Pharmaceuticals\nBiotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.\nInovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.\nFor example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.\nIf you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.\nAMC Entertainment\nFinally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.\nAMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.\nAMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.\nI've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.","news_type":1,"symbols_score_info":{"SAVA":0.9,"INO":0.9,"GME":0.9,"COIN":0.9,"AMC":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":154419104,"gmtCreate":1625538265108,"gmtModify":1631891392238,"author":{"id":"3569291088297790","authorId":"3569291088297790","name":"Prashant","avatar":"https://static.tigerbbs.com/d8814671cf4887208a8404f7fc63d9fd","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3569291088297790","authorIdStr":"3569291088297790"},"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/154419104","repostId":1164348327,"repostType":4,"repost":{"id":"1164348327","kind":"news","pubTimestamp":1625535165,"share":"https://www.laohu8.com/m/news/1164348327?lang=zh_CN&edition=full","pubTime":"2021-07-06 09:32","market":"us","language":"en","title":"5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1164348327","media":"The motley fool","summary":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The ben","content":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&amp;P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.<blockquote>在过去的15个月里，华尔街和投资者享受了历史性的反弹。基准标普500自2020年3月23日触及熊市底部以来，已上涨超过90%。</blockquote> While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.<blockquote>虽然许多高质量和创新的企业引领了这场反弹，但它也让相当多糟糕的公司蓬勃发展。我建议像七月瘟疫一样避开以下五只超受欢迎的股票。</blockquote> Coinbase Global<blockquote>比特币基地全球</blockquote> First up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin&nbsp;andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.<blockquote>首先是加密货币交易所和生态系统比特币基地全球（纳斯达克：硬币）。Coinbase很受欢迎，因为投资者纷纷涌入Coinbase等公司，其第一季度收入和利润飙升得如此之快比特币和以太币.问题是有三种催化剂对Coinbase经纪模式不利。</blockquote> To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.<blockquote>首先，没有什么可以阻止竞争交易所降低Coinbase Global的费用。目前它可能具有经过验证的用户优势，但不要低估加密货币投资者为节省交易费用而跳槽的意愿。我们在传统券商中目睹了这一点，该行业最终实现了免佣金。</blockquote> Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.<blockquote>其次，加密货币有繁荣和萧条周期的历史。在过去十年中，比特币曾发生过三起独立的事件，其价值至少缩水80%。这是一项完全基于动量的投资，当上行动力枯竭时，Coinbase的交易收入也会枯竭。继2017年达到峰值后，Coinbase的收入在随后几年几乎减半。</blockquote> And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.<blockquote>第三，根据CoinShares数字资产基金流量周刊的数据，截至6月28日的过去四周内，加密货币资金流出量为2.573亿美元。这进一步证明，随着这些资产远低于高点，人们对加密货币的兴趣已经在下降。可以说，Coinbase并不是一只您未来想要拥有的股票。</blockquote> Cassava Sciences<blockquote>木薯科学</blockquote> Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).<blockquote>另一家风险回报比糟糕的超受欢迎公司是临床阶段的生物技术股票木薯科学（纳斯达克：萨瓦）。</blockquote> Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.<blockquote>Cassava在2月份宣布了simufilam治疗阿尔茨海默病的中期分析的积极临床数据，这理所当然地引起了轰动。这项开放标签试验显示，在六个月时认知和行为有所改善，最近允许Cassava概述其涉及其主要候选药物的3期试验计划。</blockquote> I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.<blockquote>我希望simufilam能够成功，但历史表明阿尔茨海默氏症是<a href=\"https://laohu8.com/S/AONE\">一</a>最难治疗的疾病。除了BiogenAduhelm获得了美国食品和药物管理局(FDA)的批准，但因缺乏明确的益处而受到严厉批评，十多年来，每种阿尔茨海默病药物都在后期研究中失败。投资者所要做的就是一项旨在招募100名患者的试验的早期开放标签数据。在大型3期阿尔茨海默病试验中，早期或中期的积极结果被粉碎的情况并不罕见。</blockquote> Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.<blockquote>尽管Cassava筹集了大量现金来继续其研究，但历史表明simufilam成功的机会非常渺茫。这使得木薯科学很容易避免。</blockquote> GameStop<blockquote>游戏驿站</blockquote> If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).<blockquote>如果您一直在关注零售贸易运动（即Reddit股票），散户投资者正在寻找大量卖空的公司并试图进行轧空，您可能知道视频游戏和配件零售商游戏驿站（纽约证券交易所代码：GME）。</blockquote> On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.<blockquote>在<a href=\"https://laohu8.com/S/AONE.U\">一</a>另一方面，游戏驿站能够利用其最近的名气，通过出售股票为其正在进行的向数字游戏公司的转型筹集资金。这是一项急需的举措，此前电子商务销售额在2020财年增长了191%，在假期期间比去年同期增长了四倍多。</blockquote> However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.<blockquote>然而，这些融资并没有忽视前任管理团队让公司失望的事实。二十年来，实体游戏模式运行良好。然而，当游戏走向数字化时，坚持这种实体模式会让公司陷入不稳定的境地。如今，即使电子商务快速增长，游戏驿站仍在继续亏损，去年同店销售额下降了近10%。数字销售可能在增长，但随着游戏驿站关闭其实体店以降低成本，总收入将无处可去。</blockquote> GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.<blockquote>游戏驿站绝不是破产的候选者，我实际上可以看到几年后实现盈利的道路。但话虽如此，考虑到未来漫长的转型和运营亏损，所看到的收益毫无意义。</blockquote> Inovio Pharmaceuticals<blockquote>Inovio制药公司</blockquote> Biotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.<blockquote>生物科技股可以提供充足的机会，或者Inovio制药公司（纳斯达克：INO）案例，吸走长期投资者的命脉。</blockquote> Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.<blockquote>Inovio似乎是一家仅基于纸张的有趣公司。它的产品线目前包括十几种治疗癌症、传染病和人乳头瘤病毒的临床候选药物。最有前途的看起来是INO-4800，这是该公司的冠状病毒病2019（COVID-19）候选疫苗，已准备好进行3期研究。但如果你深入研究Inovio的临床表现，你会非常失望。</blockquote> For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.<blockquote>例如，INO-4800在美国已被部分临床搁置，而监管机构要求提供有关Inovio疫苗及其输送系统Cellectra的更多数据。最近，INO-4800的后期资金被美国政府取消，这就是为什么它现在正在为其COVID-19候选药物寻求国际研究。</blockquote> If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.<blockquote>如果你认为我不公平地指责Inovio在新冠肺炎的挣扎，那就更进一步吧。四十年来，Inovio一直未能获得FDA批准的药物。这并不是我希望Inovio发生不好的事情——这是现实，希望和结果很长一段时间都没有与这家公司保持一致。在Inovio在后期临床试验中证明自己之前，值得避免使用。</blockquote> AMC Entertainment<blockquote>AMC院线</blockquote> Finally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.<blockquote>最后，我不能忘记正在进行的抽水和转储计划AMC院线（纽约证券交易所代码：AMC）。尽管在AMC通过发行大量股票和高息债务自救后，散户投资者能够通过1月份的轧空来宣称胜利，但最近的上涨与轧空无关。相反，它主要基于炒作，在留言板上故意混淆具体的基本数据，以及广泛的，公然的错误信息。</blockquote> AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.<blockquote>AMC的散户投资者希望你相信基本面并不重要，但尝试驾驶一辆没有发动机的汽车，看看你能走多远。AMC正在应对行业票房收入连续19年下降的问题，并且随着电影制片厂依赖流媒体，其部分电影独家经营权正在消失。电影院将会有一席之地，但AMC的潜在市场逐年萎缩。</blockquote> AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.<blockquote>AMC的散户投资者还会让您相信该公司在筹集20亿美元资本后状况良好。尽管近期破产传闻已被搁置，但2027年债券价格远未接近面值。你会问，为什么？因为债券持有人不相信AMC会逃脱破产。</blockquote> I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.<blockquote>我一生中见过足够多的泵和转储活动来识别它们，并且AMC检查了所有的框。我的建议是不要做空AMC。我的建议是完全避免。所有的抽水和转储计划最终都会崩溃，AMC也不例外。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nThe motley fool2021-07-06 09:32\n\n</h4>\n</header>\n<article>\nFor the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&amp;P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.<blockquote>在过去的15个月里，华尔街和投资者享受了历史性的反弹。基准标普500自2020年3月23日触及熊市底部以来，已上涨超过90%。</blockquote> While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.<blockquote>虽然许多高质量和创新的企业引领了这场反弹，但它也让相当多糟糕的公司蓬勃发展。我建议像七月瘟疫一样避开以下五只超受欢迎的股票。</blockquote> Coinbase Global<blockquote>比特币基地全球</blockquote> First up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin&nbsp;andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.<blockquote>首先是加密货币交易所和生态系统比特币基地全球（纳斯达克：硬币）。Coinbase很受欢迎，因为投资者纷纷涌入Coinbase等公司，其第一季度收入和利润飙升得如此之快比特币和以太币.问题是有三种催化剂对Coinbase经纪模式不利。</blockquote> To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.<blockquote>首先，没有什么可以阻止竞争交易所降低Coinbase Global的费用。目前它可能具有经过验证的用户优势，但不要低估加密货币投资者为节省交易费用而跳槽的意愿。我们在传统券商中目睹了这一点，该行业最终实现了免佣金。</blockquote> Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.<blockquote>其次，加密货币有繁荣和萧条周期的历史。在过去十年中，比特币曾发生过三起独立的事件，其价值至少缩水80%。这是一项完全基于动量的投资，当上行动力枯竭时，Coinbase的交易收入也会枯竭。继2017年达到峰值后，Coinbase的收入在随后几年几乎减半。</blockquote> And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.<blockquote>第三，根据CoinShares数字资产基金流量周刊的数据，截至6月28日的过去四周内，加密货币资金流出量为2.573亿美元。这进一步证明，随着这些资产远低于高点，人们对加密货币的兴趣已经在下降。可以说，Coinbase并不是一只您未来想要拥有的股票。</blockquote> Cassava Sciences<blockquote>木薯科学</blockquote> Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).<blockquote>另一家风险回报比糟糕的超受欢迎公司是临床阶段的生物技术股票木薯科学（纳斯达克：萨瓦）。</blockquote> Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.<blockquote>Cassava在2月份宣布了simufilam治疗阿尔茨海默病的中期分析的积极临床数据，这理所当然地引起了轰动。这项开放标签试验显示，在六个月时认知和行为有所改善，最近允许Cassava概述其涉及其主要候选药物的3期试验计划。</blockquote> I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.<blockquote>我希望simufilam能够成功，但历史表明阿尔茨海默氏症是<a href=\"https://laohu8.com/S/AONE\">一</a>最难治疗的疾病。除了BiogenAduhelm获得了美国食品和药物管理局(FDA)的批准，但因缺乏明确的益处而受到严厉批评，十多年来，每种阿尔茨海默病药物都在后期研究中失败。投资者所要做的就是一项旨在招募100名患者的试验的早期开放标签数据。在大型3期阿尔茨海默病试验中，早期或中期的积极结果被粉碎的情况并不罕见。</blockquote> Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.<blockquote>尽管Cassava筹集了大量现金来继续其研究，但历史表明simufilam成功的机会非常渺茫。这使得木薯科学很容易避免。</blockquote> GameStop<blockquote>游戏驿站</blockquote> If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).<blockquote>如果您一直在关注零售贸易运动（即Reddit股票），散户投资者正在寻找大量卖空的公司并试图进行轧空，您可能知道视频游戏和配件零售商游戏驿站（纽约证券交易所代码：GME）。</blockquote> On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.<blockquote>在<a href=\"https://laohu8.com/S/AONE.U\">一</a>另一方面，游戏驿站能够利用其最近的名气，通过出售股票为其正在进行的向数字游戏公司的转型筹集资金。这是一项急需的举措，此前电子商务销售额在2020财年增长了191%，在假期期间比去年同期增长了四倍多。</blockquote> However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.<blockquote>然而，这些融资并没有忽视前任管理团队让公司失望的事实。二十年来，实体游戏模式运行良好。然而，当游戏走向数字化时，坚持这种实体模式会让公司陷入不稳定的境地。如今，即使电子商务快速增长，游戏驿站仍在继续亏损，去年同店销售额下降了近10%。数字销售可能在增长，但随着游戏驿站关闭其实体店以降低成本，总收入将无处可去。</blockquote> GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.<blockquote>游戏驿站绝不是破产的候选者，我实际上可以看到几年后实现盈利的道路。但话虽如此，考虑到未来漫长的转型和运营亏损，所看到的收益毫无意义。</blockquote> Inovio Pharmaceuticals<blockquote>Inovio制药公司</blockquote> Biotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.<blockquote>生物科技股可以提供充足的机会，或者Inovio制药公司（纳斯达克：INO）案例，吸走长期投资者的命脉。</blockquote> Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.<blockquote>Inovio似乎是一家仅基于纸张的有趣公司。它的产品线目前包括十几种治疗癌症、传染病和人乳头瘤病毒的临床候选药物。最有前途的看起来是INO-4800，这是该公司的冠状病毒病2019（COVID-19）候选疫苗，已准备好进行3期研究。但如果你深入研究Inovio的临床表现，你会非常失望。</blockquote> For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.<blockquote>例如，INO-4800在美国已被部分临床搁置，而监管机构要求提供有关Inovio疫苗及其输送系统Cellectra的更多数据。最近，INO-4800的后期资金被美国政府取消，这就是为什么它现在正在为其COVID-19候选药物寻求国际研究。</blockquote> If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.<blockquote>如果你认为我不公平地指责Inovio在新冠肺炎的挣扎，那就更进一步吧。四十年来，Inovio一直未能获得FDA批准的药物。这并不是我希望Inovio发生不好的事情——这是现实，希望和结果很长一段时间都没有与这家公司保持一致。在Inovio在后期临床试验中证明自己之前，值得避免使用。</blockquote> AMC Entertainment<blockquote>AMC院线</blockquote> Finally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.<blockquote>最后，我不能忘记正在进行的抽水和转储计划AMC院线（纽约证券交易所代码：AMC）。尽管在AMC通过发行大量股票和高息债务自救后，散户投资者能够通过1月份的轧空来宣称胜利，但最近的上涨与轧空无关。相反，它主要基于炒作，在留言板上故意混淆具体的基本数据，以及广泛的，公然的错误信息。</blockquote> AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.<blockquote>AMC的散户投资者希望你相信基本面并不重要，但尝试驾驶一辆没有发动机的汽车，看看你能走多远。AMC正在应对行业票房收入连续19年下降的问题，并且随着电影制片厂依赖流媒体，其部分电影独家经营权正在消失。电影院将会有一席之地，但AMC的潜在市场逐年萎缩。</blockquote> AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.<blockquote>AMC的散户投资者还会让您相信该公司在筹集20亿美元资本后状况良好。尽管近期破产传闻已被搁置，但2027年债券价格远未接近面值。你会问，为什么？因为债券持有人不相信AMC会逃脱破产。</blockquote> I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.<blockquote>我一生中见过足够多的泵和转储活动来识别它们，并且AMC检查了所有的框。我的建议是不要做空AMC。我的建议是完全避免。所有的抽水和转储计划最终都会崩溃，AMC也不例外。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/\">The motley fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GME":"游戏驿站","SAVA":"Cassava Sciences Inc","INO":"伊诺维奥制药","COIN":"Coinbase Global, Inc.","AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164348327","content_text":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.\nWhile a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.\nCoinbase Global\nFirst up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.\nTo start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.\nSecond,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.\nAnd third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.\nCassava Sciences\nAnother ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).\nCassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.\nI'd love for simufilam to be successful, but history has shown that Alzheimer's is one of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.\nAlthough Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.\nGameStop\nIf you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).\nOn one hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.\nHowever, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.\nGameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.\nInovio Pharmaceuticals\nBiotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.\nInovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.\nFor example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.\nIf you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.\nAMC Entertainment\nFinally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.\nAMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.\nAMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.\nI've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.","news_type":1,"symbols_score_info":{"SAVA":0.9,"INO":0.9,"GME":0.9,"COIN":0.9,"AMC":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":154439273,"gmtCreate":1625537827292,"gmtModify":1633939859300,"author":{"id":"3554873215379647","authorId":"3554873215379647","name":"Jenjorjack","avatar":"https://static.tigerbbs.com/d9d4687aa5519f0d2fb1b18f916be861","vip":1,"crmLevel":12,"crmLevelSwitch":0,"idStr":"3554873215379647","authorIdStr":"3554873215379647"},"htmlText":"Popular usually means you are too late","listText":"Popular usually means you are too late","text":"Popular usually means you are too late","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/154439273","repostId":1164348327,"repostType":4,"repost":{"id":"1164348327","kind":"news","pubTimestamp":1625535165,"share":"https://www.laohu8.com/m/news/1164348327?lang=zh_CN&edition=full","pubTime":"2021-07-06 09:32","market":"us","language":"en","title":"5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1164348327","media":"The motley fool","summary":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The ben","content":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&amp;P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.<blockquote>在过去的15个月里，华尔街和投资者享受了历史性的反弹。基准标普500自2020年3月23日触及熊市底部以来，已上涨超过90%。</blockquote> While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.<blockquote>虽然许多高质量和创新的企业引领了这场反弹，但它也让相当多糟糕的公司蓬勃发展。我建议像七月瘟疫一样避开以下五只超受欢迎的股票。</blockquote> Coinbase Global<blockquote>比特币基地全球</blockquote> First up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin&nbsp;andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.<blockquote>首先是加密货币交易所和生态系统比特币基地全球（纳斯达克：硬币）。Coinbase很受欢迎，因为投资者纷纷涌入Coinbase等公司，其第一季度收入和利润飙升得如此之快比特币和以太币.问题是有三种催化剂对Coinbase经纪模式不利。</blockquote> To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.<blockquote>首先，没有什么可以阻止竞争交易所降低Coinbase Global的费用。目前它可能具有经过验证的用户优势，但不要低估加密货币投资者为节省交易费用而跳槽的意愿。我们在传统券商中目睹了这一点，该行业最终实现了免佣金。</blockquote> Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.<blockquote>其次，加密货币有繁荣和萧条周期的历史。在过去十年中，比特币曾发生过三起独立的事件，其价值至少缩水80%。这是一项完全基于动量的投资，当上行动力枯竭时，Coinbase的交易收入也会枯竭。继2017年达到峰值后，Coinbase的收入在随后几年几乎减半。</blockquote> And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.<blockquote>第三，根据CoinShares数字资产基金流量周刊的数据，截至6月28日的过去四周内，加密货币资金流出量为2.573亿美元。这进一步证明，随着这些资产远低于高点，人们对加密货币的兴趣已经在下降。可以说，Coinbase并不是一只您未来想要拥有的股票。</blockquote> Cassava Sciences<blockquote>木薯科学</blockquote> Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).<blockquote>另一家风险回报比糟糕的超受欢迎公司是临床阶段的生物技术股票木薯科学（纳斯达克：萨瓦）。</blockquote> Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.<blockquote>Cassava在2月份宣布了simufilam治疗阿尔茨海默病的中期分析的积极临床数据，这理所当然地引起了轰动。这项开放标签试验显示，在六个月时认知和行为有所改善，最近允许Cassava概述其涉及其主要候选药物的3期试验计划。</blockquote> I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.<blockquote>我希望simufilam能够成功，但历史表明阿尔茨海默氏症是<a href=\"https://laohu8.com/S/AONE\">一</a>最难治疗的疾病。除了BiogenAduhelm获得了美国食品和药物管理局(FDA)的批准，但因缺乏明确的益处而受到严厉批评，十多年来，每种阿尔茨海默病药物都在后期研究中失败。投资者所要做的就是一项旨在招募100名患者的试验的早期开放标签数据。在大型3期阿尔茨海默病试验中，早期或中期的积极结果被粉碎的情况并不罕见。</blockquote> Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.<blockquote>尽管Cassava筹集了大量现金来继续其研究，但历史表明simufilam成功的机会非常渺茫。这使得木薯科学很容易避免。</blockquote> GameStop<blockquote>游戏驿站</blockquote> If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).<blockquote>如果您一直在关注零售贸易运动（即Reddit股票），散户投资者正在寻找大量卖空的公司并试图进行轧空，您可能知道视频游戏和配件零售商游戏驿站（纽约证券交易所代码：GME）。</blockquote> On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.<blockquote>在<a href=\"https://laohu8.com/S/AONE.U\">一</a>另一方面，游戏驿站能够利用其最近的名气，通过出售股票为其正在进行的向数字游戏公司的转型筹集资金。这是一项急需的举措，此前电子商务销售额在2020财年增长了191%，在假期期间比去年同期增长了四倍多。</blockquote> However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.<blockquote>然而，这些融资并没有忽视前任管理团队让公司失望的事实。二十年来，实体游戏模式运行良好。然而，当游戏走向数字化时，坚持这种实体模式会让公司陷入不稳定的境地。如今，即使电子商务快速增长，游戏驿站仍在继续亏损，去年同店销售额下降了近10%。数字销售可能在增长，但随着游戏驿站关闭其实体店以降低成本，总收入将无处可去。</blockquote> GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.<blockquote>游戏驿站绝不是破产的候选者，我实际上可以看到几年后实现盈利的道路。但话虽如此，考虑到未来漫长的转型和运营亏损，所看到的收益毫无意义。</blockquote> Inovio Pharmaceuticals<blockquote>Inovio制药公司</blockquote> Biotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.<blockquote>生物科技股可以提供充足的机会，或者Inovio制药公司（纳斯达克：INO）案例，吸走长期投资者的命脉。</blockquote> Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.<blockquote>Inovio似乎是一家仅基于纸张的有趣公司。它的产品线目前包括十几种治疗癌症、传染病和人乳头瘤病毒的临床候选药物。最有前途的看起来是INO-4800，这是该公司的冠状病毒病2019（COVID-19）候选疫苗，已准备好进行3期研究。但如果你深入研究Inovio的临床表现，你会非常失望。</blockquote> For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.<blockquote>例如，INO-4800在美国已被部分临床搁置，而监管机构要求提供有关Inovio疫苗及其输送系统Cellectra的更多数据。最近，INO-4800的后期资金被美国政府取消，这就是为什么它现在正在为其COVID-19候选药物寻求国际研究。</blockquote> If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.<blockquote>如果你认为我不公平地指责Inovio在新冠肺炎的挣扎，那就更进一步吧。四十年来，Inovio一直未能获得FDA批准的药物。这并不是我希望Inovio发生不好的事情——这是现实，希望和结果很长一段时间都没有与这家公司保持一致。在Inovio在后期临床试验中证明自己之前，值得避免使用。</blockquote> AMC Entertainment<blockquote>AMC院线</blockquote> Finally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.<blockquote>最后，我不能忘记正在进行的抽水和转储计划AMC院线（纽约证券交易所代码：AMC）。尽管在AMC通过发行大量股票和高息债务自救后，散户投资者能够通过1月份的轧空来宣称胜利，但最近的上涨与轧空无关。相反，它主要基于炒作，在留言板上故意混淆具体的基本数据，以及广泛的，公然的错误信息。</blockquote> AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.<blockquote>AMC的散户投资者希望你相信基本面并不重要，但尝试驾驶一辆没有发动机的汽车，看看你能走多远。AMC正在应对行业票房收入连续19年下降的问题，并且随着电影制片厂依赖流媒体，其部分电影独家经营权正在消失。电影院将会有一席之地，但AMC的潜在市场逐年萎缩。</blockquote> AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.<blockquote>AMC的散户投资者还会让您相信该公司在筹集20亿美元资本后状况良好。尽管近期破产传闻已被搁置，但2027年债券价格远未接近面值。你会问，为什么？因为债券持有人不相信AMC会逃脱破产。</blockquote> I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.<blockquote>我一生中见过足够多的泵和转储活动来识别它们，并且AMC检查了所有的框。我的建议是不要做空AMC。我的建议是完全避免。所有的抽水和转储计划最终都会崩溃，AMC也不例外。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nThe motley fool2021-07-06 09:32\n\n</h4>\n</header>\n<article>\nFor the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&amp;P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.<blockquote>在过去的15个月里，华尔街和投资者享受了历史性的反弹。基准标普500自2020年3月23日触及熊市底部以来，已上涨超过90%。</blockquote> While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.<blockquote>虽然许多高质量和创新的企业引领了这场反弹，但它也让相当多糟糕的公司蓬勃发展。我建议像七月瘟疫一样避开以下五只超受欢迎的股票。</blockquote> Coinbase Global<blockquote>比特币基地全球</blockquote> First up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin&nbsp;andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.<blockquote>首先是加密货币交易所和生态系统比特币基地全球（纳斯达克：硬币）。Coinbase很受欢迎，因为投资者纷纷涌入Coinbase等公司，其第一季度收入和利润飙升得如此之快比特币和以太币.问题是有三种催化剂对Coinbase经纪模式不利。</blockquote> To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.<blockquote>首先，没有什么可以阻止竞争交易所降低Coinbase Global的费用。目前它可能具有经过验证的用户优势，但不要低估加密货币投资者为节省交易费用而跳槽的意愿。我们在传统券商中目睹了这一点，该行业最终实现了免佣金。</blockquote> Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.<blockquote>其次，加密货币有繁荣和萧条周期的历史。在过去十年中，比特币曾发生过三起独立的事件，其价值至少缩水80%。这是一项完全基于动量的投资，当上行动力枯竭时，Coinbase的交易收入也会枯竭。继2017年达到峰值后，Coinbase的收入在随后几年几乎减半。</blockquote> And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.<blockquote>第三，根据CoinShares数字资产基金流量周刊的数据，截至6月28日的过去四周内，加密货币资金流出量为2.573亿美元。这进一步证明，随着这些资产远低于高点，人们对加密货币的兴趣已经在下降。可以说，Coinbase并不是一只您未来想要拥有的股票。</blockquote> Cassava Sciences<blockquote>木薯科学</blockquote> Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).<blockquote>另一家风险回报比糟糕的超受欢迎公司是临床阶段的生物技术股票木薯科学（纳斯达克：萨瓦）。</blockquote> Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.<blockquote>Cassava在2月份宣布了simufilam治疗阿尔茨海默病的中期分析的积极临床数据，这理所当然地引起了轰动。这项开放标签试验显示，在六个月时认知和行为有所改善，最近允许Cassava概述其涉及其主要候选药物的3期试验计划。</blockquote> I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.<blockquote>我希望simufilam能够成功，但历史表明阿尔茨海默氏症是<a href=\"https://laohu8.com/S/AONE\">一</a>最难治疗的疾病。除了BiogenAduhelm获得了美国食品和药物管理局(FDA)的批准，但因缺乏明确的益处而受到严厉批评，十多年来，每种阿尔茨海默病药物都在后期研究中失败。投资者所要做的就是一项旨在招募100名患者的试验的早期开放标签数据。在大型3期阿尔茨海默病试验中，早期或中期的积极结果被粉碎的情况并不罕见。</blockquote> Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.<blockquote>尽管Cassava筹集了大量现金来继续其研究，但历史表明simufilam成功的机会非常渺茫。这使得木薯科学很容易避免。</blockquote> GameStop<blockquote>游戏驿站</blockquote> If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).<blockquote>如果您一直在关注零售贸易运动（即Reddit股票），散户投资者正在寻找大量卖空的公司并试图进行轧空，您可能知道视频游戏和配件零售商游戏驿站（纽约证券交易所代码：GME）。</blockquote> On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.<blockquote>在<a href=\"https://laohu8.com/S/AONE.U\">一</a>另一方面，游戏驿站能够利用其最近的名气，通过出售股票为其正在进行的向数字游戏公司的转型筹集资金。这是一项急需的举措，此前电子商务销售额在2020财年增长了191%，在假期期间比去年同期增长了四倍多。</blockquote> However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.<blockquote>然而，这些融资并没有忽视前任管理团队让公司失望的事实。二十年来，实体游戏模式运行良好。然而，当游戏走向数字化时，坚持这种实体模式会让公司陷入不稳定的境地。如今，即使电子商务快速增长，游戏驿站仍在继续亏损，去年同店销售额下降了近10%。数字销售可能在增长，但随着游戏驿站关闭其实体店以降低成本，总收入将无处可去。</blockquote> GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.<blockquote>游戏驿站绝不是破产的候选者，我实际上可以看到几年后实现盈利的道路。但话虽如此，考虑到未来漫长的转型和运营亏损，所看到的收益毫无意义。</blockquote> Inovio Pharmaceuticals<blockquote>Inovio制药公司</blockquote> Biotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.<blockquote>生物科技股可以提供充足的机会，或者Inovio制药公司（纳斯达克：INO）案例，吸走长期投资者的命脉。</blockquote> Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.<blockquote>Inovio似乎是一家仅基于纸张的有趣公司。它的产品线目前包括十几种治疗癌症、传染病和人乳头瘤病毒的临床候选药物。最有前途的看起来是INO-4800，这是该公司的冠状病毒病2019（COVID-19）候选疫苗，已准备好进行3期研究。但如果你深入研究Inovio的临床表现，你会非常失望。</blockquote> For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.<blockquote>例如，INO-4800在美国已被部分临床搁置，而监管机构要求提供有关Inovio疫苗及其输送系统Cellectra的更多数据。最近，INO-4800的后期资金被美国政府取消，这就是为什么它现在正在为其COVID-19候选药物寻求国际研究。</blockquote> If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.<blockquote>如果你认为我不公平地指责Inovio在新冠肺炎的挣扎，那就更进一步吧。四十年来，Inovio一直未能获得FDA批准的药物。这并不是我希望Inovio发生不好的事情——这是现实，希望和结果很长一段时间都没有与这家公司保持一致。在Inovio在后期临床试验中证明自己之前，值得避免使用。</blockquote> AMC Entertainment<blockquote>AMC院线</blockquote> Finally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.<blockquote>最后，我不能忘记正在进行的抽水和转储计划AMC院线（纽约证券交易所代码：AMC）。尽管在AMC通过发行大量股票和高息债务自救后，散户投资者能够通过1月份的轧空来宣称胜利，但最近的上涨与轧空无关。相反，它主要基于炒作，在留言板上故意混淆具体的基本数据，以及广泛的，公然的错误信息。</blockquote> AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.<blockquote>AMC的散户投资者希望你相信基本面并不重要，但尝试驾驶一辆没有发动机的汽车，看看你能走多远。AMC正在应对行业票房收入连续19年下降的问题，并且随着电影制片厂依赖流媒体，其部分电影独家经营权正在消失。电影院将会有一席之地，但AMC的潜在市场逐年萎缩。</blockquote> AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.<blockquote>AMC的散户投资者还会让您相信该公司在筹集20亿美元资本后状况良好。尽管近期破产传闻已被搁置，但2027年债券价格远未接近面值。你会问，为什么？因为债券持有人不相信AMC会逃脱破产。</blockquote> I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.<blockquote>我一生中见过足够多的泵和转储活动来识别它们，并且AMC检查了所有的框。我的建议是不要做空AMC。我的建议是完全避免。所有的抽水和转储计划最终都会崩溃，AMC也不例外。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/\">The motley fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GME":"游戏驿站","SAVA":"Cassava Sciences Inc","INO":"伊诺维奥制药","COIN":"Coinbase Global, Inc.","AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164348327","content_text":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.\nWhile a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.\nCoinbase Global\nFirst up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.\nTo start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.\nSecond,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.\nAnd third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.\nCassava Sciences\nAnother ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).\nCassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.\nI'd love for simufilam to be successful, but history has shown that Alzheimer's is one of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.\nAlthough Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.\nGameStop\nIf you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).\nOn one hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.\nHowever, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.\nGameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.\nInovio Pharmaceuticals\nBiotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.\nInovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.\nFor example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.\nIf you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.\nAMC Entertainment\nFinally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.\nAMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.\nAMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.\nI've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.","news_type":1,"symbols_score_info":{"SAVA":0.9,"INO":0.9,"GME":0.9,"COIN":0.9,"AMC":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5132772,"gmtCreate":1625537990816,"gmtModify":1635236305622,"authorId":3574980039957190,"author":{"id":3574980039957190,"idStr":"3574980039957190","authorId":3574980039957190,"name":"Poopingmons","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":154439273,"type":1,"supId":0,"prevId":0,"content":"Yeah ikr","text":"Yeah ikr","html":"Yeah ikr"},{"id":5132834,"gmtCreate":1625538224351,"gmtModify":1635236299857,"authorId":3575944618458188,"author":{"id":3575944618458188,"idStr":"3575944618458188","authorId":3575944618458188,"name":"ZJ0429","avatar":"https://static.tigerbbs.com/cf7036ebe7fa36be18d7ae7011969bab","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":154439273,"type":1,"supId":0,"prevId":0,"content":"AMC!","text":"AMC!","html":"AMC!"},{"id":5133647,"gmtCreate":1625544312180,"gmtModify":1635236228461,"authorId":3585192718156791,"author":{"id":3585192718156791,"idStr":"3585192718156791","authorId":3585192718156791,"name":"yvneyng","avatar":"https://static.tigerbbs.com/76e9d3dda84e38df5f92fb2edf5f1be0","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":154439273,"type":1,"supId":0,"prevId":0,"content":"Agreed","text":"Agreed","html":"Agreed"}],"langContent":"EN"},{"id":154495014,"gmtCreate":1625537545438,"gmtModify":1631885505736,"author":{"id":"3581586498974106","authorId":"3581586498974106","name":"JensenLee","avatar":"https://static.tigerbbs.com/bec66649dc5418f64e826f6f16f3f8af","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3581586498974106","authorIdStr":"3581586498974106"},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/154495014","repostId":1164348327,"repostType":4,"repost":{"id":"1164348327","kind":"news","pubTimestamp":1625535165,"share":"https://www.laohu8.com/m/news/1164348327?lang=zh_CN&edition=full","pubTime":"2021-07-06 09:32","market":"us","language":"en","title":"5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1164348327","media":"The motley fool","summary":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The ben","content":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&amp;P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.<blockquote>在过去的15个月里，华尔街和投资者享受了历史性的反弹。基准标普500自2020年3月23日触及熊市底部以来，已上涨超过90%。</blockquote> While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.<blockquote>虽然许多高质量和创新的企业引领了这场反弹，但它也让相当多糟糕的公司蓬勃发展。我建议像七月瘟疫一样避开以下五只超受欢迎的股票。</blockquote> Coinbase Global<blockquote>比特币基地全球</blockquote> First up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin&nbsp;andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.<blockquote>首先是加密货币交易所和生态系统比特币基地全球（纳斯达克：硬币）。Coinbase很受欢迎，因为投资者纷纷涌入Coinbase等公司，其第一季度收入和利润飙升得如此之快比特币和以太币.问题是有三种催化剂对Coinbase经纪模式不利。</blockquote> To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.<blockquote>首先，没有什么可以阻止竞争交易所降低Coinbase Global的费用。目前它可能具有经过验证的用户优势，但不要低估加密货币投资者为节省交易费用而跳槽的意愿。我们在传统券商中目睹了这一点，该行业最终实现了免佣金。</blockquote> Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.<blockquote>其次，加密货币有繁荣和萧条周期的历史。在过去十年中，比特币曾发生过三起独立的事件，其价值至少缩水80%。这是一项完全基于动量的投资，当上行动力枯竭时，Coinbase的交易收入也会枯竭。继2017年达到峰值后，Coinbase的收入在随后几年几乎减半。</blockquote> And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.<blockquote>第三，根据CoinShares数字资产基金流量周刊的数据，截至6月28日的过去四周内，加密货币资金流出量为2.573亿美元。这进一步证明，随着这些资产远低于高点，人们对加密货币的兴趣已经在下降。可以说，Coinbase并不是一只您未来想要拥有的股票。</blockquote> Cassava Sciences<blockquote>木薯科学</blockquote> Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).<blockquote>另一家风险回报比糟糕的超受欢迎公司是临床阶段的生物技术股票木薯科学（纳斯达克：萨瓦）。</blockquote> Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.<blockquote>Cassava在2月份宣布了simufilam治疗阿尔茨海默病的中期分析的积极临床数据，这理所当然地引起了轰动。这项开放标签试验显示，在六个月时认知和行为有所改善，最近允许Cassava概述其涉及其主要候选药物的3期试验计划。</blockquote> I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.<blockquote>我希望simufilam能够成功，但历史表明阿尔茨海默氏症是<a href=\"https://laohu8.com/S/AONE\">一</a>最难治疗的疾病。除了BiogenAduhelm获得了美国食品和药物管理局(FDA)的批准，但因缺乏明确的益处而受到严厉批评，十多年来，每种阿尔茨海默病药物都在后期研究中失败。投资者所要做的就是一项旨在招募100名患者的试验的早期开放标签数据。在大型3期阿尔茨海默病试验中，早期或中期的积极结果被粉碎的情况并不罕见。</blockquote> Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.<blockquote>尽管Cassava筹集了大量现金来继续其研究，但历史表明simufilam成功的机会非常渺茫。这使得木薯科学很容易避免。</blockquote> GameStop<blockquote>游戏驿站</blockquote> If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).<blockquote>如果您一直在关注零售贸易运动（即Reddit股票），散户投资者正在寻找大量卖空的公司并试图进行轧空，您可能知道视频游戏和配件零售商游戏驿站（纽约证券交易所代码：GME）。</blockquote> On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.<blockquote>在<a href=\"https://laohu8.com/S/AONE.U\">一</a>另一方面，游戏驿站能够利用其最近的名气，通过出售股票为其正在进行的向数字游戏公司的转型筹集资金。这是一项急需的举措，此前电子商务销售额在2020财年增长了191%，在假期期间比去年同期增长了四倍多。</blockquote> However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.<blockquote>然而，这些融资并没有忽视前任管理团队让公司失望的事实。二十年来，实体游戏模式运行良好。然而，当游戏走向数字化时，坚持这种实体模式会让公司陷入不稳定的境地。如今，即使电子商务快速增长，游戏驿站仍在继续亏损，去年同店销售额下降了近10%。数字销售可能在增长，但随着游戏驿站关闭其实体店以降低成本，总收入将无处可去。</blockquote> GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.<blockquote>游戏驿站绝不是破产的候选者，我实际上可以看到几年后实现盈利的道路。但话虽如此，考虑到未来漫长的转型和运营亏损，所看到的收益毫无意义。</blockquote> Inovio Pharmaceuticals<blockquote>Inovio制药公司</blockquote> Biotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.<blockquote>生物科技股可以提供充足的机会，或者Inovio制药公司（纳斯达克：INO）案例，吸走长期投资者的命脉。</blockquote> Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.<blockquote>Inovio似乎是一家仅基于纸张的有趣公司。它的产品线目前包括十几种治疗癌症、传染病和人乳头瘤病毒的临床候选药物。最有前途的看起来是INO-4800，这是该公司的冠状病毒病2019（COVID-19）候选疫苗，已准备好进行3期研究。但如果你深入研究Inovio的临床表现，你会非常失望。</blockquote> For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.<blockquote>例如，INO-4800在美国已被部分临床搁置，而监管机构要求提供有关Inovio疫苗及其输送系统Cellectra的更多数据。最近，INO-4800的后期资金被美国政府取消，这就是为什么它现在正在为其COVID-19候选药物寻求国际研究。</blockquote> If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.<blockquote>如果你认为我不公平地指责Inovio在新冠肺炎的挣扎，那就更进一步吧。四十年来，Inovio一直未能获得FDA批准的药物。这并不是我希望Inovio发生不好的事情——这是现实，希望和结果很长一段时间都没有与这家公司保持一致。在Inovio在后期临床试验中证明自己之前，值得避免使用。</blockquote> AMC Entertainment<blockquote>AMC院线</blockquote> Finally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.<blockquote>最后，我不能忘记正在进行的抽水和转储计划AMC院线（纽约证券交易所代码：AMC）。尽管在AMC通过发行大量股票和高息债务自救后，散户投资者能够通过1月份的轧空来宣称胜利，但最近的上涨与轧空无关。相反，它主要基于炒作，在留言板上故意混淆具体的基本数据，以及广泛的，公然的错误信息。</blockquote> AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.<blockquote>AMC的散户投资者希望你相信基本面并不重要，但尝试驾驶一辆没有发动机的汽车，看看你能走多远。AMC正在应对行业票房收入连续19年下降的问题，并且随着电影制片厂依赖流媒体，其部分电影独家经营权正在消失。电影院将会有一席之地，但AMC的潜在市场逐年萎缩。</blockquote> AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.<blockquote>AMC的散户投资者还会让您相信该公司在筹集20亿美元资本后状况良好。尽管近期破产传闻已被搁置，但2027年债券价格远未接近面值。你会问，为什么？因为债券持有人不相信AMC会逃脱破产。</blockquote> I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.<blockquote>我一生中见过足够多的泵和转储活动来识别它们，并且AMC检查了所有的框。我的建议是不要做空AMC。我的建议是完全避免。所有的抽水和转储计划最终都会崩溃，AMC也不例外。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Ultra-Popular Stocks to Avoid Like the Plague in July<blockquote>7月份要像瘟疫一样避开的5只超热门股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nThe motley fool2021-07-06 09:32\n\n</h4>\n</header>\n<article>\nFor the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&amp;P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.<blockquote>在过去的15个月里，华尔街和投资者享受了历史性的反弹。基准标普500自2020年3月23日触及熊市底部以来，已上涨超过90%。</blockquote> While a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.<blockquote>虽然许多高质量和创新的企业引领了这场反弹，但它也让相当多糟糕的公司蓬勃发展。我建议像七月瘟疫一样避开以下五只超受欢迎的股票。</blockquote> Coinbase Global<blockquote>比特币基地全球</blockquote> First up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin&nbsp;andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.<blockquote>首先是加密货币交易所和生态系统比特币基地全球（纳斯达克：硬币）。Coinbase很受欢迎，因为投资者纷纷涌入Coinbase等公司，其第一季度收入和利润飙升得如此之快比特币和以太币.问题是有三种催化剂对Coinbase经纪模式不利。</blockquote> To start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.<blockquote>首先，没有什么可以阻止竞争交易所降低Coinbase Global的费用。目前它可能具有经过验证的用户优势，但不要低估加密货币投资者为节省交易费用而跳槽的意愿。我们在传统券商中目睹了这一点，该行业最终实现了免佣金。</blockquote> Second,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.<blockquote>其次，加密货币有繁荣和萧条周期的历史。在过去十年中，比特币曾发生过三起独立的事件，其价值至少缩水80%。这是一项完全基于动量的投资，当上行动力枯竭时，Coinbase的交易收入也会枯竭。继2017年达到峰值后，Coinbase的收入在随后几年几乎减半。</blockquote> And third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.<blockquote>第三，根据CoinShares数字资产基金流量周刊的数据，截至6月28日的过去四周内，加密货币资金流出量为2.573亿美元。这进一步证明，随着这些资产远低于高点，人们对加密货币的兴趣已经在下降。可以说，Coinbase并不是一只您未来想要拥有的股票。</blockquote> Cassava Sciences<blockquote>木薯科学</blockquote> Another ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).<blockquote>另一家风险回报比糟糕的超受欢迎公司是临床阶段的生物技术股票木薯科学（纳斯达克：萨瓦）。</blockquote> Cassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.<blockquote>Cassava在2月份宣布了simufilam治疗阿尔茨海默病的中期分析的积极临床数据，这理所当然地引起了轰动。这项开放标签试验显示，在六个月时认知和行为有所改善，最近允许Cassava概述其涉及其主要候选药物的3期试验计划。</blockquote> I'd love for simufilam to be successful, but history has shown that Alzheimer's is <a href=\"https://laohu8.com/S/AONE\">one</a> of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.<blockquote>我希望simufilam能够成功，但历史表明阿尔茨海默氏症是<a href=\"https://laohu8.com/S/AONE\">一</a>最难治疗的疾病。除了BiogenAduhelm获得了美国食品和药物管理局(FDA)的批准，但因缺乏明确的益处而受到严厉批评，十多年来，每种阿尔茨海默病药物都在后期研究中失败。投资者所要做的就是一项旨在招募100名患者的试验的早期开放标签数据。在大型3期阿尔茨海默病试验中，早期或中期的积极结果被粉碎的情况并不罕见。</blockquote> Although Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.<blockquote>尽管Cassava筹集了大量现金来继续其研究，但历史表明simufilam成功的机会非常渺茫。这使得木薯科学很容易避免。</blockquote> GameStop<blockquote>游戏驿站</blockquote> If you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).<blockquote>如果您一直在关注零售贸易运动（即Reddit股票），散户投资者正在寻找大量卖空的公司并试图进行轧空，您可能知道视频游戏和配件零售商游戏驿站（纽约证券交易所代码：GME）。</blockquote> On <a href=\"https://laohu8.com/S/AONE.U\">one</a> hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.<blockquote>在<a href=\"https://laohu8.com/S/AONE.U\">一</a>另一方面，游戏驿站能够利用其最近的名气，通过出售股票为其正在进行的向数字游戏公司的转型筹集资金。这是一项急需的举措，此前电子商务销售额在2020财年增长了191%，在假期期间比去年同期增长了四倍多。</blockquote> However, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.<blockquote>然而，这些融资并没有忽视前任管理团队让公司失望的事实。二十年来，实体游戏模式运行良好。然而，当游戏走向数字化时，坚持这种实体模式会让公司陷入不稳定的境地。如今，即使电子商务快速增长，游戏驿站仍在继续亏损，去年同店销售额下降了近10%。数字销售可能在增长，但随着游戏驿站关闭其实体店以降低成本，总收入将无处可去。</blockquote> GameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.<blockquote>游戏驿站绝不是破产的候选者，我实际上可以看到几年后实现盈利的道路。但话虽如此，考虑到未来漫长的转型和运营亏损，所看到的收益毫无意义。</blockquote> Inovio Pharmaceuticals<blockquote>Inovio制药公司</blockquote> Biotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.<blockquote>生物科技股可以提供充足的机会，或者Inovio制药公司（纳斯达克：INO）案例，吸走长期投资者的命脉。</blockquote> Inovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.<blockquote>Inovio似乎是一家仅基于纸张的有趣公司。它的产品线目前包括十几种治疗癌症、传染病和人乳头瘤病毒的临床候选药物。最有前途的看起来是INO-4800，这是该公司的冠状病毒病2019（COVID-19）候选疫苗，已准备好进行3期研究。但如果你深入研究Inovio的临床表现，你会非常失望。</blockquote> For example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.<blockquote>例如，INO-4800在美国已被部分临床搁置，而监管机构要求提供有关Inovio疫苗及其输送系统Cellectra的更多数据。最近，INO-4800的后期资金被美国政府取消，这就是为什么它现在正在为其COVID-19候选药物寻求国际研究。</blockquote> If you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.<blockquote>如果你认为我不公平地指责Inovio在新冠肺炎的挣扎，那就更进一步吧。四十年来，Inovio一直未能获得FDA批准的药物。这并不是我希望Inovio发生不好的事情——这是现实，希望和结果很长一段时间都没有与这家公司保持一致。在Inovio在后期临床试验中证明自己之前，值得避免使用。</blockquote> AMC Entertainment<blockquote>AMC院线</blockquote> Finally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.<blockquote>最后，我不能忘记正在进行的抽水和转储计划AMC院线（纽约证券交易所代码：AMC）。尽管在AMC通过发行大量股票和高息债务自救后，散户投资者能够通过1月份的轧空来宣称胜利，但最近的上涨与轧空无关。相反，它主要基于炒作，在留言板上故意混淆具体的基本数据，以及广泛的，公然的错误信息。</blockquote> AMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.<blockquote>AMC的散户投资者希望你相信基本面并不重要，但尝试驾驶一辆没有发动机的汽车，看看你能走多远。AMC正在应对行业票房收入连续19年下降的问题，并且随着电影制片厂依赖流媒体，其部分电影独家经营权正在消失。电影院将会有一席之地，但AMC的潜在市场逐年萎缩。</blockquote> AMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.<blockquote>AMC的散户投资者还会让您相信该公司在筹集20亿美元资本后状况良好。尽管近期破产传闻已被搁置，但2027年债券价格远未接近面值。你会问，为什么？因为债券持有人不相信AMC会逃脱破产。</blockquote> I've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.<blockquote>我一生中见过足够多的泵和转储活动来识别它们，并且AMC检查了所有的框。我的建议是不要做空AMC。我的建议是完全避免。所有的抽水和转储计划最终都会崩溃，AMC也不例外。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/\">The motley fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GME":"游戏驿站","SAVA":"Cassava Sciences Inc","INO":"伊诺维奥制药","COIN":"Coinbase Global, Inc.","AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/07/05/5-ultra-popular-stocks-avoid-like-plague-in-july/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164348327","content_text":"For the past 15 months, Wall Street and investors have enjoyed a historic bounce-back rally. The benchmarkS&P 500has gained more than 90% since hitting its bear-market bottom on March 23, 2020.\nWhile a number of high-quality and innovative businesses have led this rally, it's also allowed quite a few terrible companies to thrive. It's my suggestion that the following five ultra-popular stocks be avoided like the plague in July.\nCoinbase Global\nFirst up is cryptocurrency exchange and ecosystemCoinbase Global(NASDAQ:COIN). Coinbase is popular given how quickly its revenue and profits surged in the first quarter as investors piled into the likes ofBitcoin andEthereum. The problem is there are a trio of catalysts working against the Coinbase brokerage model.\nTo start with, there's nothing that prevents competing exchanges from undercutting Coinbase Global's fees. It might have the verified user advantage at the moment, but don't underestimate the willingness of crypto investors to jump ship to save on transaction fees. We witnessed it among traditional brokerages, and the industry eventually wound up going commission-free.\nSecond,crypto has a history of boom-and-bust cycles. Bitcoin has had three separate instances over the last decade where it's shed at least 80% of its value. This is an entirely momentum-based investment, and when upside momentum dries up, so does Coinbase's trading revenue. Following a 2017 peak, Coinbase saw its revenue nearly halve in subsequent years.\nAnd third, the past four weeks, through June 28, saw outflows from crypto of $257.3 million, according to CoinShares Digital Asset Fund Flows Weekly. This is more evidence that interest in crypto is already dwindling with these assets well off their highs. Suffice it to say, Coinbase isnot a stock you're going to want to ownmoving forward.\nCassava Sciences\nAnother ultra-popular company with a terrible risk-versus-reward ratio is clinical-stagebiotech stockCassava Sciences(NASDAQ:SAVA).\nCassava rightly made waves in February when it announced positive clinical data from an interim analysis of simufilam as a treatment for Alzheimer's disease. The open-label trial showed improvement in cognition and behavior at the six-month mark, and more recently allowed Cassava to outline its plans for a phase 3 trial involving its lead drug candidate.\nI'd love for simufilam to be successful, but history has shown that Alzheimer's is one of the toughest-to-treat diseases. With the exception ofBiogen's Aduhelm, which was approved by the Food and Drug Administration (FDA) but has been criticized heavily for its lack of clear benefit, every Alzheimer's drughas failed in late-stage studies for more than a decade. All investors have to go on is early stage, open-label data from a trial that aimed to enroll 100 patients. It's not been uncommon to see positive early or-mid-stage results get pulverized come a large phase 3 Alzheimer's trial.\nAlthough Cassava raised a good amount of cash to continue its research, history suggests that simufilam's chance of success is very slim. That makes Cassava Sciences easily avoidable.\nGameStop\nIf you've been following the retail trade movement (i.e. Reddit stocks), whereby retail investors are seeking out heavily short-sold companies and attempting to effect a short squeeze, you probably know video game and accessories retailerGameStop(NYSE:GME).\nOn one hand, GameStop has been able to capitalize on its recent fame byselling stock to raise capitalfor its ongoing transformation to a digital gaming company. It's a much-needed move after e-commerce sales jumped 191% in fiscal 2020 and more than quadrupled during the holiday season, from the prior-year period.\nHowever, these capital raises don't overlook the fact that theprevious management team failed the company. For two decades, a brick-and-mortar gaming model worked well. However, sticking to this brick-and-mortar model when gaming was going digital left the company in a precarious position. Today, GameStop continues to lose money, even with rapid e-commerce growth, and saw its same-store sales decline by almost 10% last year. Digital sales may be growing, but total revenue is going nowhere as GameStop shutters its physical locations to lower costs.\nGameStop is in no way a bankruptcy candidate, and I can actually see a path to profitability years down the road. But with that being said, the gains it's seen make no sense given the long transformation and operating losses that lie ahead.\nInovio Pharmaceuticals\nBiotech stocks can offer ample opportunity, or inInovio Pharmaceuticals'(NASDAQ:INO)case, suck the lifeblood out of long-term investors.\nInovio would appear to be an intriguing company based solely on paper. It has a pipeline that currently includes over a dozen clinical candidates to treat cancer, infectious diseases, and human papilloma virus. The most-promising looks to be INO-4800, the company's coronavirus disease 2019 (COVID-19) vaccine candidate that's readying for phase 3 studies. But if you do any digging into Inovio's clinical performance, you'll be sorely disappointed.\nFor example, INO-4800had been placed on partial clinical holdin the U.S. while regulators requested additional data on Inovio's vaccine and its delivery system, Cellectra. More recently, INO-4800 had its late-stage funding pulled by the U.S. government, which is why it's now seeking an international study for its COVID-19 candidate.\nIf you think I'm unfairly picking on Inovio for its COVID-19 struggles, pan out even further. In four decades, Inoviohasn't managed to get a drug approved by the FDA. This isn't me wishing bad things on Inovio -- this is the reality that hope and results haven't aligned with this company for a long time. Until Inovio proves itself in a late-stage clinical trial, it's worth avoiding.\nAMC Entertainment\nFinally, I can't forgetongoing pump-and-dump schemeAMC Entertainment(NYSE:AMC). While retail investors were able to claim victory by effecting a short squeeze in January after AMC saved itself by issuing a bunch of shares and high-interest debt, the most recent run-up has nothing to do with a short squeeze. Rather, it's based predominantly on hype, the purposeful obfuscation of concrete fundamental data on message boards, and broad-based, blatant misinformation.\nAMC's retail investors would like you to believe that fundamentals don't matter -- but try driving a car without an engine and see how far you get. AMC is dealing with a 19-year decline in industry ticket sales and is seeing some of its film exclusivity evaporate as movie studios lean on streaming. There will be a place for movie theaters, but AMC'saddressable market keeps shrinkingwith each passing year.\nAMC's retail investors would also have you believe the company is in great shape after raising $2 billion in capital. While it has put bankruptcy rumors in the near-term on the backburner, the 2027 bond price is nowhere near par. Why, you ask? Because bondholders aren't convinced that AMC is going to escape bankruptcy.\nI've seen enough pump-and-dump campaigns in my life to recognize them, andAMC checks all the boxes. My suggestion isn't to short AMC. My suggestion is to avoid it completely. All pump-and-dump schemes eventually collapse, and AMC will be no exception.","news_type":1,"symbols_score_info":{"SAVA":0.9,"INO":0.9,"GME":0.9,"COIN":0.9,"AMC":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5132742,"gmtCreate":1625537869844,"gmtModify":1631885505738,"authorId":3574119575606145,"author":{"id":3574119575606145,"idStr":"3574119575606145","authorId":3574119575606145,"name":"L1324","avatar":"https://static.tigerbbs.com/b05b9f32dd8af2590c80da38d48e37fc","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":154495014,"type":1,"supId":0,"prevId":0,"content":"done, i need like too.tia","text":"done, i need like too.tia","html":"done, i need like too.tia"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":181,"commentSize":33,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}